

Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/US05/003560

International filing date: 27 January 2005 (27.01.2005)

Document type: Certified copy of priority document


Document details: Country/Office: US
Number: 60/539,837
Filing date: 28 January 2004 (28.01.2004)

Date of receipt at the International Bureau: 07 April 2005 (07.04.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse



THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

April 01, 2005

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE.

APPLICATION NUMBER: 60/539,837

FILING DATE: *January 28, 2004*

RELATED PCT APPLICATION NUMBER: PCT/US05/03560



Certified by

Under Secretary of Commerce
for Intellectual Property
and Director of the United States
Patent and Trademark Office

16905 U.S. PTO
012804

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.
PTO/SB/16 (08-03)
Approved for use through 07/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

PROVISIONAL APPLICATION FOR PATENT COVER SHEET

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53(c).

Express Mail Label No. EV385630135US

607539837
U.S. PTO
012804

INVENTOR(S)					
Given Name (first and middle (if any))		Family Name or Surname		Residence (City and either State or Foreign Country)	
Lori		Friedman		San Carlos, California	
Additional inventors are being named on the <u>1</u> separately numbered sheets attached hereto					
TITLE OF THE INVENTION (500 characters max)					
MIGFRS AS MODIFIERS OF THE IGFR PATHWAY AND METHODS OF USE					
Direct all correspondence to: CORRESPONDENCE ADDRESS					
<input checked="" type="checkbox"/> Customer Number:		23500			
OR					
<input type="checkbox"/> Firm or Individual Name					
Address					
Address					
City		State		Zip	
Country		Telephone		Fax	
ENCLOSED APPLICATION PARTS (check all that apply)					
<input checked="" type="checkbox"/> Specification Number of Pages <u>80</u>		<input type="checkbox"/> CD(s), Number _____			
<input type="checkbox"/> Drawing(s) Number of Sheets _____		<input checked="" type="checkbox"/> Other (specify) <u>return postcard</u>			
<input type="checkbox"/> Application Date Sheet. See 37 CFR 1.76					
METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT					
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27.		FILING FEE Amount (\$)			
<input type="checkbox"/> A check or money order is enclosed to cover the filing fees.		160.00			
<input checked="" type="checkbox"/> The Director is hereby authorized to charge filing fees or credit any overpayment to Deposit Account Number: <u>50-1108</u>					
<input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached.					
The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.					
<input checked="" type="checkbox"/> No.					
<input type="checkbox"/> Yes, the name of the U.S. Government agency and the Government contract number are: _____					

Respectfully submitted,

[Page 1 of 2]

Date January 28, 2004

SIGNATURE

[Signature]

REGISTRATION NO. 47,937

TYPED or PRINTED NAME Laleh Shayesteh

(If appropriate)

Docket Number: EX04-007P

TELEPHONE 650.837.8223

USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT

This collection of information is required by 37 CFR 1.51. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 8 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop Provisional Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Additional Page

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Docket Number EX04-007P

INVENTOR(S)/APPLICANT(S)		
Given Name (first and middle [if any])	Family or Surname	Residence (City and either State or Foreign Country)
Helen	Francis-Lang	San Francisco, California
Annette	Parks	Daly City, California
Kenneth	Shaw	
HaiGuang	Zhang	El Sobrante, California
Lynn Margaret	Bjerke	San Francisco, California
Montique	Nicoll	Pacific, California
Joanne I.	Adamkewicz	San Francisco, California

[Page 2 of 2]

Number 1 of 1

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

MIGFRS AS MODIFIERS OF THE IGFR PATHWAY AND METHODS OF USE

BACKGROUND OF THE INVENTION

Somatic mutations in the PTEN (Phosphatase and Tensin homolog deleted on chromosome 10) gene are known to cause tumors in a variety of human tissues. In addition, germline mutations in PTEN are the cause of human diseases (Cowden disease and Bannayan-Zonana syndrome) associated with increased risk of breast and thyroid cancer (Nelen MR et al. (1997) *Hum Mol Genet*, 8:1383-1387; Liaw D et al. (1997) *Nat Genet*, 1:64-67; Marsh DJ et al. (1998) *Hum Mol Genet*, 3:507-515). PTEN is thought to act as a tumor suppressor by regulating several signaling pathways through the second messenger phosphatidylinositol 3,4,5 triphosphate (PIP3). PTEN dephosphorylates the D3 position of PIP3 and downregulates signaling events dependent on PIP3 levels (Maehama T and Dixon JE (1998) *J Biol Chem*, 273:13375-8). In particular, pro-survival pathways downstream of the insulin-like growth factor (IGF) pathway are regulated by PTEN activity. Stimulation of the IGF pathway, or loss of PTEN function, elevates PIP3 levels and activates pro-survival pathways associated with tumorigenesis (Stambolic V et al. (1998) *Cell*, 95:29-39). Consistent with this model, elevated levels of insulin-like growth factors I and II correlate with increased risk of cancer (Yu H et al (1999) *J Natl Cancer Inst* 91:151-156) and poor prognosis (Takanami I et al, 1996, *J Surg Oncol* 61(3):205-8). In addition, increased levels or activity of positive effectors of the IGF pathway, such as Akt and PI(3) kinase, have been implicated in several types of human cancer (Nicholson KM and Anderson NG (2002) *Cellular Signalling*, 14:381-395). In *Drosophila melanogaster*, as in vertebrates, the Insulin Growth Factor Receptor (IGFR) pathway includes the positive effectors PI(3) kinase, Akt, and PDK and the inhibitor, PTEN. These proteins have been implicated in multiple processes, including the regulation of cell growth and size as well as cell division and survival (Oldham S and Hafen E. (2003) *Trends Cell Biol.* 13:79-85; Garafalo RS. (2002) *Trends Endocr. Metab.* 13:156-162; Backman SA et al. (2002) *Curr. Op. Neurobio.* 12:1-7; Tapon N et al. (2001) *Curr Op. Cell Biol.* 13:731-737). Activation of the pathway in *Drosophila* can result in increases in cell size, cell number and organ size (Oldham S et al. (2002) *Dev.* 129:4103-

4109; Prober DA and Edgar BA. (2002) *Genes&Dev.* 16:2286-2299; Potter CJ et al. (2001) *Cell* 105:357-368; Verdu J et al. (1999) *Cell Biol.* 1:500-506).

The ability to manipulate the genomes of model organisms such as *Drosophila* provides a powerful means to analyze biochemical processes that, due to significant evolutionary conservation, have direct relevance to more complex vertebrate organisms. Due to a high level of gene and pathway conservation, the strong similarity of cellular processes, and the functional conservation of genes between these model organisms and mammals, identification of the involvement of novel genes in particular pathways and their functions in such model organisms can directly contribute to the understanding of the correlative pathways and methods of modulating them in mammals (see, for example, Mechler BM et al., 1985 *EMBO J* 4:1551-1557; Gateff E. 1982 *Adv. Cancer Res.* 37: 33-74; Watson KL., et al., 1994 *J Cell Sci.* 18: 19-33; Miklos GL, and Rubin GM. 1996 *Cell* 86:521-529; Wassarman DA, et al., 1995 *Curr Opin Gen Dev* 5: 44-50; and Booth DR. 1999 *Cancer Metastasis Rev.* 18: 261-284). For example, a genetic screen can be carried out in an invertebrate model organism having underexpression (e.g. knockout) or overexpression of a gene (referred to as a “genetic entry point”) that yields a visible phenotype. Additional genes are mutated in a random or targeted manner. When a gene mutation changes the original phenotype caused by the mutation in the genetic entry point, the gene is identified as a “modifier” involved in the same or overlapping pathway as the genetic entry point. When the genetic entry point is an ortholog of a human gene implicated in a disease pathway, such as IGFR, modifier genes can be identified that may be attractive candidate targets for novel therapeutics.

All references cited herein, including patents, patent applications, publications, and sequence information in referenced Genbank identifier numbers, are incorporated herein in their entireties.

SUMMARY OF THE INVENTION

We have discovered genes that modify the IGFR pathway in *Drosophila*, and identified their human orthologs, hereinafter referred to as Modifier of IGFR (MIGFR). The invention provides methods for utilizing these IGFR modifier genes

and polypeptides to identify MIGFR-modulating agents that are candidate therapeutic agents that can be used in the treatment of disorders associated with defective or impaired IGFR function and/or MIGFR function. Preferred MIGFR-modulating agents specifically bind to MIGFR polypeptides and restore IGFR function. Other preferred MIGFR-modulating agents are nucleic acid modulators such as antisense oligomers and RNAi that repress MIGFR gene expression or product activity by, for example, binding to and inhibiting the respective nucleic acid (i.e. DNA or mRNA).

MIGFR modulating agents may be evaluated by any convenient *in vitro* or *in vivo* assay for molecular interaction with an MIGFR polypeptide or nucleic acid. In one embodiment, candidate MIGFR modulating agents are tested with an assay system comprising a MIGFR polypeptide or nucleic acid. Agents that produce a change in the activity of the assay system relative to controls are identified as candidate IGFR modulating agents. The assay system may be cell-based or cell-free. MIGFR-modulating agents include MIGFR related proteins (e.g. dominant negative mutants, and biotherapeutics); MIGFR -specific antibodies; MIGFR -specific antisense oligomers and other nucleic acid modulators; and chemical agents that specifically bind to or interact with MIGFR or compete with MIGFR binding partner (e.g. by binding to an MIGFR binding partner). In one specific embodiment, a small molecule modulator is identified using a binding assay. In specific embodiments, the screening assay system is selected from an apoptosis assay, a cell proliferation assay, an angiogenesis assay, and a hypoxic induction assay.

In another embodiment, candidate IGFR pathway modulating agents are further tested using a second assay system that detects changes in the IGFR pathway, such as angiogenic, apoptotic, or cell proliferation changes produced by the originally identified candidate agent or an agent derived from the original agent. The second assay system may use cultured cells or non-human animals. In specific embodiments, the secondary assay system uses non-human animals, including animals predetermined to have a disease or disorder implicating the IGFR pathway, such as an angiogenic, apoptotic, or cell proliferation disorder (e.g. cancer).

The invention further provides methods for modulating the MIGFR function and/or the IGFR pathway in a mammalian cell by contacting the mammalian cell with

an agent that specifically binds a MIGFR polypeptide or nucleic acid. The agent may be a small molecule modulator, a nucleic acid modulator, or an antibody and may be administered to a mammalian animal predetermined to have a pathology associated with the IGFR pathway.

DETAILED DESCRIPTION OF THE INVENTION

A dominant loss of function screen was carried out in *Drosophila* to identify genes that interact with or modulate the IGFR signaling pathway. Modifiers of the IGFR pathway and their orthologs were identified. Accordingly, vertebrate orthologs of these modifiers, and preferably the human orthologs, MIGFR genes (i.e., nucleic acids and polypeptides) are attractive drug targets for the treatment of pathologies associated with a defective IGFR signaling pathway, such as cancer. Table 1 (Example II) lists the modifiers and their orthologs.

In vitro and in vivo methods of assessing MIGFR function are provided herein. Modulation of the MIGFR or their respective binding partners is useful for understanding the association of the IGFR pathway and its members in normal and disease conditions and for developing diagnostics and therapeutic modalities for IGFR related pathologies. MIGFR-modulating agents that act by inhibiting or enhancing MIGFR expression, directly or indirectly, for example, by affecting an MIGFR function such as enzymatic (e.g., catalytic) or binding activity, can be identified using methods provided herein. MIGFR modulating agents are useful in diagnosis, therapy and pharmaceutical development.

Nucleic acids and polypeptides of the invention

Sequences related to MIGFR nucleic acids and polypeptides that can be used in the invention are disclosed in Genbank (referenced by Genbank identifier (GI) or RefSeq number), shown in Table 1 and in the appended sequence listing.

The term "MIGFR polypeptide" refers to a full-length MIGFR protein or a functionally active fragment or derivative thereof. A "functionally active" MIGFR fragment or derivative exhibits one or more functional activities associated with a full-length, wild-type MIGFR protein, such as antigenic or immunogenic activity,

enzymatic activity, ability to bind natural cellular substrates, etc. The functional activity of MIGFR proteins, derivatives and fragments can be assayed by various methods known to one skilled in the art (Current Protocols in Protein Science (1998) Coligan *et al.*, eds., John Wiley & Sons, Inc., Somerset, New Jersey) and as further discussed below. In one embodiment, a functionally active MIGFR polypeptide is a MIGFR derivative capable of rescuing defective endogenous MIGFR activity, such as in cell based or animal assays; the rescuing derivative may be from the same or a different species. For purposes herein, functionally active fragments also include those fragments that comprise one or more structural domains of an MIGFR, such as a kinase domain or a binding domain. Protein domains can be identified using the PFAM program (Bateman A., et al., Nucleic Acids Res, 1999, 27:260-2). Methods for obtaining MIGFR polypeptides are also further described below. In some embodiments, preferred fragments are functionally active, domain-containing fragments comprising at least 25 contiguous amino acids, preferably at least 50, more preferably 75, and most preferably at least 100 contiguous amino acids of an MIGFR. In further preferred embodiments, the fragment comprises the entire functionally active domain.

The term "MIGFR nucleic acid" refers to a DNA or RNA molecule that encodes a MIGFR polypeptide. Preferably, the MIGFR polypeptide or nucleic acid or fragment thereof is from a human, but can also be an ortholog, or derivative thereof with at least 70% sequence identity, preferably at least 80%, more preferably 85%, still more preferably 90%, and most preferably at least 95% sequence identity with human MIGFR. Methods of identifying orthologs are known in the art. Normally, orthologs in different species retain the same function, due to presence of one or more protein motifs and/or 3-dimensional structures. Orthologs are generally identified by sequence homology analysis, such as BLAST analysis, usually using protein bait sequences. Sequences are assigned as a potential ortholog if the best hit sequence from the forward BLAST result retrieves the original query sequence in the reverse BLAST (Huynen MA and Bork P, Proc Natl Acad Sci (1998) 95:5849-5856; Huynen MA *et al.*, Genome Research (2000) 10:1204-1210). Programs for multiple sequence alignment, such as CLUSTAL (Thompson JD et al, 1994, Nucleic Acids Res

22:4673-4680) may be used to highlight conserved regions and/or residues of orthologous proteins and to generate phylogenetic trees. In a phylogenetic tree representing multiple homologous sequences from diverse species (e.g., retrieved through BLAST analysis), orthologous sequences from two species generally appear closest on the tree with respect to all other sequences from these two species. Structural threading or other analysis of protein folding (e.g., using software by ProCeryon, Biosciences, Salzburg, Austria) may also identify potential orthologs. In evolution, when a gene duplication event follows speciation, a single gene in one species, such as *Drosophila*, may correspond to multiple genes (paralogs) in another, such as human. As used herein, the term "orthologs" encompasses paralogs. As used herein, "percent (%) sequence identity" with respect to a subject sequence, or a specified portion of a subject sequence, is defined as the percentage of nucleotides or amino acids in the candidate derivative sequence identical with the nucleotides or amino acids in the subject sequence (or specified portion thereof), after aligning the sequences and introducing gaps, if necessary to achieve the maximum percent sequence identity, as generated by the program WU-BLAST-2.0a19 (Altschul *et al.*, J. Mol. Biol. (1997) 215:403-410) with all the search parameters set to default values. The HSP S and HSP S2 parameters are dynamic values and are established by the program itself depending upon the composition of the particular sequence and composition of the particular database against which the sequence of interest is being searched. A % identity value is determined by the number of matching identical nucleotides or amino acids divided by the sequence length for which the percent identity is being reported. "Percent (%) amino acid sequence similarity" is determined by doing the same calculation as for determining % amino acid sequence identity, but including conservative amino acid substitutions in addition to identical amino acids in the computation.

A conservative amino acid substitution is one in which an amino acid is substituted for another amino acid having similar properties such that the folding or activity of the protein is not significantly affected. Aromatic amino acids that can be substituted for each other are phenylalanine, tryptophan, and tyrosine; interchangeable hydrophobic amino acids are leucine, isoleucine, methionine, and

valine; interchangeable polar amino acids are glutamine and asparagine; interchangeable basic amino acids are arginine, lysine and histidine; interchangeable acidic amino acids are aspartic acid and glutamic acid; and interchangeable small amino acids are alanine, serine, threonine, cysteine and glycine.

Alternatively, an alignment for nucleic acid sequences is provided by the local homology algorithm of Smith and Waterman (Smith and Waterman, 1981, *Advances in Applied Mathematics* 2:482-489; database: European Bioinformatics Institute; Smith and Waterman, 1981, *J. of Molec.Biol.*, 147:195-197; Nicholas et al., 1998, "A Tutorial on Searching Sequence Databases and Sequence Scoring Methods" (www.psc.edu) and references cited therein.; W.R. Pearson, 1991, *Genomics* 11:635-650). This algorithm can be applied to amino acid sequences by using the scoring matrix developed by Dayhoff (Dayhoff: *Atlas of Protein Sequences and Structure*, M. O. Dayhoff ed., 5 suppl. 3:353-358, National Biomedical Research Foundation, Washington, D.C., USA), and normalized by Gribskov (Gribskov 1986 *Nucl. Acids Res.* 14(6):6745-6763). The Smith-Waterman algorithm may be employed where default parameters are used for scoring (for example, gap open penalty of 12, gap extension penalty of two). From the data generated, the "Match" value reflects "sequence identity."

Derivative nucleic acid molecules of the subject nucleic acid molecules include sequences that hybridize to the nucleic acid sequence of an MIGFR. The stringency of hybridization can be controlled by temperature, ionic strength, pH, and the presence of denaturing agents such as formamide during hybridization and washing. Conditions routinely used are set out in readily available procedure texts (*e.g.*, *Current Protocol in Molecular Biology*, Vol. 1, Chap. 2.10, John Wiley & Sons, Publishers (1994); Sambrook *et al.*, *Molecular Cloning*, Cold Spring Harbor (1989)). In some embodiments, a nucleic acid molecule of the invention is capable of hybridizing to a nucleic acid molecule containing the nucleotide sequence of an MIGFR under high stringency hybridization conditions that are: prehybridization of filters containing nucleic acid for 8 hours to overnight at 65° C in a solution comprising 6X single strength citrate (SSC) (1X SSC is 0.15 M NaCl, 0.015 M Na citrate; pH 7.0), 5X Denhardt's solution, 0.05% sodium pyrophosphate and 100 µg/ml

herring sperm DNA; hybridization for 18-20 hours at 65° C in a solution containing 6X SSC, 1X Denhardt's solution, 100 µg/ml yeast tRNA and 0.05% sodium pyrophosphate; and washing of filters at 65° C for 1h in a solution containing 0.1X SSC and 0.1% SDS (sodium dodecyl sulfate).

In other embodiments, moderately stringent hybridization conditions are used that are: pretreatment of filters containing nucleic acid for 6 h at 40° C in a solution containing 35% formamide, 5X SSC, 50 mM Tris-HCl (pH7.5), 5mM EDTA, 0.1% PVP, 0.1% Ficoll, 1% BSA, and 500 µg/ml denatured salmon sperm DNA; hybridization for 18-20h at 40° C in a solution containing 35% formamide, 5X SSC, 50 mM Tris-HCl (pH7.5), 5mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.2% BSA, 100 µg/ml salmon sperm DNA, and 10% (wt/vol) dextran sulfate; followed by washing twice for 1 hour at 55° C in a solution containing 2X SSC and 0.1% SDS.

Alternatively, low stringency conditions can be used that are: incubation for 8 hours to overnight at 37° C in a solution comprising 20% formamide, 5 x SSC, 50 mM sodium phosphate (pH 7.6), 5X Denhardt's solution, 10% dextran sulfate, and 20 µg/ml denatured sheared salmon sperm DNA; hybridization in the same buffer for 18 to 20 hours; and washing of filters in 1 x SSC at about 37° C for 1 hour.

Isolation, Production, Expression, and Mis-expression of MIGFR Nucleic Acids and Polypeptides

MIGFR nucleic acids and polypeptides are useful for identifying and testing agents that modulate MIGFR function and for other applications related to the involvement of MIGFR in the IGFR pathway. MIGFR nucleic acids and derivatives and orthologs thereof may be obtained using any available method. For instance, techniques for isolating cDNA or genomic DNA sequences of interest by screening DNA libraries or by using polymerase chain reaction (PCR) are well known in the art. In general, the particular use for the protein will dictate the particulars of expression, production, and purification methods. For instance, production of proteins for use in screening for modulating agents may require methods that preserve specific biological activities of these proteins, whereas production of proteins for antibody generation may require structural integrity of particular epitopes. Expression of

proteins to be purified for screening or antibody production may require the addition of specific tags (*e.g.*, generation of fusion proteins). Overexpression of an MIGFR protein for assays used to assess MIGFR function, such as involvement in cell cycle regulation or hypoxic response, may require expression in eukaryotic cell lines capable of these cellular activities. Techniques for the expression, production, and purification of proteins are well known in the art; any suitable means therefore may be used (*e.g.*, Higgins SJ and Hames BD (eds.) *Protein Expression: A Practical Approach*, Oxford University Press Inc., New York 1999; Stanbury PF et al., *Principles of Fermentation Technology*, 2nd edition, Elsevier Science, New York, 1995; Doonan S (ed.) *Protein Purification Protocols*, Humana Press, New Jersey, 1996; Coligan JE et al, *Current Protocols in Protein Science* (eds.), 1999, John Wiley & Sons, New York). In particular embodiments, recombinant MIGFR is expressed in a cell line known to have defective IGFR function. The recombinant cells are used in cell-based screening assay systems of the invention, as described further below.

The nucleotide sequence encoding an MIGFR polypeptide can be inserted into any appropriate expression vector. The necessary transcriptional and translational signals, including promoter/enhancer element, can derive from the native MIGFR gene and/or its flanking regions or can be heterologous. A variety of host-vector expression systems may be utilized, such as mammalian cell systems infected with virus (*e.g.* vaccinia virus, adenovirus, *etc.*); insect cell systems infected with virus (*e.g.* baculovirus); microorganisms such as yeast containing yeast vectors, or bacteria transformed with bacteriophage, plasmid, or cosmid DNA. An isolated host cell strain that modulates the expression of, modifies, and/or specifically processes the gene product may be used.

To detect expression of the MIGFR gene product, the expression vector can comprise a promoter operably linked to an MIGFR gene nucleic acid, one or more origins of replication, and, one or more selectable markers (*e.g.* thymidine kinase activity, resistance to antibiotics, *etc.*). Alternatively, recombinant expression vectors can be identified by assaying for the expression of the MIGFR gene product based on the physical or functional properties of the MIGFR protein in *in vitro* assay systems (*e.g.* immunoassays).

The MIGFR protein, fragment, or derivative may be optionally expressed as a fusion, or chimeric protein product (i.e. it is joined via a peptide bond to a heterologous protein sequence of a different protein), for example to facilitate purification or detection. A chimeric product can be made by ligating the appropriate nucleic acid sequences encoding the desired amino acid sequences to each other using standard methods and expressing the chimeric product. A chimeric product may also be made by protein synthetic techniques, *e.g.* by use of a peptide synthesizer (Hunkapiller *et al.*, Nature (1984) 310:105-111).

Once a recombinant cell that expresses the MIGFR gene sequence is identified, the gene product can be isolated and purified using standard methods (*e.g.* ion exchange, affinity, and gel exclusion chromatography; centrifugation; differential solubility; electrophoresis). Alternatively, native MIGFR proteins can be purified from natural sources, by standard methods (*e.g.* immunoaffinity purification). Once a protein is obtained, it may be quantified and its activity measured by appropriate methods, such as immunoassay, bioassay, or other measurements of physical properties, such as crystallography.

The methods of this invention may also use cells that have been engineered for altered expression (mis-expression) of MIGFR or other genes associated with the IGFR pathway. As used herein, mis-expression encompasses ectopic expression, over-expression, under-expression, and non-expression (*e.g.* by gene knock-out or blocking expression that would otherwise normally occur).

Genetically modified animals

Animal models that have been genetically modified to alter MIGFR expression may be used in *in vivo* assays to test for activity of a candidate IGFR modulating agent, or to further assess the role of MIGFR in a IGFR pathway process such as apoptosis or cell proliferation. Preferably, the altered MIGFR expression results in a detectable phenotype, such as decreased or increased levels of cell proliferation, angiogenesis, or apoptosis compared to control animals having normal MIGFR expression. The genetically modified animal may additionally have altered IGFR expression (*e.g.* IGFR knockout). Preferred genetically modified animals are

mammals such as primates, rodents (preferably mice or rats), among others. Preferred non-mammalian species include zebrafish, *C. elegans*, and *Drosophila*. Preferred genetically modified animals are transgenic animals having a heterologous nucleic acid sequence present as an extrachromosomal element in a portion of its cells, i.e. mosaic animals (see, for example, techniques described by Jakobovits, 1994, Curr. Biol. 4:761-763.) or stably integrated into its germ line DNA (i.e., in the genomic sequence of most or all of its cells). Heterologous nucleic acid is introduced into the germ line of such transgenic animals by genetic manipulation of, for example, embryos or embryonic stem cells of the host animal.

Methods of making transgenic animals are well-known in the art (for transgenic mice see Brinster et al., Proc. Nat. Acad. Sci. USA 82: 4438-4442 (1985), U.S. Pat. Nos. 4,736,866 and 4,870,009, both by Leder et al., U.S. Pat. No. 4,873,191 by Wagner et al., and Hogan, B., Manipulating the Mouse Embryo, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., (1986); for particle bombardment see U.S. Pat. No., 4,945,050, by Sandford *et al.*; for transgenic *Drosophila* see Rubin and Spradling, Science (1982) 218:348-53 and U.S. Pat. No. 4,670,388; for transgenic insects see Berghammer A.J. *et al.*, A Universal Marker for Transgenic Insects (1999) Nature 402:370-371; for transgenic Zebrafish see Lin S., Transgenic Zebrafish, Methods Mol Biol. (2000);136:375-3830); for microinjection procedures for fish, amphibian eggs and birds see Houdebine and Chourrout, Experientia (1991) 47:897-905; for transgenic rats see Hammer *et al.*, Cell (1990) 63:1099-1112; and for culturing of embryonic stem (ES) cells and the subsequent production of transgenic animals by the introduction of DNA into ES cells using methods such as electroporation, calcium phosphate/DNA precipitation and direct injection see, e.g., Teratocarcinomas and Embryonic Stem Cells, A Practical Approach, E. J. Robertson, ed., IRL Press (1987)). Clones of the nonhuman transgenic animals can be produced according to available methods (see Wilmut, I. *et al.* (1997) Nature 385:810-813; and PCT International Publication Nos. WO 97/07668 and WO 97/07669).

In one embodiment, the transgenic animal is a "knock-out" animal having a heterozygous or homozygous alteration in the sequence of an endogenous MIGFR gene that results in a decrease of MIGFR function, preferably such that MIGFR

expression is undetectable or insignificant. Knock-out animals are typically generated by homologous recombination with a vector comprising a transgene having at least a portion of the gene to be knocked out. Typically a deletion, addition or substitution has been introduced into the transgene to functionally disrupt it. The transgene can be a human gene (e.g., from a human genomic clone) but more preferably is an ortholog of the human gene derived from the transgenic host species. For example, a mouse *MIGFR* gene is used to construct a homologous recombination vector suitable for altering an endogenous *MIGFR* gene in the mouse genome. Detailed methodologies for homologous recombination in mice are available (see Capecchi, *Science* (1989) 244:1288-1292; Joyner *et al.*, *Nature* (1989) 338:153-156). Procedures for the production of non-rodent transgenic mammals and other animals are also available (Houdebine and Chourrout, *supra*; Pursel *et al.*, *Science* (1989) 244:1281-1288; Simms *et al.*, *Bio/Technology* (1988) 6:179-183). In a preferred embodiment, knock-out animals, such as mice harboring a knockout of a specific gene, may be used to produce antibodies against the human counterpart of the gene that has been knocked out (Claesson MH *et al.*, (1994) *Scan J Immunol* 40:257-264; Declercq PJ *et al.*, (1995) *J Biol Chem.* 270:8397-400).

In another embodiment, the transgenic animal is a "knock-in" animal having an alteration in its genome that results in altered expression (e.g., increased (including ectopic) or decreased expression) of the *MIGFR* gene, e.g., by introduction of additional copies of *MIGFR*, or by operatively inserting a regulatory sequence that provides for altered expression of an endogenous copy of the *MIGFR* gene. Such regulatory sequences include inducible, tissue-specific, and constitutive promoters and enhancer elements. The knock-in can be homozygous or heterozygous.

Transgenic nonhuman animals can also be produced that contain selected systems allowing for regulated expression of the transgene. One example of such a system that may be produced is the *cre/loxP* recombinase system of bacteriophage P1 (Lakso *et al.*, *PNAS* (1992) 89:6232-6236; U.S. Pat. No. 4,959,317). If a *cre/loxP* recombinase system is used to regulate expression of the transgene, animals containing transgenes encoding both the Cre recombinase and a selected protein are required. Such animals can be provided through the construction of "double" transgenic animals, e.g., by mating two

transgenic animals, one containing a transgene encoding a selected protein and the other containing a transgene encoding a recombinase. Another example of a recombinase system is the FLP recombinase system of *Saccharomyces cerevisiae* (O'Gorman et al. (1991) Science 251:1351-1355; U.S. Pat. No. 5,654,182). In a preferred embodiment, both Cre-LoxP and Flp-Frt are used in the same system to regulate expression of the transgene, and for sequential deletion of vector sequences in the same cell (Sun X et al (2000) Nat Genet 25:83-6).

The genetically modified animals can be used in genetic studies to further elucidate the IGFR pathway, as animal models of disease and disorders implicating defective IGFR function, and for *in vivo* testing of candidate therapeutic agents, such as those identified in screens described below. The candidate therapeutic agents are administered to a genetically modified animal having altered MIGFR function and phenotypic changes are compared with appropriate control animals such as genetically modified animals that receive placebo treatment, and/or animals with unaltered MIGFR expression that receive candidate therapeutic agent.

In addition to the above-described genetically modified animals having altered MIGFR function, animal models having defective IGFR function (and otherwise normal MIGFR function), can be used in the methods of the present invention. For example, a IGFR knockout mouse can be used to assess, *in vivo*, the activity of a candidate IGFR modulating agent identified in one of the *in vitro* assays described below. Preferably, the candidate IGFR modulating agent when administered to a model system with cells defective in IGFR function, produces a detectable phenotypic change in the model system indicating that the IGFR function is restored, i.e., the cells exhibit normal cell cycle progression.

Modulating Agents

The invention provides methods to identify agents that interact with and/or modulate the function of MIGFR and/or the IGFR pathway. Modulating agents identified by the methods are also part of the invention. Such agents are useful in a variety of diagnostic and therapeutic applications associated with the IGFR pathway, as well as in further analysis of the MIGFR protein and its contribution to the IGFR pathway. Accordingly,

the invention also provides methods for modulating the IGFR pathway comprising the step of specifically modulating MIGFR activity by administering a MIGFR-interacting or -modulating agent.

As used herein, an "MIGFR-modulating agent" is any agent that modulates MIGFR function, for example, an agent that interacts with MIGFR to inhibit or enhance MIGFR activity or otherwise affect normal MIGFR function. MIGFR function can be affected at any level, including transcription, protein expression, protein localization, and cellular or extra-cellular activity. In a preferred embodiment, the MIGFR - modulating agent specifically modulates the function of the MIGFR. The phrases "specific modulating agent", "specifically modulates", etc., are used herein to refer to modulating agents that directly bind to the MIGFR polypeptide or nucleic acid, and preferably inhibit, enhance, or otherwise alter, the function of the MIGFR. These phrases also encompass modulating agents that alter the interaction of the MIGFR with a binding partner, substrate, or cofactor (e.g. by binding to a binding partner of an MIGFR, or to a protein/binding partner complex, and altering MIGFR function). In a further preferred embodiment, the MIGFR- modulating agent is a modulator of the IGFR pathway (e.g. it restores and/or upregulates IGFR function) and thus is also a IGFR-modulating agent.

Preferred MIGFR-modulating agents include small molecule compounds; MIGFR-interacting proteins, including antibodies and other biotherapeutics; and nucleic acid modulators such as antisense and RNA inhibitors. The modulating agents may be formulated in pharmaceutical compositions, for example, as compositions that may comprise other active ingredients, as in combination therapy, and/or suitable carriers or excipients. Techniques for formulation and administration of the compounds may be found in "Remington's Pharmaceutical Sciences" Mack Publishing Co., Easton, PA, 19th edition.

Small molecule modulators

Small molecules are often preferred to modulate function of proteins with enzymatic function, and/or containing protein interaction domains. Chemical agents, referred to in the art as "small molecule" compounds are typically organic, non-peptide molecules, having a molecular weight up to 10,000, preferably up to 5,000, more preferably up to

1,000, and most preferably up to 500 daltons. This class of modulators includes chemically synthesized molecules, for instance, compounds from combinatorial chemical libraries. Synthetic compounds may be rationally designed or identified based on known or inferred properties of the MIGFR protein or may be identified by screening compound libraries. Alternative appropriate modulators of this class are natural products, particularly secondary metabolites from organisms such as plants or fungi, which can also be identified by screening compound libraries for MIGFR-modulating activity. Methods for generating and obtaining compounds are well known in the art (Schreiber SL, Science (2000) 151: 1964-1969; Radmann J and Gunther J, Science (2000) 151:1947-1948).

Small molecule modulators identified from screening assays, as described below, can be used as lead compounds from which candidate clinical compounds may be designed, optimized, and synthesized. Such clinical compounds may have utility in treating pathologies associated with the IGFR pathway. The activity of candidate small molecule modulating agents may be improved several-fold through iterative secondary functional validation, as further described below, structure determination, and candidate modulator modification and testing. Additionally, candidate clinical compounds are generated with specific regard to clinical and pharmacological properties. For example, the reagents may be derivatized and re-screened using *in vitro* and *in vivo* assays to optimize activity and minimize toxicity for pharmaceutical development.

Protein Modulators

Specific MIGFR-interacting proteins are useful in a variety of diagnostic and therapeutic applications related to the IGFR pathway and related disorders, as well as in validation assays for other MIGFR-modulating agents. In a preferred embodiment, MIGFR-interacting proteins affect normal MIGFR function, including transcription, protein expression, protein localization, and cellular or extra-cellular activity. In another embodiment, MIGFR-interacting proteins are useful in detecting and providing information about the function of MIGFR proteins, as is relevant to IGFR related disorders, such as cancer (e.g., for diagnostic means).

An MIGFR-interacting protein may be endogenous, i.e. one that naturally interacts genetically or biochemically with an MIGFR, such as a member of the MIGFR pathway that modulates MIGFR expression, localization, and/or activity. MIGFR-modulators include dominant negative forms of MIGFR-interacting proteins and of MIGFR proteins themselves. Yeast two-hybrid and variant screens offer preferred methods for identifying endogenous MIGFR-interacting proteins (Finley, R. L. et al. (1996) in *DNA Cloning-Expression Systems: A Practical Approach*, eds. Glover D. & Hames B. D (Oxford University Press, Oxford, England), pp. 169-203; Fashema SF et al., *Gene* (2000) 250:1-14; Drees BL *Curr Opin Chem Biol* (1999) 3:64-70; Vidal M and Legrain P *Nucleic Acids Res* (1999) 27:919-29; and U.S. Pat. No. 5,928,868). Mass spectrometry is an alternative preferred method for the elucidation of protein complexes (reviewed in, e.g., Pandley A and Mann M, *Nature* (2000) 405:837-846; Yates JR 3rd, *Trends Genet* (2000) 16:5-8).

An MIGFR-interacting protein may be an exogenous protein, such as an MIGFR-specific antibody or a T-cell antigen receptor (see, e.g., Harlow and Lane (1988) *Antibodies, A Laboratory Manual*, Cold Spring Harbor Laboratory; Harlow and Lane (1999) *Using antibodies: a laboratory manual*. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press). MIGFR antibodies are further discussed below.

In preferred embodiments, an MIGFR-interacting protein specifically binds an MIGFR protein. In alternative preferred embodiments, an MIGFR-modulating agent binds an MIGFR substrate, binding partner, or cofactor.

Antibodies

In another embodiment, the protein modulator is an MIGFR specific antibody agonist or antagonist. The antibodies have therapeutic and diagnostic utilities, and can be used in screening assays to identify MIGFR modulators. The antibodies can also be used in dissecting the portions of the MIGFR pathway responsible for various cellular responses and in the general processing and maturation of the MIGFR.

Antibodies that specifically bind MIGFR polypeptides can be generated using known methods. Preferably the antibody is specific to a mammalian ortholog of MIGFR polypeptide, and more preferably, to human MIGFR. Antibodies may be polyclonal,

monoclonal (mAbs), humanized or chimeric antibodies, single chain antibodies, Fab fragments, F(ab')₂ fragments, fragments produced by a FAb expression library, anti-idiotypic (anti-Id) antibodies, and epitope-binding fragments of any of the above. Epitopes of MIGFR which are particularly antigenic can be selected, for example, by routine screening of MIGFR polypeptides for antigenicity or by applying a theoretical method for selecting antigenic regions of a protein (Hopp and Wood (1981), Proc. Natl. Acad. Sci. U.S.A. 78:3824-28; Hopp and Wood, (1983) Mol. Immunol. 20:483-89; Sutcliffe et al., (1983) Science 219:660-66) to the amino acid sequence of an MIGFR. Monoclonal antibodies with affinities of 10^8 M^{-1} preferably 10^9 M^{-1} to 10^{10} M^{-1} , or stronger can be made by standard procedures as described (Harlow and Lane, *supra*; Goding (1986) Monoclonal Antibodies: Principles and Practice (2d ed) Academic Press, New York; and U.S. Pat. Nos. 4,381,292; 4,451,570; and 4,618,577). Antibodies may be generated against crude cell extracts of MIGFR or substantially purified fragments thereof. If MIGFR fragments are used, they preferably comprise at least 10, and more preferably, at least 20 contiguous amino acids of an MIGFR protein. In a particular embodiment, MIGFR-specific antigens and/or immunogens are coupled to carrier proteins that stimulate the immune response. For example, the subject polypeptides are covalently coupled to the keyhole limpet hemocyanin (KLH) carrier, and the conjugate is emulsified in Freund's complete adjuvant, which enhances the immune response. An appropriate immune system such as a laboratory rabbit or mouse is immunized according to conventional protocols.

The presence of MIGFR-specific antibodies is assayed by an appropriate assay such as a solid phase enzyme-linked immunosorbant assay (ELISA) using immobilized corresponding MIGFR polypeptides. Other assays, such as radioimmunoassays or fluorescent assays might also be used.

Chimeric antibodies specific to MIGFR polypeptides can be made that contain different portions from different animal species. For instance, a human immunoglobulin constant region may be linked to a variable region of a murine mAb, such that the antibody derives its biological activity from the human antibody, and its binding specificity from the murine fragment. Chimeric antibodies are produced by splicing together genes that encode the appropriate regions from each species (Morrison et al.,

Proc. Natl. Acad. Sci. (1984) 81:6851-6855; Neuberger et al., Nature (1984) 312:604-608; Takeda et al., Nature (1985) 31:452-454). Humanized antibodies, which are a form of chimeric antibodies, can be generated by grafting complementary-determining regions (CDRs) (Carlos, T. M., J. M. Harlan. 1994. Blood 84:2068-2101) of mouse antibodies into a background of human framework regions and constant regions by recombinant DNA technology (Riechmann LM, et al., 1988 Nature 323: 323-327). Humanized antibodies contain ~10% murine sequences and ~90% human sequences, and thus further reduce or eliminate immunogenicity, while retaining the antibody specificities (Co MS, and Queen C. 1991 Nature 351: 501-501; Morrison SL. 1992 Ann. Rev. Immun. 10:239-265). Humanized antibodies and methods of their production are well-known in the art (U.S. Pat. Nos. 5,530,101, 5,585,089, 5,693,762, and 6,180,370).

MIGFR-specific single chain antibodies which are recombinant, single chain polypeptides formed by linking the heavy and light chain fragments of the Fv regions via an amino acid bridge, can be produced by methods known in the art (U.S. Pat. No. 4,946,778; Bird, Science (1988) 242:423-426; Huston et al., Proc. Natl. Acad. Sci. USA (1988) 85:5879-5883; and Ward et al., Nature (1989) 334:544-546).

Other suitable techniques for antibody production involve in vitro exposure of lymphocytes to the antigenic polypeptides or alternatively to selection of libraries of antibodies in phage or similar vectors (Huse et al., Science (1989) 246:1275-1281). As used herein, T-cell antigen receptors are included within the scope of antibody modulators (Harlow and Lane, 1988, *supra*).

The polypeptides and antibodies of the present invention may be used with or without modification. Frequently, antibodies will be labeled by joining, either covalently or non-covalently, a substance that provides for a detectable signal, or that is toxic to cells that express the targeted protein (Menard S, et al., Int J. Biol Markers (1989) 4:131-134). A wide variety of labels and conjugation techniques are known and are reported extensively in both the scientific and patent literature. Suitable labels include radionuclides, enzymes, substrates, cofactors, inhibitors, fluorescent moieties, fluorescent emitting lanthanide metals, chemiluminescent moieties, bioluminescent moieties, magnetic particles, and the like (U.S. Pat. Nos. 3,817,837; 3,850,752; 3,939,350; 3,996,345; 4,277,437; 4,275,149; and 4,366,241). Also, recombinant immunoglobulins may be

produced (U.S. Pat. No. 4,816,567). Antibodies to cytoplasmic polypeptides may be delivered and reach their targets by conjugation with membrane-penetrating toxin proteins (U.S. Pat. No. 6,086,900).

When used therapeutically in a patient, the antibodies of the subject invention are typically administered parenterally, when possible at the target site, or intravenously. The therapeutically effective dose and dosage regimen is determined by clinical studies. Typically, the amount of antibody administered is in the range of about 0.1 mg/kg –to about 10 mg/kg of patient weight. For parenteral administration, the antibodies are formulated in a unit dosage injectable form (e.g., solution, suspension, emulsion) in association with a pharmaceutically acceptable vehicle. Such vehicles are inherently nontoxic and non-therapeutic. Examples are water, saline, Ringer's solution, dextrose solution, and 5% human serum albumin. Nonaqueous vehicles such as fixed oils, ethyl oleate, or liposome carriers may also be used. The vehicle may contain minor amounts of additives, such as buffers and preservatives, which enhance isotonicity and chemical stability or otherwise enhance therapeutic potential. The antibodies' concentrations in such vehicles are typically in the range of about 1 mg/ml to about 10 mg/ml. Immunotherapeutic methods are further described in the literature (US Pat. No. 5,859,206; WO0073469).

Specific biotherapeutics

In a preferred embodiment, an MIGFR-interacting protein may have biotherapeutic applications. Biotherapeutic agents formulated in pharmaceutically acceptable carriers and dosages may be used to activate or inhibit signal transduction pathways. This modulation may be accomplished by binding a ligand, thus inhibiting the activity of the pathway; or by binding a receptor, either to inhibit activation of, or to activate, the receptor. Alternatively, the biotherapeutic may itself be a ligand capable of activating or inhibiting a receptor. Biotherapeutic agents and methods of producing them are described in detail in U.S. Pat. No. 6,146,628.

When the MIGFR is a ligand, it may be used as a biotherapeutic agent to activate or inhibit its natural receptor. Alternatively, antibodies against MIGFR, as described in the previous section, may be used as biotherapeutic agents.

When the MIGFR is a receptor, its ligand(s), antibodies to the ligand(s) or the MIGFR itself may be used as biotherapeutics to modulate the activity of MIGFR in the IGFR pathway.

Nucleic Acid Modulators

Other preferred MIGFR-modulating agents comprise nucleic acid molecules, such as antisense oligomers or double stranded RNA (dsRNA), which generally inhibit MIGFR activity. Preferred nucleic acid modulators interfere with the function of the MIGFR nucleic acid such as DNA replication, transcription, translocation of the MIGFR RNA to the site of protein translation, translation of protein from the MIGFR RNA, splicing of the MIGFR RNA to yield one or more mRNA species, or catalytic activity which may be engaged in or facilitated by the MIGFR RNA.

In one embodiment, the antisense oligomer is an oligonucleotide that is sufficiently complementary to an MIGFR mRNA to bind to and prevent translation, preferably by binding to the 5' untranslated region. MIGFR-specific antisense oligonucleotides, preferably range from at least 6 to about 200 nucleotides. In some embodiments the oligonucleotide is preferably at least 10, 15, or 20 nucleotides in length. In other embodiments, the oligonucleotide is preferably less than 50, 40, or 30 nucleotides in length. The oligonucleotide can be DNA or RNA or a chimeric mixture or derivatives or modified versions thereof, single-stranded or double-stranded. The oligonucleotide can be modified at the base moiety, sugar moiety, or phosphate backbone. The oligonucleotide may include other appending groups such as peptides, agents that facilitate transport across the cell membrane, hybridization-triggered cleavage agents, and intercalating agents.

In another embodiment, the antisense oligomer is a phosphothioate morpholino oligomer (PMO). PMOs are assembled from four different morpholino subunits, each of which contain one of four genetic bases (A, C, G, or T) linked to a six-membered morpholine ring. Polymers of these subunits are joined by non-ionic phosphodiarnidate intersubunit linkages. Details of how to make and use PMOs and other antisense oligomers are well known in the art (e.g. see WO99/18193; Probst JC, Antisense Oligodeoxynucleotide and Ribozyme Design, Methods. (2000) 22(3):271-281;

Summerton J, and Weller D. 1997 Antisense Nucleic Acid Drug Dev. :7:187-95; US Pat. No. 5,235,033; and US Pat No. 5,378,841).

Alternative preferred MIGFR nucleic acid modulators are double-stranded RNA species mediating RNA interference (RNAi). RNAi is the process of sequence-specific, post-transcriptional gene silencing in animals and plants, initiated by double-stranded RNA (dsRNA) that is homologous in sequence to the silenced gene. Methods relating to the use of RNAi to silence genes in *C. elegans*, *Drosophila*, plants, and humans are known in the art (Fire A, et al., 1998 Nature 391:806-811; Fire, A. Trends Genet. 15, 358-363 (1999); Sharp, P. A. RNA interference 2001. Genes Dev. 15, 485-490 (2001); Hammond, S. M., et al., Nature Rev. Genet. 2, 110-1119 (2001); Tuschl, T. Chem. Biochem. 2, 239-245 (2001); Hamilton, A. et al., Science 286, 950-952 (1999); Hammond, S. M., et al., Nature 404, 293-296 (2000); Zamore, P. D., et al., Cell 101, 25-33 (2000); Bernstein, E., et al., Nature 409, 363-366 (2001); Elbashir, S. M., et al., Genes Dev. 15, 188-200 (2001); WO0129058; WO9932619; Elbashir SM, et al., 2001 Nature 411:494-498).

Nucleic acid modulators are commonly used as research reagents, diagnostics, and therapeutics. For example, antisense oligonucleotides, which are able to inhibit gene expression with exquisite specificity, are often used to elucidate the function of particular genes (see, for example, U.S. Pat. No. 6,165,790). Nucleic acid modulators are also used, for example, to distinguish between functions of various members of a biological pathway. For example, antisense oligomers have been employed as therapeutic moieties in the treatment of disease states in animals and man and have been demonstrated in numerous clinical trials to be safe and effective (Milligan JF, *et al.*, Current Concepts in Antisense Drug Design, J Med Chem. (1993) 36:1923-1937; Tonkinson JL *et al.*, Antisense Oligodeoxynucleotides as Clinical Therapeutic Agents, Cancer Invest. (1996) 14:54-65). Accordingly, in one aspect of the invention, an MIGFR-specific nucleic acid modulator is used in an assay to further elucidate the role of the MIGFR in the IGF1R pathway, and/or its relationship to other members of the pathway. In another aspect of the invention, an MIGFR-specific antisense oligomer is used as a therapeutic agent for treatment of IGF1R-related disease states.

Assay Systems

The invention provides assay systems and screening methods for identifying specific modulators of MIGFR activity. As used herein, an "assay system" encompasses all the components required for performing and analyzing results of an assay that detects and/or measures a particular event. In general, primary assays are used to identify or confirm a modulator's specific biochemical or molecular effect with respect to the MIGFR nucleic acid or protein. In general, secondary assays further assess the activity of a MIGFR modulating agent identified by a primary assay and may confirm that the modulating agent affects MIGFR in a manner relevant to the IGFR pathway. In some cases, MIGFR modulators will be directly tested in a secondary assay.

In a preferred embodiment, the screening method comprises contacting a suitable assay system comprising an MIGFR polypeptide or nucleic acid with a candidate agent under conditions whereby, but for the presence of the agent, the system provides a reference activity (e.g. binding activity), which is based on the particular molecular event the screening method detects. A statistically significant difference between the agent-biased activity and the reference activity indicates that the candidate agent modulates MIGFR activity, and hence the IGFR pathway. The MIGFR polypeptide or nucleic acid used in the assay may comprise any of the nucleic acids or polypeptides described above.

Primary Assays

The type of modulator tested generally determines the type of primary assay.

Primary assays for small molecule modulators

For small molecule modulators, screening assays are used to identify candidate modulators. Screening assays may be cell-based or may use a cell-free system that recreates or retains the relevant biochemical reaction of the target protein (reviewed in Sittampalam GS *et al.*, Curr Opin Chem Biol (1997) 1:384-91 and accompanying references). As used herein the term "cell-based" refers to assays using live cells, dead cells, or a particular cellular fraction, such as a membrane, endoplasmic reticulum, or mitochondrial fraction. The term "cell free" encompasses assays using substantially purified protein (either endogenous or recombinantly produced), partially purified or

crude cellular extracts. Screening assays may detect a variety of molecular events, including protein-DNA interactions, protein-protein interactions (*e.g.*, receptor-ligand binding), transcriptional activity (*e.g.*, using a reporter gene), enzymatic activity (*e.g.*, via a property of the substrate), activity of second messengers, immunogenicity and changes in cellular morphology or other cellular characteristics. Appropriate screening assays may use a wide range of detection methods including fluorescent, radioactive, colorimetric, spectrophotometric, and amperometric methods, to provide a read-out for the particular molecular event detected.

Cell-based screening assays usually require systems for recombinant expression of MIGFR and any auxiliary proteins demanded by the particular assay. Appropriate methods for generating recombinant proteins produce sufficient quantities of proteins that retain their relevant biological activities and are of sufficient purity to optimize activity and assure assay reproducibility. Yeast two-hybrid and variant screens, and mass spectrometry provide preferred methods for determining protein-protein interactions and elucidation of protein complexes. In certain applications, when MIGFR-interacting proteins are used in screens to identify small molecule modulators, the binding specificity of the interacting protein to the MIGFR protein may be assayed by various known methods such as substrate processing (*e.g.* ability of the candidate MIGFR-specific binding agents to function as negative effectors in MIGFR-expressing cells), binding equilibrium constants (usually at least about 10^7 M^{-1} , preferably at least about 10^8 M^{-1} , more preferably at least about 10^9 M^{-1}), and immunogenicity (*e.g.* ability to elicit MIGFR specific antibody in a heterologous host such as a mouse, rat, goat or rabbit). For enzymes and receptors, binding may be assayed by, respectively, substrate and ligand processing.

The screening assay may measure a candidate agent's ability to specifically bind to or modulate activity of a MIGFR polypeptide, a fusion protein thereof, or to cells or membranes bearing the polypeptide or fusion protein. The MIGFR polypeptide can be full length or a fragment thereof that retains functional MIGFR activity. The MIGFR polypeptide may be fused to another polypeptide, such as a peptide tag for detection or anchoring, or to another tag. The MIGFR polypeptide is preferably human MIGFR, or is an ortholog or derivative thereof as described above. In a preferred embodiment, the

screening assay detects candidate agent-based modulation of MIGFR interaction with a binding target, such as an endogenous or exogenous protein or other substrate that has MIGFR –specific binding activity, and can be used to assess normal MIGFR gene function.

Suitable assay formats that may be adapted to screen for MIGFR modulators are known in the art. Preferred screening assays are high throughput or ultra high throughput and thus provide automated, cost-effective means of screening compound libraries for lead compounds (Fernandes PB, *Curr Opin Chem Biol* (1998) 2:597-603; Sundberg SA, *Curr Opin Biotechnol* 2000, 11:47-53). In one preferred embodiment, screening assays uses fluorescence technologies, including fluorescence polarization, time-resolved fluorescence, and fluorescence resonance energy transfer. These systems offer means to monitor protein-protein or DNA-protein interactions in which the intensity of the signal emitted from dye-labeled molecules depends upon their interactions with partner molecules (*e.g.*, Selvin PR, *Nat Struct Biol* (2000) 7:730-4; Fernandes PB, *supra*; Hertzberg RP and Pope AJ, *Curr Opin Chem Biol* (2000) 4:445-451).

A variety of suitable assay systems may be used to identify candidate MIGFR and IGFR pathway modulators (*e.g.* U.S. Pat. No. 6,165,992 (kinase assays); U.S. Pat. Nos. 5,550,019 and 6,133,437 (apoptosis assays); U.S. Pat. No. 6,114,132 (phosphatase and protease assays), U.S. Pat. Nos. 5,976,782, 6,225,118 and 6,444,434 (angiogenesis assays), among others). Specific preferred assays are described in more detail below.

Protein kinases, key signal transduction proteins that may be either membrane-associated or intracellular, catalyze the transfer of gamma phosphate from adenosine triphosphate (ATP) to a serine, threonine or tyrosine residue in a protein substrate. Radioassays, which monitor the transfer from [γ - ^{32}P or ^{33}P]ATP, are frequently used to assay kinase activity. For instance, a scintillation assay for p56 (lck) kinase activity monitors the transfer of the gamma phosphate from [γ - ^{33}P] ATP to a biotinylated peptide substrate. The substrate is captured on a streptavidin coated bead that transmits the signal (Beveridge M *et al.*, *J Biomol Screen* (2000) 5:205-212). This assay uses the scintillation proximity assay (SPA), in which only radio-ligand bound to receptors tethered to the surface of an SPA bead are detected by the scintillant immobilized within it, allowing binding to be measured without separation of bound from

free ligand. Other assays for protein kinase activity may use antibodies that specifically recognize phosphorylated substrates. For instance, the kinase receptor activation (KIRA) assay measures receptor tyrosine kinase activity by ligand stimulating the intact receptor in cultured cells, then capturing solubilized receptor with specific antibodies and quantifying phosphorylation via phosphotyrosine ELISA (Sadick MD, Dev Biol Stand (1999) 97:121-133). Another example of antibody based assays for protein kinase activity is TRF (time-resolved fluorometry). This method utilizes europium chelate-labeled anti-phosphotyrosine antibodies to detect phosphate transfer to a polymeric substrate coated onto microtiter plate wells. The amount of phosphorylation is then detected using time-resolved, dissociation-enhanced fluorescence (Braunwalder AF, et al., Anal Biochem 1996 Jul 1;238(2):159-64).

Protein phosphatases catalyze the removal of a gamma phosphate from a serine, threonine or tyrosine residue in a protein substrate. Since phosphatases act in opposition to kinases, appropriate assays measure the same parameters as kinase assays. In one example, the dephosphorylation of a fluorescently labeled peptide substrate allows trypsin cleavage of the substrate, which in turn renders the cleaved substrate significantly more fluorescent (Nishikata M *et al.*, Biochem J (1999) 343:35-391). In another example, fluorescence polarization (FP), a solution-based, homogeneous technique requiring no immobilization or separation of reaction components, is used to develop high throughput screening (HTS) assays for protein phosphatases. This assay uses direct binding of the phosphatase with the target, and increasing concentrations of target-phosphatase increase the rate of dephosphorylation, leading to a change in polarization (Parker GJ et al., (2000) J Biomol Screen 5:77-88).

High-throughput assays, such as scintillation proximity assays, for synthase enzymes involved in fatty acid synthesis are known in the art (He X et al (2000) Anal Biochem 2000 Jun 15;282(1):107-14).

Apoptosis assays. Assays for apoptosis may be performed by terminal deoxynucleotidyl transferase-mediated digoxigenin-11-dUTP nick end labeling (TUNEL) assay. The TUNEL assay is used to measure nuclear DNA fragmentation characteristic of apoptosis (Lazebnik *et al.*, 1994, Nature 371, 346), by following the incorporation of

fluorescein-dUTP (Yonehara *et al.*, 1989, J. Exp. Med. 169, 1747). Apoptosis may further be assayed by acridine orange staining of tissue culture cells (Lucas, R., et al., 1998, Blood 15:4730-41). Other cell-based apoptosis assays include the caspase-3/7 assay and the cell death nucleosome ELISA assay. The caspase 3/7 assay is based on the activation of the caspase cleavage activity as part of a cascade of events that occur during programmed cell death in many apoptotic pathways. In the caspase 3/7 assay (commercially available Apo-ONE™ Homogeneous Caspase-3/7 assay from Promega, cat# 67790), lysis buffer and caspase substrate are mixed and added to cells. The caspase substrate becomes fluorescent when cleaved by active caspase 3/7. The nucleosome ELISA assay is a general cell death assay known to those skilled in the art, and available commercially (Roche, Cat# 1774425). This assay is a quantitative sandwich-enzyme-immunoassay which uses monoclonal antibodies directed against DNA and histones respectively, thus specifically determining amount of mono- and oligonucleosomes in the cytoplasmic fraction of cell lysates. Mono and oligonucleosomes are enriched in the cytoplasm during apoptosis due to the fact that DNA fragmentation occurs several hours before the plasma membrane breaks down, allowing for accumulation in the cytoplasm. Nucleosomes are not present in the cytoplasmic fraction of cells that are not undergoing apoptosis. An apoptosis assay system may comprise a cell that expresses an MIGFR, and that optionally has defective IGFR function (e.g. IGFR is over-expressed or under-expressed relative to wild-type cells). A test agent can be added to the apoptosis assay system and changes in induction of apoptosis relative to controls where no test agent is added, identify candidate IGFR modulating agents. In some embodiments of the invention, an apoptosis assay may be used as a secondary assay to test a candidate IGFR modulating agents that is initially identified using a cell-free assay system. An apoptosis assay may also be used to test whether MIGFR function plays a direct role in apoptosis. For example, an apoptosis assay may be performed on cells that over- or under-express MIGFR relative to wild type cells. Differences in apoptotic response compared to wild type cells suggests that the MIGFR plays a direct role in the apoptotic response. Apoptosis assays are described further in US Pat. No. 6,133,437.

Cell proliferation and cell cycle assays. Cell proliferation may be assayed via bromodeoxyuridine (BRDU) incorporation. This assay identifies a cell population undergoing DNA synthesis by incorporation of BRDU into newly-synthesized DNA. Newly-synthesized DNA may then be detected using an anti-BRDU antibody (Hoshino *et al.*, 1986, *Int. J. Cancer* 38, 369; Campana *et al.*, 1988, *J. Immunol. Meth.* 107, 79), or by other means.

Cell proliferation is also assayed via phospho-histone H3 staining, which identifies a cell population undergoing mitosis by phosphorylation of histone H3. Phosphorylation of histone H3 at serine 10 is detected using an antibody specific to the phosphorylated form of the serine 10 residue of histone H3. (Chadlee, D.N. 1995, *J. Biol. Chem* 270:20098-105). Cell Proliferation may also be examined using [³H]-thymidine incorporation (Chen, J., 1996, *Oncogene* 13:1395-403; Jeoung, J., 1995, *J. Biol. Chem.* 270:18367-73). This assay allows for quantitative characterization of S-phase DNA syntheses. In this assay, cells synthesizing DNA will incorporate [³H]-thymidine into newly synthesized DNA. Incorporation can then be measured by standard techniques such as by counting of radioisotope in a scintillation counter (e.g., Beckman LS 3800 Liquid Scintillation Counter). Another proliferation assay uses the dye Alamar Blue (available from Biosource International), which fluoresces when reduced in living cells and provides an indirect measurement of cell number (Voytik-Harbin SL *et al.*, 1998, *In Vitro Cell Dev Biol Anim* 34:239-46). Yet another proliferation assay, the MTS assay, is based on in vitro cytotoxicity assessment of industrial chemicals, and uses the soluble tetrazolium salt, MTS. MTS assays are commercially available, for example, the Promega CellTiter 96® Aqueous Non-Radioactive Cell Proliferation Assay (Cat.# G5421).

Cell proliferation may also be assayed by colony formation in soft agar (Sambrook *et al.*, *Molecular Cloning*, Cold Spring Harbor (1989)). For example, cells transformed with MIGR are seeded in soft agar plates, and colonies are measured and counted after two weeks incubation.

Cell proliferation may also be assayed by measuring ATP levels as indicator of metabolically active cells. Such assays are commercially available, for example Cell Titer-Glo™, which is a luminescent homogeneous assay available from Promega.

Involvement of a gene in the cell cycle may be assayed by flow cytometry (Gray JW et al. (1986) *Int J Radiat Biol Relat Stud Phys Chem Med* 49:237-55). Cells transfected with an MIGFR may be stained with propidium iodide and evaluated in a flow cytometer (available from Becton Dickinson), which indicates accumulation of cells in different stages of the cell cycle.

Accordingly, a cell proliferation or cell cycle assay system may comprise a cell that expresses an MIGFR, and that optionally has defective IGFR function (e.g. IGFR is over-expressed or under-expressed relative to wild-type cells). A test agent can be added to the assay system and changes in cell proliferation or cell cycle relative to controls where no test agent is added, identify candidate IGFR modulating agents. In some embodiments of the invention, the cell proliferation or cell cycle assay may be used as a secondary assay to test a candidate IGFR modulating agents that is initially identified using another assay system such as a cell-free assay system. A cell proliferation assay may also be used to test whether MIGFR function plays a direct role in cell proliferation or cell cycle. For example, a cell proliferation or cell cycle assay may be performed on cells that over- or under-express MIGFR relative to wild type cells. Differences in proliferation or cell cycle compared to wild type cells suggests that the MIGFR plays a direct role in cell proliferation or cell cycle.

Angiogenesis. Angiogenesis may be assayed using various human endothelial cell systems, such as umbilical vein, coronary artery, or dermal cells. Suitable assays include Alamar Blue based assays (available from Biosource International) to measure proliferation; migration assays using fluorescent molecules, such as the use of Becton Dickinson Falcon HTS FluoroBlock cell culture inserts to measure migration of cells through membranes in presence or absence of angiogenesis enhancer or suppressors; and tubule formation assays based on the formation of tubular structures by endothelial cells on Matrigel® (Becton Dickinson). Accordingly, an angiogenesis assay system may comprise a cell that expresses an MIGFR, and that optionally has defective IGFR function (e.g. IGFR is over-expressed or under-expressed relative to wild-type cells). A test agent can be added to the angiogenesis assay system and changes in angiogenesis relative to controls where no test agent is added, identify candidate IGFR modulating

agents. In some embodiments of the invention, the angiogenesis assay may be used as a secondary assay to test a candidate IGFR modulating agents that is initially identified using another assay system. An angiogenesis assay may also be used to test whether MIGFR function plays a direct role in cell proliferation. For example, an angiogenesis assay may be performed on cells that over- or under-express MIGFR relative to wild type cells. Differences in angiogenesis compared to wild type cells suggests that the MIGFR plays a direct role in angiogenesis. U.S. Pat. Nos. 5,976,782, 6,225,118 and 6,444,434, among others, describe various angiogenesis assays.

Hypoxic induction. The alpha subunit of the transcription factor, hypoxia inducible factor-1 (HIF-1), is upregulated in tumor cells following exposure to hypoxia in vitro. Under hypoxic conditions, HIF-1 stimulates the expression of genes known to be important in tumour cell survival, such as those encoding glycolytic enzymes and VEGF. Induction of such genes by hypoxic conditions may be assayed by growing cells transfected with MIGFR in hypoxic conditions (such as with 0.1% O₂, 5% CO₂, and balance N₂, generated in a Napco 7001 incubator (Precision Scientific)) and normoxic conditions, followed by assessment of gene activity or expression by Taqman®. For example, a hypoxic induction assay system may comprise a cell that expresses an MIGFR, and that optionally has defective IGFR function (e.g. IGFR is over-expressed or under-expressed relative to wild-type cells). A test agent can be added to the hypoxic induction assay system and changes in hypoxic response relative to controls where no test agent is added, identify candidate IGFR modulating agents. In some embodiments of the invention, the hypoxic induction assay may be used as a secondary assay to test a candidate IGFR modulating agents that is initially identified using another assay system. A hypoxic induction assay may also be used to test whether MIGFR function plays a direct role in the hypoxic response. For example, a hypoxic induction assay may be performed on cells that over- or under-express MIGFR relative to wild type cells. Differences in hypoxic response compared to wild type cells suggests that the MIGFR plays a direct role in hypoxic induction.

Cell adhesion. Cell adhesion assays measure adhesion of cells to purified adhesion proteins, or adhesion of cells to each other, in presence or absence of candidate modulating agents. Cell-protein adhesion assays measure the ability of agents to modulate the adhesion of cells to purified proteins. For example, recombinant proteins are produced, diluted to 2.5g/mL in PBS, and used to coat the wells of a microtiter plate. The wells used for negative control are not coated. Coated wells are then washed, blocked with 1% BSA, and washed again. Compounds are diluted to 2× final test concentration and added to the blocked, coated wells. Cells are then added to the wells, and the unbound cells are washed off. Retained cells are labeled directly on the plate by adding a membrane-permeable fluorescent dye, such as calcein-AM, and the signal is quantified in a fluorescent microplate reader.

Cell-cell adhesion assays measure the ability of agents to modulate binding of cell adhesion proteins with their native ligands. These assays use cells that naturally or recombinantly express the adhesion protein of choice. In an exemplary assay, cells expressing the cell adhesion protein are plated in wells of a multiwell plate. Cells expressing the ligand are labeled with a membrane-permeable fluorescent dye, such as BCECF, and allowed to adhere to the monolayers in the presence of candidate agents. Unbound cells are washed off, and bound cells are detected using a fluorescence plate reader.

High-throughput cell adhesion assays have also been described. In one such assay, small molecule ligands and peptides are bound to the surface of microscope slides using a microarray spotter, intact cells are then contacted with the slides, and unbound cells are washed off. In this assay, not only the binding specificity of the peptides and modulators against cell lines are determined, but also the functional cell signaling of attached cells using immunofluorescence techniques in situ on the microchip is measured (Falsey JR et al., Bioconjug Chem. 2001 May-Jun;12(3):346-53).

Tubulogenesis. Tubulogenesis assays monitor the ability of cultured cells, generally endothelial cells, to form tubular structures on a matrix substrate, which generally simulates the environment of the extracellular matrix. Exemplary substrates include Matrigel™ (Becton Dickinson), an extract of basement membrane proteins

containing laminin, collagen IV, and heparin sulfate proteoglycan, which is liquid at 4°C and forms a solid gel at 37°C. Other suitable matrices comprise extracellular components such as collagen, fibronectin, and/or fibrin. Cells are stimulated with a pro-angiogenic stimulant, and their ability to form tubules is detected by imaging. Tubules can generally be detected after an overnight incubation with stimuli, but longer or shorter time frames may also be used. Tube formation assays are well known in the art (e.g., Jones MK et al., 1999, *Nature Medicine* 5:1418-1423). These assays have traditionally involved stimulation with serum or with the growth factors FGF or VEGF. Serum represents an undefined source of growth factors. In a preferred embodiment, the assay is performed with cells cultured in serum free medium, in order to control which process or pathway a candidate agent modulates. Moreover, we have found that different target genes respond differently to stimulation with different pro-angiogenic agents, including inflammatory angiogenic factors such as TNF- α . Thus, in a further preferred embodiment, a tubulogenesis assay system comprises testing an MIGFR's response to a variety of factors, such as FGF, VEGF, phorbol myristate acetate (PMA), TNF- α , ephrin, etc.

Cell Migration. An invasion/migration assay (also called a migration assay) tests the ability of cells to overcome a physical barrier and to migrate towards pro-angiogenic signals. Migration assays are known in the art (e.g., Paik JH et al., 2001, *J Biol Chem* 276:11830-11837). In a typical experimental set-up, cultured endothelial cells are seeded onto a matrix-coated porous lamina, with pore sizes generally smaller than typical cell size. The matrix generally simulates the environment of the extracellular matrix, as described above. The lamina is typically a membrane, such as the transwell polycarbonate membrane (Corning Costar Corporation, Cambridge, MA), and is generally part of an upper chamber that is in fluid contact with a lower chamber containing pro-angiogenic stimuli. Migration is generally assayed after an overnight incubation with stimuli, but longer or shorter time frames may also be used. Migration is assessed as the number of cells that crossed the lamina, and may be detected by staining cells with hemotoxylin solution (VWR Scientific, South San Francisco, CA), or by any other method for determining cell number. In another exemplary set up, cells are

fluorescently labeled and migration is detected using fluorescent readings, for instance using the Falcon HTS FluoroBlok (Becton Dickinson). While some migration is observed in the absence of stimulus, migration is greatly increased in response to pro-angiogenic factors. As described above, a preferred assay system for migration/invasion assays comprises testing an MIGFR's response to a variety of pro-angiogenic factors, including tumor angiogenic and inflammatory angiogenic agents, and culturing the cells in serum free medium.

Sprouting assay. A sprouting assay is a three-dimensional *in vitro* angiogenesis assay that uses a cell-number defined spheroid aggregation of endothelial cells ("spheroid"), embedded in a collagen gel-based matrix. The spheroid can serve as a starting point for the sprouting of capillary-like structures by invasion into the extracellular matrix (termed "cell sprouting") and the subsequent formation of complex anastomosing networks (Korff and Augustin, 1999, J Cell Sci 112:3249-58). In an exemplary experimental set-up, spheroids are prepared by pipetting 400 human umbilical vein endothelial cells into individual wells of a nonadhesive 96-well plates to allow overnight spheroidal aggregation (Korff and Augustin: J Cell Biol 143: 1341-52, 1998). Spheroids are harvested and seeded in 900 μ l of methocel-collagen solution and pipetted into individual wells of a 24 well plate to allow collagen gel polymerization. Test agents are added after 30 min by pipetting 100 μ l of 10-fold concentrated working dilution of the test substances on top of the gel. Plates are incubated at 37°C for 24h. Dishes are fixed at the end of the experimental incubation period by addition of paraformaldehyde. Sprouting intensity of endothelial cells can be quantitated by an automated image analysis system to determine the cumulative sprout length per spheroid.

Primary assays for antibody modulators

For antibody modulators, appropriate primary assays test is a binding assay that tests the antibody's affinity to and specificity for the MIGFR protein. Methods for testing antibody affinity and specificity are well known in the art (Harlow and Lane, 1988, 1999, *supra*). The enzyme-linked immunosorbant assay (ELISA) is a preferred method for

detecting MIGFR-specific antibodies; others include FACS assays, radioimmunoassays, and fluorescent assays.

In some cases, screening assays described for small molecule modulators may also be used to test antibody modulators.

Primary assays for nucleic acid modulators

For nucleic acid modulators, primary assays may test the ability of the nucleic acid modulator to inhibit or enhance MIGFR gene expression, preferably mRNA expression. In general, expression analysis comprises comparing MIGFR expression in like populations of cells (*e.g.*, two pools of cells that endogenously or recombinantly express MIGFR) in the presence and absence of the nucleic acid modulator. Methods for analyzing mRNA and protein expression are well known in the art. For instance, Northern blotting, slot blotting, ribonuclease protection, quantitative RT-PCR (*e.g.*, using the TaqMan®, PE Applied Biosystems), or microarray analysis may be used to confirm that MIGFR mRNA expression is reduced in cells treated with the nucleic acid modulator (*e.g.*, Current Protocols in Molecular Biology (1994) Ausubel FM *et al.*, eds., John Wiley & Sons, Inc., chapter 4; Freeman WM *et al.*, Biotechniques (1999) 26:112-125; Kallioniemi OP, Ann Med 2001, 33:142-147; Blohm DH and Guiseppi-Elie, A Curr Opin Biotechnol 2001, 12:41-47). Protein expression may also be monitored. Proteins are most commonly detected with specific antibodies or antisera directed against either the MIGFR protein or specific peptides. A variety of means including Western blotting, ELISA, or in situ detection, are available (Harlow E and Lane D, 1988 and 1999, *supra*).

In some cases, screening assays described for small molecule modulators, particularly in assay systems that involve MIGFR mRNA expression, may also be used to test nucleic acid modulators.

Secondary Assays

Secondary assays may be used to further assess the activity of MIGFR-modulating agent identified by any of the above methods to confirm that the modulating agent affects MIGFR in a manner relevant to the IGFR pathway. As used herein, MIGFR-modulating agents encompass candidate clinical compounds or other agents derived from previously

identified modulating agent. Secondary assays can also be used to test the activity of a modulating agent on a particular genetic or biochemical pathway or to test the specificity of the modulating agent's interaction with MIGFR.

Secondary assays generally compare like populations of cells or animals (*e.g.*, two pools of cells or animals that endogenously or recombinantly express MIGFR) in the presence and absence of the candidate modulator. In general, such assays test whether treatment of cells or animals with a candidate MIGFR–modulating agent results in changes in the IGFR pathway in comparison to untreated (or mock- or placebo-treated) cells or animals. Certain assays use “sensitized genetic backgrounds”, which, as used herein, describe cells or animals engineered for altered expression of genes in the IGFR or interacting pathways.

Cell-based assays

Cell based assays may detect endogenous IGFR pathway activity or may rely on recombinant expression of IGFR pathway components. Any of the aforementioned assays may be used in this cell-based format. Candidate modulators are typically added to the cell media but may also be injected into cells or delivered by any other efficacious means.

Animal Assays

A variety of non-human animal models of normal or defective IGFR pathway may be used to test candidate MIGFR modulators. Models for defective IGFR pathway typically use genetically modified animals that have been engineered to mis-express (*e.g.*, over-express or lack expression in) genes involved in the IGFR pathway. Assays generally require systemic delivery of the candidate modulators, such as by oral administration, injection, etc.

In a preferred embodiment, IGFR pathway activity is assessed by monitoring neovascularization and angiogenesis. Animal models with defective and normal IGFR are used to test the candidate modulator's affect on MIGFR in Matrigel® assays. Matrigel® is an extract of basement membrane proteins, and is composed primarily of laminin, collagen IV, and heparin sulfate proteoglycan. It is provided as a sterile liquid at

4°C, but rapidly forms a solid gel at 37°C. Liquid Matrigel® is mixed with various angiogenic agents, such as bFGF and VEGF, or with human tumor cells which over-express the MIGFR. The mixture is then injected subcutaneously(SC) into female athymic nude mice (Taconic, Germantown, NY) to support an intense vascular response. Mice with Matrigel® pellets may be dosed via oral (PO), intraperitoneal (IP), or intravenous (IV) routes with the candidate modulator. Mice are euthanized 5 - 12 days post-injection, and the Matrigel® pellet is harvested for hemoglobin analysis (Sigma plasma hemoglobin kit). Hemoglobin content of the gel is found to correlate the degree of neovascularization in the gel.

In another preferred embodiment, the effect of the candidate modulator on MIGFR is assessed via tumorigenicity assays. Tumor xenograft assays are known in the art (see, e.g., Ogawa K et al., 2000, *Oncogene* 19:6043-6052). Xenografts are typically implanted SC into female athymic mice, 6-7 week old, as single cell suspensions either from a pre-existing tumor or from *in vitro* culture. The tumors which express the MIGFR endogenously are injected in the flank, 1×10^5 to 1×10^7 cells per mouse in a volume of 100 μ L using a 27gauge needle. Mice are then ear tagged and tumors are measured twice weekly. Candidate modulator treatment is initiated on the day the mean tumor weight reaches 100 mg. Candidate modulator is delivered IV, SC, IP, or PO by bolus administration. Depending upon the pharmacokinetics of each unique candidate modulator, dosing can be performed multiple times per day. The tumor weight is assessed by measuring perpendicular diameters with a caliper and calculated by multiplying the measurements of diameters in two dimensions. At the end of the experiment, the excised tumors maybe utilized for biomarker identification or further analyses. For immunohistochemistry staining, xenograft tumors are fixed in 4% paraformaldehyde, 0.1M phosphate, pH 7.2, for 6 hours at 4°C, immersed in 30% sucrose in PBS, and rapidly frozen in isopentane cooled with liquid nitrogen.

In another preferred embodiment, tumorigenicity is monitored using a hollow fiber assay, which is described in U.S. Pat No. US 5,698,413. Briefly, the method comprises implanting into a laboratory animal a biocompatible, semi-permeable encapsulation device containing target cells, treating the laboratory animal with a candidate modulating agent, and evaluating the target cells for reaction to the candidate

modulator. Implanted cells are generally human cells from a pre-existing tumor or a tumor cell line. After an appropriate period of time, generally around six days, the implanted samples are harvested for evaluation of the candidate modulator.

Tumorigenicity and modulator efficacy may be evaluated by assaying the quantity of viable cells present in the macrocapsule, which can be determined by tests known in the art, for example, MTT dye conversion assay, neutral red dye uptake, trypan blue staining, viable cell counts, the number of colonies formed in soft agar, the capacity of the cells to recover and replicate in vitro, etc.

In another preferred embodiment, a tumorigenicity assay use a transgenic animal, usually a mouse, carrying a dominant oncogene or tumor suppressor gene knockout under the control of tissue specific regulatory sequences; these assays are generally referred to as transgenic tumor assays. In a preferred application, tumor development in the transgenic model is well characterized or is controlled. In an exemplary model, the "RIP1-Tag2" transgene, comprising the SV40 large T-antigen oncogene under control of the insulin gene regulatory regions is expressed in pancreatic beta cells and results in islet cell carcinomas (Hanahan D, 1985, *Nature* 315:115-122; Parangi S et al, 1996, *Proc Natl Acad Sci USA* 93: 2002-2007; Bergers G et al, 1999, *Science* 284:808-812). An "angiogenic switch," occurs at approximately five weeks, as normally quiescent capillaries in a subset of hyperproliferative islets become angiogenic. The RIP1-TAG2 mice die by age 14 weeks. Candidate modulators may be administered at a variety of stages, including just prior to the angiogenic switch (e.g., for a model of tumor prevention), during the growth of small tumors (e.g., for a model of intervention), or during the growth of large and/or invasive tumors (e.g., for a model of regression). Tumorigenicity and modulator efficacy can be evaluating life-span extension and/or tumor characteristics, including number of tumors, tumor size, tumor morphology, vessel density, apoptotic index, etc.

Diagnostic and therapeutic uses

Specific MIGFR-modulating agents are useful in a variety of diagnostic and therapeutic applications where disease or disease prognosis is related to defects in the IGFR pathway, such as angiogenic, apoptotic, or cell proliferation disorders.

Accordingly, the invention also provides methods for modulating the IGFR pathway in a cell, preferably a cell pre-determined to have defective or impaired IGFR function (e.g. due to overexpression, underexpression, or misexpression of IGFR, or due to gene mutations), comprising the step of administering an agent to the cell that specifically modulates MIGFR activity. Preferably, the modulating agent produces a detectable phenotypic change in the cell indicating that the IGFR function is restored. The phrase "function is restored", and equivalents, as used herein, means that the desired phenotype is achieved, or is brought closer to normal compared to untreated cells. For example, with restored IGFR function, cell proliferation and/or progression through cell cycle may normalize, or be brought closer to normal relative to untreated cells. The invention also provides methods for treating disorders or disease associated with impaired IGFR function by administering a therapeutically effective amount of an MIGFR -modulating agent that modulates the IGFR pathway. The invention further provides methods for modulating MIGFR function in a cell, preferably a cell pre-determined to have defective or impaired MIGFR function, by administering an MIGFR -modulating agent. Additionally, the invention provides a method for treating disorders or disease associated with impaired MIGFR function by administering a therapeutically effective amount of an MIGFR -modulating agent.

The discovery that MIGFR is implicated in IGFR pathway provides for a variety of methods that can be employed for the diagnostic and prognostic evaluation of diseases and disorders involving defects in the IGFR pathway and for the identification of subjects having a predisposition to such diseases and disorders.

Various expression analysis methods can be used to diagnose whether MIGFR expression occurs in a particular sample, including Northern blotting, slot blotting, ribonuclease protection, quantitative RT-PCR, and microarray analysis. (*e.g.*, Current Protocols in Molecular Biology (1994) Ausubel FM *et al.*, eds., John Wiley & Sons, Inc., chapter 4; Freeman WM *et al.*, Biotechniques (1999) 26:112-125; Kallioniemi OP, Ann Med 2001, 33:142-147; Blohm and Guiseppi-Elie, Curr Opin Biotechnol 2001, 12:41-47). Tissues having a disease or disorder implicating defective IGFR signaling that express an MIGFR, are identified as amenable to treatment with an MIGFR modulating agent. In a preferred application, the IGFR defective tissue overexpresses an MIGFR

relative to normal tissue. For example, a Northern blot analysis of mRNA from tumor and normal cell lines, or from tumor and matching normal tissue samples from the same patient, using full or partial MIGFR cDNA sequences as probes, can determine whether particular tumors express or overexpress MIGFR. Alternatively, the TaqMan® is used for quantitative RT-PCR analysis of MIGFR expression in cell lines, normal tissues and tumor samples (PE Applied Biosystems).

Various other diagnostic methods may be performed, for example, utilizing reagents such as the MIGFR oligonucleotides, and antibodies directed against an MIGFR, as described above for: (1) the detection of the presence of MIGFR gene mutations, or the detection of either over- or under-expression of MIGFR mRNA relative to the non-disorder state; (2) the detection of either an over- or an under-abundance of MIGFR gene product relative to the non-disorder state; and (3) the detection of perturbations or abnormalities in the signal transduction pathway mediated by MIGFR.

Kits for detecting expression of MIGFR in various samples, comprising at least one antibody specific to MIGFR, all reagents and/or devices suitable for the detection of antibodies, the immobilization of antibodies, and the like, and instructions for using such kits in diagnosis or therapy are also provided.

Thus, in a specific embodiment, the invention is drawn to a method for diagnosing a disease or disorder in a patient that is associated with alterations in MIGFR expression, the method comprising: a) obtaining a biological sample from the patient; b) contacting the sample with a probe for MIGFR expression; c) comparing results from step (b) with a control; and d) determining whether step (c) indicates a likelihood of the disease or disorder. Preferably, the disease is cancer. The probe may be either DNA or protein, including an antibody.

EXAMPLES

The following experimental section and examples are offered by way of illustration and not by way of limitation.

I. *Drosophila* IGFR screen

A dominant loss of function screen was carried out in *Drosophila* to identify genes that interact with or modulate the IGFR signaling pathway. Activation of the pathway by overexpression of IGFR at early stages in the developing *Drosophila* eye leads to an increase in cell number which results in a larger and rougher adult eye (Potter CJ et al. (2001) Cell 105:357-368; Huang et al., 1999. Dev. 126:5365-5372). We generated a fly stock with an enlarged eye due to overexpression of IGFR and identified modifiers of this phenotype. We then identified human orthologues of these modifiers.

The screening stock carried two transgenes. The genotype is as follows:

+; +; P{DmIGFR-pExp-UAS} P{Gal4-pExp-IXey}/TM6B

Screening stock females of the above genotype were crossed to males from a collection of 3 classes of piggyBac-based transposons. The resulting progeny, which contain both the transgenes and the transposon, were scored for the effect of the transposon on the eye overgrowth phenotype (either enhancement, suppression or no effect). All data was recorded and all modifiers were retested with a repeat of the original cross.

II. Analysis of Table 1

BLAST analysis (Altschul et al., *supra*) was employed to identify orthologs of *Drosophila* modifiers. The columns "MIGFR symbol", and "MIGFR name aliases" provide a symbol and the known name abbreviations for the Targets, where available, from Genbank. "MIGFR RefSeq_NA or GI_NA", "MIGFR GI_AA", "MIGFR NAME", and "MIGFR Description" provide the reference DNA sequences for the MIGFRs as available from National Center for Biology Information (NCBI), MIGFR protein Genbank identifier number (GI#), MIGFR name, and MIGFR description, all available from Genbank, respectively. The length of each amino acid is in the "MIGFR Protein Length" column.

Names and Protein sequences of *Drosophila* modifiers of IGFR from screen (Example I), are represented in the "Modifier Name" and "Modifier GI_AA" column by GI#, respectively.

Table 1

MIGFR symbol	MIGFR name aliases	MIGFR RefSeq_NA or GI_AA	MIGFR GI_AA	MIGFR name	MIGFR description	MIGFR protein length	Modifier name	Modified gi_aa
NOS3	nitric oxide synthase 3 (endothelial cell)[ECNOS]e NOS NOS3	NM_000603	40254422	nitric oxide synthase 3 (endothelial cell)	nitric oxide synthase; electron transporter; apoptosis inhibitor	1203	Nos	24583543
PRKAG1	AMPK gamma 1 PRKAG1 Protein kinase, AMP-activated, noncatalytic, gamma-1 protein kinase, AMP-activated, gamma 1 non-catalytic subunit	NM_002733	4506061	protein kinase, AMP-activated, gamma 1 non-catalytic subunit	protein kinase; protein serine/threonine kinase; protein binding	331	SNF4 Agamma	24648661
PRKAG2	AAKG AAKG2 H91620P H91620p H91620p protein PRKAG2 WPWS protein kinase, AMP-activated, gamma 2 non-catalytic subunit	NM_016203	33186925	protein kinase, AMP-activated, gamma 2 non-catalytic subunit	SNF1A/AMP-activated protein kinase; AMP binding	569	SNF4 Agamma	24648661
PRKAG3	AMPK gamma 3 protein kinase, AMP-activated, gamma 3 non-catalytic subunit PRKAG3	NM_017431	8394044	protein kinase, AMP-activated, gamma 3 non-catalytic subunit	nucleotide binding; protein binding; SNF1A/AMP-activated protein kinase	492	SNF4 Agamma	24648661
NOS2A	HEP-NOS NOS NOS1NOS, type II NOS2 NOS2A nitric oxide synthase 2A (inducible, hepatocytes) nitric oxide synthase, macrophage	NM_000625 NM_153292	24041029	nitric oxide synthase 2A (inducible, hepatocytes)	calcium channel inhibitor; nitric oxide synthase; calmodulin binding; electron transporter; antiviral response protein	1153	Nos	24583543
ITPKA	IP3K IP3K A IP3K-A ITPKA inositol 1,4,5-	NM_002220	4504789	inositol 1,4,5-trisphosphate 3-kinase A	1D-myo-inositol-trisphosphate 3-kinase	461	IP3K1	24583132

	ol 1,4,5-trisphosphate 3-kinase A			e 3-kinase A				
ITPKB	IP3 3-kinase IP3K IP3K B IP3K-B IP3KB ITPKB inositol 1,4,5-trisphosphate 3-kinase B	NM_002221	38569400	inositol 1,4,5-trisphosphate 3-kinase B	ID-myo-inositol-trisphosphate 3-kinase	946	IP3K1	24583132
ITPKC	IP3K C IP3K-C ITPKC inositol 1,4,5-trisphosphate 3-kinase C	NM_025194	18643383	inositol 1,4,5-trisphosphate 3-kinase C	inositol/phosphatidylinositol kinase	683	IP3K1	24583132
MAN2A1	Golgi alpha-mannosidase II mannosidase, alpha, class 2A, member 1 mannosidase, alpha type II MANA2 MAN2A1	NM_002372	4758698	mannosidase, alpha, class 2A, member 1	mannosyloligosaccharide 1,3-1,6-alpha-mannosidase	1143	alpha-Man-IIb	24647249
MAN2A2	alpha-mannosidase IIX mannosidase, alpha, class 2A, member 2 manosidase, alpha-, type II, isozyme X mannosidase, alpha type II-X PRO2198 MANA2X MAN2A2	NM_006122 NM_018621	3123244	mannosidase, alpha, class 2A, member 2	alpha-mannosidase	1139	alpha-Man-IIb	24647249
NOS1	nitric oxide synthase 1 (neuronal) NOS1	NM_000620	10835173	nitric oxide synthase 1 (neuronal)	nitric oxide synthase; electron transporter	1434	Nos	24583543
KIAA1815	FLJ23309 KIAA1815	XM_291315	37540252	KIAA1815	na	904	CG11961	24655610
POMT1	POMT1 RT protein-O-mannosyltransferase 1	NM_007171	21361382	protein-O-mannosyltransferase 1	mannosyltransferase	747	rt	10727985

PTPRN	IA-2 IA-2/PTP IA2 ICA512 PTPRN R-PTP-N islet cell antigen 2 islet cell antigen 512 islet cell autoantigen 3 protein tyrosine phosphatase, receptor type, N protein tyrosine phosphatase-like N precursor	NM_002846	4506321	protein tyrosine phosphatase, receptor type, N	transmembrane receptor protein tyrosine phosphatase; transmembrane receptor protein tyrosine phosphatase	979	ia2	24580758
PTPRN2	IA-2beta [AR [AR PTPRP AR/receptor-like protein-tyrosine phosphatase [CAAR KIAA0387 PHOGRIN PTPRN2 PTPRP phogrin protein tyrosine phosphatase receptor pi protein tyrosine phosphatase, receptor type, N polypeptide 2 tyrosine phosphatase IA-2 beta	NM_002847 NM_130842 NM_130843	11386149	protein tyrosine phosphatase, receptor type, N polypeptide 2	transmembrane receptor protein tyrosine phosphatase	1015	ia2	24580758
SYNJ1	INPP5G SYNJ1 inositol 5'-phosphatase (synaptojanin 1) synaptojanin 1 synaptojanin-1, polyphosphoinositide phosphatase	NM_003895	4507335	synaptojanin 1	polyphosphoinositide phosphatase; inositol-1,4,5-trisphosphate 5-phosphatase	1575	synaptojanin	18497296
SYNJ2	INPP5H SYNJ2 inositol phosphate 5'-phosphatase 2 (synaptojanin 2) synaptojanin 2	NM_003898	26190608	synaptojanin 2	protein binding; inositol/phosphatidylinositol phosphatase; inositol-1,4,5-trisphosphate 5-phosphatase	1496	synaptojanin	18497296

LOC284767	na similar to dJ680N4.2 (ubiquitin-conjugating enzyme E2D 3 (homologous to yeast UBC4/5)) LOC 284767	XM_209367	27485630	similar to dJ680N4.2 (ubiquitin-conjugating enzyme E2D 3 (homologous to yeast UBC4/5))	na	147	eff	24646906
LOC51619	ubiquitin-conjugating enzyme HBUCE1 LOC 51619	NM_015983	8393719	ubiquitin-conjugating enzyme HBUCE1	ubiquitin conjugating enzyme; enzyme	147	eff	24646906
UBE2D2	ubiquitin-conjugating enzyme E2D 2 (UBC4/5 homolog, yeast) ubiquitin-conjugating enzyme E2-17 kDa 2 ubiquitin carrier protein E2(17)KB2 UBCH5B UBC4/5 PUBC1 UBC4 UBE2D2	NM_003339 NM_181838	33188456	ubiquitin-conjugating enzyme E2D 2 (UBC4/5 homolog, yeast)	ubiquitin conjugating enzyme;	118	eff	24646906
UBE2D3	ubiquitin-conjugating enzyme E2D 3 (UBC4/5 homolog, yeast) ubiquitin-conjugating enzyme E2-17 kDa 3 ubiquitin carrier protein E2(17)KB3 MGC43926 MGC5416 UBCH5C UBC4/5 UBE2D3	NM_003340 NM_181886 NM_181887 NM_181888 NM_181889 NM_181890 NM_181891 NM_181892 NM_181893	33149322	ubiquitin-conjugating enzyme E2D 3 (UBC4/5 homolog, yeast)	ubiquitin conjugating enzyme	148	eff	24646906
LOC378372	LOC378372 na similar to dopamine beta-hydroxylase-like	XM_353788	37539365	similar to dopamine beta-hydroxylase-like	na	451	olf413	28574720
MOXD1	DKFZP564G202 MOX MOXD1 dJ248E1.1 monooxygenase, DBH-like 1	NM_015529	37183305	monooxygenase, DBH-like 1	dopamine-beta-monooxygenase; copper binding; monooxygenase	613	olf413	28574720

III. High-Throughput In Vitro Fluorescence Polarization Assay

Fluorescently-labeled MIGFR peptide/substrate are added to each well of a 96-well microtiter plate, along with a test agent in a test buffer (10 mM HEPES, 10 mM NaCl, 6 mM magnesium chloride, pH 7.6). Changes in fluorescence polarization, determined by using a Fluorolite FPM-2 Fluorescence Polarization Microtiter System (Dynatech Laboratories, Inc), relative to control values indicates the test compound is a candidate modifier of MIGFR activity.

IV. High-Throughput In Vitro Binding Assay

³³P-labeled MIGFR peptide is added in an assay buffer (100 mM KCl, 20 mM HEPES pH 7.6, 1 mM MgCl₂, 1% glycerol, 0.5% NP-40, 50 mM beta-mercaptoethanol, 1 mg/ml BSA, cocktail of protease inhibitors) along with a test agent to the wells of a Neutralite-avidin coated assay plate and incubated at 25°C for 1 hour. Biotinylated substrate is then added to each well and incubated for 1 hour. Reactions are stopped by washing with PBS, and counted in a scintillation counter. Test agents that cause a difference in activity relative to control without test agent are identified as candidate IGFR modulating agents.

V. Immunoprecipitations and Immunoblotting

For coprecipitation of transfected proteins, 3×10^6 appropriate recombinant cells containing the MIGFR proteins are plated on 10-cm dishes and transfected on the following day with expression constructs. The total amount of DNA is kept constant in each transfection by adding empty vector. After 24 h, cells are collected, washed once with phosphate-buffered saline and lysed for 20 min on ice in 1 ml of lysis buffer containing 50 mM Hepes, pH 7.9, 250 mM NaCl, 20 mM -glycerophosphate, 1 mM sodium orthovanadate, 5 mM p-nitrophenyl phosphate, 2 mM dithiothreitol, protease inhibitors (complete, Roche Molecular Biochemicals), and 1% Nonidet P-40. Cellular debris is removed by centrifugation twice at $15,000 \times g$ for 15 min. The cell lysate is incubated with 25 μ l of M2 beads (Sigma) for 2 h at 4 °C with gentle rocking.

After extensive washing with lysis buffer, proteins bound to the beads are solubilized by boiling in SDS sample buffer, fractionated by SDS-polyacrylamide gel

electrophoresis, transferred to polyvinylidene difluoride membrane and blotted with the indicated antibodies. The reactive bands are visualized with horseradish peroxidase coupled to the appropriate secondary antibodies and the enhanced chemiluminescence (ECL) Western blotting detection system (Amersham Pharmacia Biotech).

VI. Kinase assay

A purified or partially purified MIGFR is diluted in a suitable reaction buffer, e.g., 50 mM Hepes, pH 7.5, containing magnesium chloride or manganese chloride (1-20 mM) and a peptide or polypeptide substrate, such as myelin basic protein or casein (1-10 $\mu\text{g/ml}$). The final concentration of the kinase is 1-20 nM. The enzyme reaction is conducted in microtiter plates to facilitate optimization of reaction conditions by increasing assay throughput. A 96-well microtiter plate is employed using a final volume 30-100 μl . The reaction is initiated by the addition of ^{33}P -gamma-ATP (0.5 $\mu\text{Ci/ml}$) and incubated for 0.5 to 3 hours at room temperature. Negative controls are provided by the addition of EDTA, which chelates the divalent cation (Mg^{2+} or Mn^{2+}) required for enzymatic activity. Following the incubation, the enzyme reaction is quenched using EDTA. Samples of the reaction are transferred to a 96-well glass fiber filter plate (MultiScreen, Millipore). The filters are subsequently washed with phosphate-buffered saline, dilute phosphoric acid (0.5%) or other suitable medium to remove excess radiolabeled ATP. Scintillation cocktail is added to the filter plate and the incorporated radioactivity is quantitated by scintillation counting (Wallac/Perkin Elmer). Activity is defined by the amount of radioactivity detected following subtraction of the negative control reaction value (EDTA quench).

VII. Expression analysis

All cell lines used in the following experiments are NCI (National Cancer Institute) lines, and are available from ATCC (American Type Culture Collection, Manassas, VA 20110-2209). Normal and tumor tissues are obtained from Impath, UC Davis, Clontech, Stratagene, Ardaïs, Genome Collaborative, and Ambion.

TaqMan® analysis is used to assess expression levels of the disclosed genes in various samples.

RNA is extracted from each tissue sample using Qiagen (Valencia, CA) RNeasy kits, following manufacturer's protocols, to a final concentration of 50ng/μl. Single stranded cDNA is then synthesized by reverse transcribing the RNA samples using random hexamers and 500ng of total RNA per reaction, following protocol 4304965 of Applied Biosystems (Foster City, CA).

Primers for expression analysis using TaqMan® assay (Applied Biosystems, Foster City, CA) are prepared according to the TaqMan® protocols, and the following criteria: a) primer pairs are designed to span introns to eliminate genomic contamination, and b) each primer pair produced only one product. Expression analysis is performed using a 7900HT instrument.

TaqMan® reactions are carried out following manufacturer's protocols, in 25 μl total volume for 96-well plates and 10 μl total volume for 384-well plates, using 300nM primer and 250 nM probe, and approximately 25ng of cDNA. The standard curve for result analysis is prepared using a universal pool of human cDNA samples, which is a mixture of cDNAs from a wide variety of tissues so that the chance that a target will be present in appreciable amounts is good. The raw data are normalized using 18S rRNA (universally expressed in all tissues and cells).

For each expression analysis, tumor tissue samples are compared with matched normal tissues from the same patient. A gene is considered overexpressed in a tumor when the level of expression of the gene is 2 fold or higher in the tumor compared with its matched normal sample. In cases where normal tissue is not available, a universal pool of cDNA samples is used instead. In these cases, a gene is considered overexpressed in a tumor sample when the difference of expression levels between a tumor sample and the average of all normal samples from the same tissue type is greater than 2 times the standard deviation of all normal samples (i.e., $\text{Tumor} - \text{average}(\text{all normal samples}) > 2 \times \text{STDEV}(\text{all normal samples})$).

A modulator identified by an assay described herein can be further validated for therapeutic effect by administration to a tumor in which the gene is overexpressed. A decrease in tumor growth confirms therapeutic utility of the modulator. Prior to treating a patient with the modulator, the likelihood that the patient will respond to treatment can be diagnosed by obtaining a tumor sample from the patient, and assaying for expression

of the gene targeted by the modulator. The expression data for the gene(s) can also be used as a diagnostic marker for disease progression. The assay can be performed by expression analysis as described above, by antibody directed to the gene target, or by any other available detection method.

WHAT IS CLAIMED IS:

1. A method of identifying a candidate IGFR pathway modulating agent, said method comprising the steps of:
 - (a) providing an assay system comprising a MIGFR polypeptide or nucleic acid;
 - (b) contacting the assay system with a test agent under conditions whereby, but for the presence of the test agent, the system provides a reference activity; and
 - (c) detecting a test agent-biased activity of the assay system, wherein a difference between the test agent-biased activity and the reference activity identifies the test agent as a candidate IGFR pathway modulating agent.
2. The method of Claim 1 wherein the assay system comprises cultured cells that express the MIGFR polypeptide.
3. The method of Claim 2 wherein the cultured cells additionally have defective IGFR function.
4. The method of Claim 1 wherein the assay system includes a screening assay comprising a MIGFR polypeptide, and the candidate test agent is a small molecule modulator.
5. The method of Claim 4 wherein the assay is a binding assay.
6. The method of Claim 1 wherein the assay system is selected from the group consisting of an apoptosis assay system, a cell proliferation assay system, an angiogenesis assay system, and a hypoxic induction assay system.
7. The method of Claim 1 wherein the assay system includes a binding assay comprising a MIGFR polypeptide and the candidate test agent is an antibody.

8. The method of Claim 1 wherein the assay system includes an expression assay comprising a MIGFR nucleic acid and the candidate test agent is a nucleic acid modulator.
9. The method of claim 8 wherein the nucleic acid modulator is an antisense oligomer.
10. The method of Claim 8 wherein the nucleic acid modulator is a PMO.
11. The method of Claim 1 additionally comprising:
 - (d) administering the candidate IGFR pathway modulating agent identified in (c) to a model system comprising cells defective in IGFR function and, detecting a phenotypic change in the model system that indicates that the IGFR function is restored.
12. The method of Claim 11 wherein the model system is a mouse model with defective IGFR function.
13. A method for modulating a IGFR pathway of a cell comprising contacting a cell defective in IGFR function with a candidate modulator that specifically binds to a MIGFR polypeptide, whereby IGFR function is restored.
14. The method of claim 13 wherein the candidate modulator is administered to a vertebrate animal predetermined to have a disease or disorder resulting from a defect in IGFR function.
15. The method of Claim 13 wherein the candidate modulator is selected from the group consisting of an antibody and a small molecule.
16. The method of Claim 1, comprising the additional steps of:
 - (d) providing a secondary assay system comprising cultured cells or a non-human animal expressing MIGFR ,

(e) contacting the secondary assay system with the test agent of (b) or an agent derived therefrom under conditions whereby, but for the presence of the test agent or agent derived therefrom, the system provides a reference activity; and

(f) detecting an agent-biased activity of the second assay system,
wherein a difference between the agent-biased activity and the reference activity of the second assay system confirms the test agent or agent derived therefrom as a candidate IGFR pathway modulating agent,
and wherein the second assay detects an agent-biased change in the IGFR pathway.

17. The method of Claim 16 wherein the secondary assay system comprises cultured cells.

18. The method of Claim 16 wherein the secondary assay system comprises a non-human animal.

19. The method of Claim 18 wherein the non-human animal mis-expresses a IGFR pathway gene.

20. A method of modulating IGFR pathway in a mammalian cell comprising contacting the cell with an agent that specifically binds a MIGFR polypeptide or nucleic acid.

21. The method of Claim 20 wherein the agent is administered to a mammalian animal predetermined to have a pathology associated with the IGFR pathway.

22. The method of Claim 20 wherein the agent is a small molecule modulator, a nucleic acid modulator, or an antibody.

23. A method for diagnosing a disease in a patient comprising:

- (a) obtaining a biological sample from the patient;
- (b) contacting the sample with a probe for MIGFR expression;
- (c) comparing results from step (b) with a control;

(d) determining whether step (c) indicates a likelihood of disease.

24. The method of claim 23 wherein said disease is cancer.

ABSTRACT OF THE DISCLOSURE

Human MIGFR genes are identified as modulators of the IGFR pathway, and thus are therapeutic targets for disorders associated with defective IGFR function. Methods for identifying modulators of IGFR, comprising screening for agents that modulate the activity of MIGFR are provided.

Nucleic Acid and Polypeptide sequences

>gi|40254421|ref|NM_000603.2| Homo sapiens nitric oxide synthase 3 (endothelial cell) (NOS3), mRNA

AAACTAGGGGCAAGGAGACGAAGAGAACATGAAGTTAAACCTTTAAGATGAAGAACAAAGCTGAACATAC
TGATGCATTGGATCTTTGGAGAGGATCTCAGAACTCATTGTACTTAATTTACAGGGTAAAAACCTTAGAAG
AGGAATTTATTATATCTCTACACAAGACTCCAGGGAGGCATGGCCCTTGGACTTGAGGCTGGGCATCTGGA
AGCTGTACAGCCACGACCTTTCTGCAGCAGGAAAGGGCAGGGCTCTGCTGGAGCAGGCACAGATGGTGG
ACGCACAGCTAACATGGGCACCTTGAAGAGCGCTGGGCCAGGAGCCTGGGCCACCCTGCGGCCCTGGGGCTGG
GGCTGGGCCCTTGGGGCTGTGGCGCAAGCAGGGCCCCAGCCACCCTCGGCCCTTGAGGCCACGCGGGCCCCAG
ATCCTCATCTCCACACAGCGCCGAACACAGCCCCCGAGCTCCCCGCTAACCCAGCCAGCCAGAGGGGGCCC
AAGTTCCCTCGTGTGAAGAACTGGGAGGTGGGGAGCATCACCTATGACACCCTCAGCGCCCCAGGCGCAGC
AGGATGGGCCCTCTGCAACCCCAAGACGCTGCCCTGGGCTCCCTGGTATTTCCACGGAAACTACAGGGCCGGCC
CTCCCCGGCCCCCGGCCCTTGAGCAGCTGCTGAGTCAGGCCCGGACCTTCATCAACCAAGTACTACAGC
TCCATTGAAGAGGAGCGGCTCCCGAGGCCACGAACAGCGGCTTCAAGAGGTTGGAAGCCGAGGTTGCGACCCA
CAGGCACTACACAGCTTAGGGAGAGCGAGCTGGTGTTCGGGGCTAAGCAGGCTTGCGCGCAACGCTCCCCG
CTGCTGTGGCCGGATCCAGTGGGGGAAGCTGCAGGTGTTTCATGCCCCGGAGCTGCAGGCTTCGACAGGAA
ATGTTTACCTACATCTGCAACCAACATCAAGTATGCGACCAACCGGGGCAACCTTCGCTCGGCCATCACAG
TGTTCCCGCAGCGCTGCCCTGGCCGAGGAGACTTCCGAATCTGGAACAGCCAGCTGGTGGCTACGCGGG
CTACCGGCAGCAGGATGGCTCTGTGCGGGGGAGCCAGCCAACTGGAGATCACCGAGCTCTGCATTCAG
CAGCGCTGGACCCCGAGAAACGGTTCGCTTCGACGTGTCGCCCTGCTGTCGAGGCCAGATGATCCCC
CAGAATCTTCCCTTCTGCCCCCGAGCTGGTCTTTCAGGTCGCCCTTGAGAGCACTCCAGCTGGAGTGGTT
TGCAGCCCTGGGCTGCGCTGGCTAGCGCTCCCGGCAAGTGTCAACATGCTGCTGTCGGAATTTGGGCGCTG
GAGTTCGCCCGAGCCCCCTTCAGTGGCTGGTACATGAGCACTGAGATCGGCACGAGGAACCTGTGTGACC
CTCACCCTACAACTCTCGGAGGATGTGGCTGTTCATGGACCTTGATACCCGAGCACTCTGCTCCCT
TGGGAAGACAGAGGCGAGCTGGGAAATCAACGTGGCCGTGCTGCACAGCTTACCAGCTAGCCAAAGTCACT
ATCGTGGACCAACAGCCGCCACGCGCTTTCATGAAGCACTGGAGAATTGAGCAAGAGGCGAGGGGG
GCTGGCTCGAGACTGGGCTGGATCTGTGCCCCCTCTCGGGCAGCTCACTCTGTTTTCATCAGGGA
GATGTCAACTATTTCCTGTCCCCGGCCTTCCGCTACAGCCAGACCCCTGGAAGGGGAGTGGCGCAAG
GGCACCAGCATCAGGAGGAAGACCTTTAAAGAGTGGCCAAACCGCTGAAGATCTCCGCTGCTCA
TGGGCACGGTGATGGCGAAGCGAGTGAAGGCGACAATCTGTATGGCTCCGAGACCGCGCGGCCAGAG
CTACGCACAGCAGCTGGGGAGACTTTCGGAAGGCTTTTGATCCCCGGGTCTGTGTATGGATGAGTAT
GACCTGGTGTCTCTGAAACACGAGACGCTGGTGTGTTGTAACCAAGCACTTTTGGAAATGGGATCCCC
CGGAGAAATGGAGAGGCTTTGACGCTGCCCTGATGGAGATGTCGCGGCCCTACAAACAGCTTCCCTCGGCC
GGAACAGCACAGAGTTATAAGATCCGCTTCAACAGCATCTCTGCTCAGACCCACTGGTGTCTCTTTGG
CGCGGAAGAGGAAGAGTCCAGTAACACAGACAGTGCAGGGGCCCTGGGCACCCCTCAGGTTCTGTGTGT
TCGGGCTCGGCTCCCGGGCACTACCCCACTTCTGCGCTTTGCTCTGTGGCTGGACACAGCGGTGGAGGA
ACTGGCGGGGAGCGGCTGCTGCAGCTGGGCGAGGCGACGAGCTGTGCGCGTACGAGGAGAGGCTTCCGA
GGCTGGGCGCCAGGCTGCCCTTCCAGGCGCGCTGTGAGACCTTCTGTGTGGGAGAGGATGCCAAGGCGCGCG
CCCGAGCATCTTCAGCCCAACAGGAGCTGGAAAGCGCCAGAGGTACCGCTAGAGCTCCGCGCGAGGG
CTTGCACTGCTGCCAGGTCTGATCCAGCTGCACAGCGGGAAGATGTTCCAGGCTACAATCCGCTCAGTG
GAAACCTGCAAGCAGCAAGTCCACGAGGGGCCACCATCTTGTGCGCTGGACACCGGAGCGGACGAGG
GGCTGCAGTACCAAGCGGGGGACCATAGAGTGTCTGCCCGCCCAACCGGCCCGGCTTGTGGAGGCGCT
GCTGAGCGCGCTGGAGGACCCGCCGCGGCCCACTGAGCCGTGGCAGTAGAGCAGCTGGAGAAAGGGACG
CTGTGTGGCTTCCCCCGGCTGGGTGCGGGACCCCGGCTGCCCCGTGACGCTACGCTAGGAGCTCTCA
CTTTCTTCTTGGACATCACTTCCCAACCAAGCCCTCAGCTCTTTCGCGCTGCTCAGCACTTGGCAAGGA
GCCAGGGAACAGCAGGAGCTGGAGGCCCTCAGCCAGGATCCCGACGCTACGAGGATGGAAGTGGTTC
CGCTGCCCAAGCTGCTGGAGGTGCTGGAGCAGTTCCCGTGGTGGCGCTGCCCTGCCCACTGCTCTCTCA
CCAGCTGCCCTTGTCTCAGCGCCGGTACTACTCAGTCAGCTCGGCACCGCCAGCCACCCAGGAGAGAT
CAACCTCACTGTAGCTGTGGTGGCATACAGGACTCAGGATGGGCTGGGCCCCCTGCACTATGGAGTCTGC
TCCAGCTGGCTAAGCAGCACTCAAGCCCGGAGACCTGTGCCCTGCTTATCATCGGGGGGCTCCCTCTTCC
GGCTGCCAACCGATCCGACGTTGCCCTGCATCTGGTGGGTTCAGGCACTGGCATTTGCCCTCTCGGGG
ATTCTGGCAGGAGCGGCTGCATGACATTGAGAGCAAAAGGGCTGCAGCCCACTCCCATGACTTTGGTGTTC
GGCTGCGGATGCTCCAACCTTGACCATCTTACCAGCAGCAGGTGCAGAACCGCCAGCAGCAGCGGGGTGT
TTGGCCGAGTCTTCAACCCCTTCTCCGCGGAACCTGACAAACCTACGCTACGCTGAGCAGCATCTTGA
GACGAGCTGGCTGGGAGGTCACCGCTGCTGTGCTCGAGCGGGGCGACATGTTTGTCTGCGGCGAT
GTTACCATGGCAACCAAGCTCTCGACAGCGTGCAGCGCATCTTGGCGACGGAGGCGCATGGAGCTGG

ACGAGGCGCGGCGAGCTCATCGCGCTGCTGCGGATCAGCAACGCTACCACGAAGACATTTTCGGGCTCAC
 GCTGCGCACCCAGGAGGTGACAAGCCGCATACGCACCAGAGCTTTTCTTGCAGGAGCGTCAGTTGCGG
 GCGCGAGTGCCCTTGGCGCTTGACCCCTCCGCGCTCAGACACCAACAGCCCTTGAGAGCCGCTGGCTTTC
 CCTTCCAGTTCCGGGAGAGCGCGCTGCCGACTCAGGTCGCGCCGACAGGATCAGCCCGCTCTCCCTCT
 CTTGAGGTGGTGCTTCTTCATCTGTCCAGAGGCTGCAAGGATTCAGCATTTATCTCCGAGGAAGGAGC
 AAAAGCGCTCTTTTCCCTCTTAGGCTGTGTGCTCGGCGCTGGGTCTCCCTCTTAATCTGGAAGGCCCTC
 CCAGCAGCGGTACCCAGGGCTACTGCCACCCGCTTCCTGTGTTCTTAGTCGAATGTTAGATTCTCTTG
 CTCTCTCAGGAGTCTTACTGTAAAGTCTAATCTCTAAATCAAGTATTTATTATTGAAGATTACCA
 TAAGGAGCTGCGCAGATGTTAGGAGAACTACTAAAGTCTACCCAGCCCAAAAAAAAAAAAAA

>gi|4506060|ref|NM_002733.1| Homo sapiens protein kinase, AMP-
 activated, gamma 1 non-catalytic subunit (PRKAG1), mRNA
 GCGCCCTTAAAGATGGTGAGGGGCTCATGCTCTGAGTAGAAGGTGGTGAACCTCCAGGAGCGGTGGGATG
 ATGAGGGCCCGGGCGCTCTTGCAATGGAGAGCGTCAATTTCTTCAGATAGCTCCCCAGCTGTGAAAAATG
 AGCATCCTCAAGAGACCCCAAGATCCAAACAATAGCGTGATATCTTCTTCAATGAAGTCTCATCTGCTGTTA
 TGACCTGATTTCCACAAGCTCAAAATGGTGTGATTTGATAGCTCCCTGCAGGTGAAGAAAGCTTTT
 GCTTTGGTGACTAACGGTGACGAGCTGCCCTTTATGGGATAGTAAGAAGCAAGTTTGTGGGACATGC
 TGACCATCACTGATTTTCAATATCTTCGACCGCTACTATAAATCAGCTTGGTACAGCTCTATGAGCT
 AGAAGAACACAGATAGAACTTGGAGAGAGGTGATCTCCAGGACTCCTTTAAACCGCTTGTCTGCATT
 TCTCTTAATGCCAGCTTGTGTGATGCTGTCTCTCATTAATTCGGAACAAGATCCACAGCGCTGCCAGTTA
 TTGACCCAGAATCAGGCAATCTTTGTACATCTCACCAACGCGCATCTTCTGAAGTTCTTCAAAATGTT
 TATCACTGAGTTTCCCAAGCCAGAGTTCATGTCCAAGTCTCTGGAAGAGCTACAGATGGCACCTTATGCC
 AATATGTCTATGGTTGCGCATACACCCCGCTCTATGTGCTCTGGGATTTTGTACAGCATCGATGCT
 CAGCCCTGCCAGTGGTGGATGAGAAGGGCGTGTGGTGGACATCTACTCCAAGTTTGTATGTTATCAATCT
 GGCACAGAAAAGACCTACAACAACCTAGATGTATCTGTGACTAAAGCTTTGCAACATCGATCACAATT
 TTTGAGGCTGTCTTCAAGTCTTACCTGCATGAGACTCTGGAGACCATCTCAACAGCGCTAGTGGGAAGCAG
 AGGTTCAACCGATTTGATGGTGGATGAAAATGATGTGGTCAAGGGAATTTGATCACTCTGTGACATCTCT
 GCAGCGCTGGTGCCTACAGTGGAGAGAAGAAGCCCTGAGCTGGGGGAAGGGGTCTATCGACAGCCAGGG
 GATATGCCAACTCACTGCTGCTGGAAGCTCTGTGGGAATCAGATGAACTTGAGGGGAATTTGTGACTCT
 GTTCCCTGTTTCAGGGTCCCTTGCCCTTCTATCTGGGAGCTAGGGAAGGTTTGGGGAGGAAAGAGAATGG
 ATTTATAGCTCAAGCTTACCTTCACATACACTTGAAAAAATTTTCAGGCTAGCCAGTTCTAGCCCTGCT
 CCTCTTAGATATATCCCTTTCCTGGGTGAACATATAGGCTCTGTGCTCTCAGACAAATTTCTGATCTCTA
 AGAGATCCCCAGACCTCACTTGCCTTGCCTCCATCTTGCCCTGATTCAACCTAAGTATAATGACACAA
 CAAAATTTCTCATAAAGATATTTTATTCACCTGTTCCTGCTATATGAGGAGGCGCAAGTCCATTTAGT
 GACATTTCTTCCATAATGTGAGTGGGAGGATTGTGG

>gi|33186924|ref|NM_016203.2| Homo sapiens protein kinase, AMP-
 activated, gamma 2 non-catalytic subunit (PRKAG2), mRNA
 GCGGCTCAGTCCGAAGGCAGCGCCCGGGGAGGGAAGGAGGGGACCAACCCCGAGGAGTTTCGCAGA
 ATCAACTTCTGGTTAGAGTTATGGAAGCGCGGTTATGACACCAAGAAGAAAAAGATGTTTCCAGCC
 CGCGGGAGCGCGGCAAGAAAAATGCCAGCCAGGAGAGGCGTTTCGCTGCGCGTGCACATTCGGGACCTG
 AGCTCTTTCGCCATGCGCGTCTTGAGCGGAGACCTGGAGGGTTTCGGAAGGATTTCTCTCGAAAGGTGG
 ACAGCCCTTCTGCGCCGGGACGCCCTTCAAAGGGTCTTCTCTCAGAGGCCCGCCAGCCCGGCGCTCCAG
 CCCCATGTCTGCACCTGTGAGGCCCAAGACAGCCCGGCTCTCCCAAAACCGTGTTCCTGTTCTCTATC
 CAGGAGTCCCGGACGCTGCTTCCCTCGACGCATGAGCTTTCAGTGGGATCTTCGCTCTCTCCGCTCTCCAAAGAT
 CTTCGCCCACTCCAACCTTGCTACTTCGCGCGGGGCGATCAGGTTTTCCTCCGCTCCAGAAAAACCTC
 CGGCTCTCTCTCTCTCGCTCAACACCCACCCCAAGTGACCAAGCAGCAGCTTTCCCTTGGAAATCTTAT
 AAGCACGAGTCAAGCGTTAGAGAATCGCATCTATGCTCTTCGCTTTCCCCCGGACACAGGAGCAGAGGT
 TCTGCGCGTCTTCTCTCCAGAGCCCGACAGGCTCCACTGGCATCACCGACACATATGCTCTCCCTCAA
 AGCCCGGCGCTGAGGAGGAGCTTTATTTACAAGAAACATTTAAGCTCTTTAGTGAAATATGACCA
 GAAGCAGTAGAAGACTCAGAAAGTGGTGTTTACATGCGGATTCATGAGGTACACAGTGTATTGACATCG
 TTCCAACAGTTCGAAAGCTTGTGTCTTTGATACATATACAAGTTAAAAAGCTCTTCTTGTCTTGGT
 AGCCAACGCTGTCCAGCAGTCCGACCTGTGGGAGAGTAAAAACAAAGTTTGTAGGAATGCTAACAAAT
 ACAGATTTCTAATAATATCTACATAGATACTATAATCACCTATGGTACAGATTTATGAATTAGAGGAC
 ATAAAAATTGAACAAGGAGGAGCTTTATTTACAAGAAACATTTAAGCTCTTTAGTGAAATATGCTCAGA
 TGCAAGCTCTTTCGATGCTGTATACCTTCTGTATCAAAAAATAAATCCAGAGATTGCCCGTATTGACCTG
 ATCAGTGGGAATGCATTTATATACTTACCCACAAAAGATCTCAAGTTCTCCAGCTTTTATGCTGTG

ATATGCCAAAGCCTGCTTTCATGAAGCAGAACCTGGATGAGCTTGGAAATAGGAACGTACCACAACATTGC
 CTTCATACATCCAGACACTCCCATCATCAAAGCCTTGAACATATTTGTGGAAAGACGAATATCAGCTCTG
 CCTGTTTGGTATGAGTCAGGAAAAGTTGTAGATATTTATTTCCAAATTTGATGTAATTAATCTTGCCTGCTG
 AGAAAACATACAAATAACCTAGATATCAGCGTGACCCAGGCCCTTACAGACCGTTACAGATCTTTTGAAGG
 TGTGTGAAGTGCAATAAAGCTGGAAATACTTGGAGACCATCGTGGACAGAAATAGTAGAGCTCAGGTCAT
 CGGTGGTGGTGGTAAATGAAGCAGATAGTATTTGTGGGTATTATTTCCCTGTGGACATCTTGCAGGCC
 TGATCCTCACACCAGCAGGTGCCAAACAAAAGGAGACAGAAACCGAGTGACCCCGTGAATGTAGACGCC
 CTAGGAGGAGAACTTGAACAAGTCTCTGGGTACAGTTTGGCTCATGAACACTGGCTCGAAGTGGTTAA
 GAATGTATCATAGGCTTAAACGATAGGTATTTCTTCCAGTGATGTTGAAATTAAGCTTAAAAAAGGAATA
 TTTTATGTGCTTGAATAATCAGGCTTGCAATAAAAAAGCTGTTTTCAGACCTTGTCTGAAGGATTTTAAAT
 GCTGTATGTCTATTAAGTGCACTGTGCTCTG

>gi|8394043|ref|NM_017431.1| Homo sapiens protein kinase, AMP-
 activated, gamma 3 non-catalytic subunit (PRKAG3), mRNA
 ACTTGGCTTGGGGCTGGCCACATGGAGCCCGGGCTGGAGCAGCAGCTGCGCAGGACCCCTTCTTGGAGCA
 GCTTGGGGGTTCTGAGCATCAAGAGATGAGCTTCTTGAAGCAAGAAACAGAGACTCATGTGCCATCACC
 AGCTGTGACCAGCAGCTCAGAAAAGATCCGTGGGAAACGAGGGGCCAAAGCCTTGAGATGGACAAGGCAG
 AAGTCGGTGGAGGAAGGGAGCCACCAGGTCAGGGGGAAGGTCCTCCCGCTCAGGCCAGCTGCTGAGTCCA
 CCGGGCTGGAGGCCACATTCACCAAGACCACACCTTGGCTCAAGCTGATCTTGCCTGGGGGGGCACTCC
 AACCAACAGGTGGGACCTGCTCCCTCTGACTGTACAGCCTCAGCTCAGCGCTCCAGCAGAGATGATGTG
 GAGCTGGCCAGGAGTTCCTCAGCCACAGAGGCCCTGGGAGTGTGAGCTAGAAGGCCCTGCTGGGAAGAGGC
 CTGCCCTGTGCTTCCGCCGAGGCCCATTTCCCAAGCTTGGGCTGGGATGACGAACCTGCGGAAACCCGG
 CGCCAGATCTACATGCGCTTTCATCGAGGAGCACACCTGCTACGATGCCATAGCTTGCACAGCTA
 GTCATCTTCGACACCATGCTGGAGATCAAGAAGGCCCTTCTTTGCTCTGGTGGCCAACGGTGTGCGGGCAG
 CCCCCCTATGGGACAGCAAGAAGCAGAGCTTTGTGGGGATGCTGACCATCACTGACTTCATCTGGTGGT
 GCATCGCTACTACAGGTCCGCCCTTGGTCCAGATCTATGAGATGAACAACATAAGATTAAGACCTGGAGG
 GAGATCTACCTGCAAGGCTGCTTCAAGCCTCTGGTCTCCATCTCTCCCTAAATGATAGCCTGTTTGAAGCTG
 TCTTACACCTCATCAAGAACCGGATCCATCGCTGCTGTTCTTGAACCCGGTGTACGGAACGTACTCCA
 CATCTCACACACAACGCCCTGCTCAAGTCTCTGCACATCTTTGGTTCCCTGCTGCCCCGCGCTCTCTTC
 CTCTACCGCATCTCAAGATTTGGGCATCGGCACATTCGCGAGACTTGGGTGTGGTGTCTGGAGACGAC
 CCATCTGACTGATCATCTGGAACATCTTTGTGGACCGCGTGTGCTGCATGCTGCTGGTCAACGAATGTGG
 TCAGGTCTGGGGCTCTATTTCCCGCTTTGATGTGATTCACTGGCTGCCACGCAAACTTACAAACCACTG
 GACATGAGTGTGGGAGAAGCCCTGAGGAAGAGGACACTATGCTGGAGGGAGTCTTTCTCTGCCACCCC
 ACGAGAGCTTGGGGGAAGTGAATGACAGGATTGCCTGGGAGCAGGTACACAGGCTGGTGCTAGTGGACGA
 GACCCAGCATCTCTTGGGCGTGGTCTCCCTCTCCGACATCTTTCAGGCACCTGGTGTCTCAGCCCTGCTGGC
 ATCGATCCCTCTGGGGCTTGAGAAAGATCTGAGTCCCAATCCCAAGCCACCTGCACACCTTGAAGGCAATG
 AAGGGAACCTGGAGAACTCAGCCTTCATCTTCCCCACCCCCATTTTGGTGGTATGATGATGATGATCAGGCT
 CTTCAGGCCCTCCCAAATTTGCCCTTGCCCTTACCAGAGCTCCCAAGAGCCCTCGCATGCTCAGTGCACCAT
 GGGATGATGAAATTAAGGAGAACAGCTGAGTCAAGCTTGGAGGTCCCTGAACACAGAGGCACATGAGTATC
 CCCAGGCCCATCTGTGCTCCATGCCGCCCATCCCTTGGCCGCTGACTGGGGTCCGATGGCCCCAGTGG
 GTTTAGTCAGGGCTCTCTGATCTCCGTCTTCTGGGCTACCTATGCTTCACTTCACTGCTCTGGGAGTTCC
 CAGCAACGCTCGCCACTGCCCCCTCTACTCTCAGGGGTGGTCACTTTCAGAGCTGCTGAAATGCTGCAAT
 TCAGGGGCCACCATGGAGCAGCGCTTATTTATAGAAGCTGCCCTGACAGCCCTCAGCTGCTGCAAGTCCCA
 TCTTGTGTCAGAGAACTCTCTAGCTCTCGCAGTGAGCCATGTTTGTAGTCTCCAGGATGGATGGCCCT
 GTATATGGACCCCTGAGAAATGAGCAATTTAGAAAAACAAAACAAAAGGACCAATCCATGAACCTAGATTTT
 ATTGGTTTCACTCAAAATGCTGCAGTCAATTGACCTGAACCTTGTGGCAAGAGACTTGTGCTTTCTAAATTT
 CAAAGACTAGAAAGGAAATGGATAAAAATCACAAGTGCCGTTTCTCTTGG

>gi|24041028|ref|NM_000625.3| Homo sapiens nitric oxide synthase 2A
 (inducible, hepatocytes) (NOS2A), transcript variant 1, mRNA
 ATAACTTTGTAGCGAGTGCAGAAATCAGGCTCCGGCCGACAGAGAACTCAGCCTCATCTCTGCTTTAAAAAT
 CTCTCGGCCACCTTTGATGAGGGGACTGGGCAGTTCTAGACAGTCCCAGAGTTCTCAAGGCACAGGCTCTC
 TCTCTGGTTTGAAGTCTTCTTACCCTGGGGAGGACGTCAGCCAGCTGCAAGGCCACAGCTGAAGAACATC
 TGAGCTCAAAATCCAGATAAGTGACATAAGTGACCTGCTTTGTAAAGCCATAGAGATGGCCCTGTCTCTGGA
 AATTTTGTGTCAGAGCAAAATTCACCAAGTATGCAATGAATGGGGAAAAAGACATCAACAACAAATGTGGA
 GAAAGCCCCCTGTGCCACCTCCAGTCCAGTGACAGAGTACGCTTTCAGTATCACAACTCAGCAAGCAG
 CAGAATGAGTCCCCGACGCCCTCTGTGGAGACGGGAAAGATCTCCAGAATCTCTGGTCAAGCTGGATG

CAACCCCATTTGCTCCCCACGGCATGTGAGGATCAAAAACTGGGGAGCGGGATGACTTTCCAAGACAC
 ACTTCACCATAAAGGCCAAAGGGATTTTAACTTGCAGGTCCAAATCTTGCCCTGGGGTCCATTATGACTCCC
 AAAAGTTTGCACAGAGGCCAGGGACAAGCCTACCCCTCCAGATGAGCTTCTACCTCAAGCTATCGAAT
 TTGTCAACCAATATTACGGCTCCTTCAAGAGGCAAAAAAGAGGAACATCTGGCGAGGTGGAAAGCGGT
 AACAAAGAGATAGAAACAACAGGAACCTACCAACTGACGGGAGATGAGCTATCTTGCCCAACCAAGCAG
 GCTGGCCCAATGGCCACGCTGCATTGGGAGGATCCAGTGGTCCAACCTGCAGGCTTCGATGGCCCGCA
 GCTGTTCACCTGCCCGGAAATGTTTGAACACATCTGCAGACACGTGCGTTACTCCACCAACAATGGCAA
 CATCAGGTGCGGCATCACCGTGTCCCCAGCGGAGTGATGGCAAGCAGCATCTCCGGGTGGAAATGCT
 CAGCTCATCTCCGCTATGCTCGCTACCAGATGCCAGATGGCAAGCTACAGGGGACCCCTGCCAACGTGGAT
 TCACCTCAGCTGAGCTCAGCTTGGGCTGGAAAGCCCAAGTACGGCCGCTTCGATGTGGTCCCTCGCTGCT
 GCAGGCAATGGCCGTGACCTGAGCTCTTCCGAAATCCACCTGACCTTTGTGCTTGAGGTGGCCATGGAA
 CATCCCAAATACGAGTGGTTTCGGGAACCTGGAGCTAAAGTGGTACGCCCTGCCGTGAGTGGCCAAACATGC
 TGCTTGAGGTGGCGGCCCTGGAGTTCACGGGTGCCCTTCAATGGCTGGTACATGGGCACAGAGATCGG
 AGTCCGGGACCTTGTTGACGCTCCAGCGCTACAACTCTGGAGGAAGTGGGCAGGAGAATGGGCCGGAA
 ACGCAACAGCTGGCCCTCGCTCTGGAAAGACAGGCTGTCTTGAGATCAACATTTGCTGTGCTCCATAGTT
 TCCCAAGCAGAAATGTGACATCATGGACCACCACCTGGCTGCAGAAATCTTCATGAAGTACGATCGAATA
 TGAATACCGGTGCCGTGGGGCTGCCCGGCAGACTGGATTGGCTGTGCCCTCCCATGTCTGGGAGCATC
 ACCCCCGTGTTCACAGGAGATGCTGAACTACGCTCTGTCCCTTTCTACTACTATCAGGTAGAGGCCCT
 GGAATAACCAATGTCTGGCAGGACGAGAAGCGGAGACCCAAAGAGAAGAGAGATTCCATTGAAAGTCTTGGT
 CAAAGCTGTGCTCTTTGGCTGTATGCTGTATGCGCAAGACAATGGCTGCCGAGTACAGCTACCATCTGTT
 TTTGCGACAGACAGGAAAAATCAGAGGCGCTGGCCCTGGGACCTGGGGGCCCTATTTCAGCTGTGCTCTCA
 ACCCAAGGTGTCTGCATGGATAAGTACAGGCTGAGCTGCCCTGGAGGAGGAACGGCTGCTGTGGGTGT
 GACCAGTACGTTTGGCAATGGAGACTGCCCTGGCAATGGAGAGAACTGAAGAAATCGCTCTTCATGCTG
 AAAGAGCTTAAACAAACAAATTCAGGTACGCTGTGTTTGGCCCTGGCTCCAGCATGTACCCCTCGGTTCTGCG
 CCTTTGCTCATGACATGTATCAGAAGCTGTCCACCTGGGGGCCCTCTCAGCTACACCCGATGGGAAGG
 GGATGAGCTCAGTGGGACAGGAGGACGCTTTCGACAGCTGGGCGCTGCAAACTCTCAAGCAGCCTGTGAG
 ACGTTGTATGTCCGAGGCAACAGCACATTCAGATCCCAAGCTCTACACCTCCAATGTGACCTGGGACC
 CGCACCATCAGGCTCGTGCAAGACTACACGCTTTGGACCTCAGCAAAAGCCCTCAGCAGCATGCATGC
 CAAGAAGCTGTTACCATCAGGCTCAAATCTCGGCAGAATCTCAAAGTCCGACATCCAGCCGTGCCACC
 ATCTCTGGTGAACCTCTCTCTGTGAGGATGGCCAGGCTGAACCTCTGCCGGGGAGCAGCATTTGGGGTTT
 GCCCAGAACCCAGCCGCCCTTGGTCCAAGGTATCTTGGAGGAGTGATGGTGAGTGGCCCAACCCACACCA
 GACAGTGGCCCTGGAGGCCCTGGATGAGAGTGGCAGCTACTGGGTGAGTGAAGAGGCTGCCCCCTGCG
 TCACCTCAGCTACAGGCTCAGCTACTTCTGGACATCACACACCCCAACCCAGCTGCTGCTCCAAAGAG
 TGGCCAGGTGGCCACAGAAGAGCTTGAGAGACAGAGGCTGGAGGGCCCTGTGCGACCCCTCAGAGTACAG
 CAAGTGAAGTTCAACCAACAGCCCCACATTCCTGGAGGTGCTAGAGGAGTTCCCGTCCCTGCGGGTGTCT
 GCTGGCTCTCCGCTTTCCCGAGCTCCCATCTTGAAGCCCAAGTTCTACTCCATCAGCTCTCCCGGGAT
 ACACGCCACAGAGATCCACCTGACTGTGGCCGTGGTCACTACCACACCCGAGATGGCCAGGGTCCCTCT
 GCACACGGCGTCTGCAGCACATGGCTCAACAGCCTGAAGCCCAAGCCAGTGGCCCTGCTTTGTGGCGG
 AATGGCAGCGGCTTCCACCTCCCGAGGATCCCTCCCATCTTGCATCTCTCAGCTCGGSCCTGGCACAGGCA
 TCGCGCCCTTCCGAGTTTCTGGCAGACACGGCTCCATGACTCCCGACCAAGGAGTATGCGGGAGGCGG
 CATGACCTTTGGTGTTTGGGTGCCCGGCCAGATGAGGACCATCTACCAAGGAGGAGATGCTGGAGATG
 GCCCAAGAGGGGGTGTCTGATGCGGTTGCACAGCCTATTCCCGCTGCTGCGCAAGCCCAAGGTTCTATG
 TTCAGAGATCTTGGCGCAGCAGCTGGCCAGCGAGGTGCTCCGTGTGCTCCACAAGGAGCCAGGCCACCT
 CTATGTTTGGGGGATGTGCCCATGGCCCGGACGTGGCCCAACCCCTGAAGCAGCTGTGTGCTGCCAAG
 CTGAAATTGAATGAGGACGAGGCTGAGGACTATTCTTTCAGCTCAAGAGCAGAGGCTATCTACGAG
 ATATCTTTGGTGTGTATTTCCTTACGAGGCGAAGAAGGACAGGGTGGCGGTGCAGCCAGCAGCCTGGA
 GATGTCAGCGCTCTGAGGGCTACAGGAGGGGTAAAGCTGGCCGCACAGAACTTAAAGATGGAGGACG
 TCTGATATTATTCAGGTCTCAGGGCCTGGGGAGATGGAGAAAGTGATACCCCCAGCTCAAAGTCTTAT
 TTCTCTCAACGTTGCTCCCATCAAGCCCTTTACTTGACCTCTTAACAAGTAGCACCTGGATTGATCGGA
 GCCTCCTCTCAAACTGGGGCTCCCTGGTCCCTTGGAGACAAATCTTAAAGTCCAGGACCTGCGAAGT
 GGGTGAAGATGGAACCTTGCCTGAGTGCACCACTCTCAAGTGACCACCAAGGAGGTGCTATCGCACCACT
 GTGTATTTAACTGCCTTGTGACAGTTATTTATGCCCTCTGTATTTAAAAAAGTAACCCAGCTGTGTTCC
 CCATGGCCACTTGGGCTTCTCCCTGTATGATTCTCTGATGGAGATATTACATGAATTCGATTTTAACTT
 ATCACAAAAAAAAAAAAAA

>gi|4504788|ref|NM_002220.1| Homo sapiens inositol 1,4,5-trisphosphate
 3-kinase A (ITPKA), mRNA

GAATTCGGAAATGACCTGCCCCGGGCCCCAAGCGGCATGGCGCGCCGGGGGGCGCAGGGCCCTGCAG
 CCGGGGGCTGGAGCGGGCCCCCGCGCCGGAGTGTCTGGGAGCTGCGCCCTGCTCTTCGAGGCGCGCTGTGCG
 CGCGTCTGCTGCGGCCCGCCCGCGGGGAGGACCCCGGCCCGCGGGGCCAAGCGGCGTGGGGGACAGGTCTC
 CCAACGGGGCTTTCGCGGGCTCCCCCGGCCCGGTGATCCTTCAGCTGACCTTGACAGCCAGGAGCCCGGA
 CTGTCGCCCGACAGCCCTGGGCCCGCGGAGCGGAGAGGAGTGCCTCCCGGCCAGCGGGCTTCTTCGAC
 CTGCAGCAGCGCGCCGCTTTCCACCTCGTCCGTCTCTCCACTTGGCTCTCTGTCTGCTGCTGAGACT
 CGGAGGACGACCTGCTGAGCGACAGTGAGAGCCGGAGCCGCGCAACGTGCAGCTGGAAGCGGCGAGGA
 CGTGGGTACAGAAAACCACTGGCAGAGAATCTCGGACCATGGTCAATCTGCGCGTCTAAGGCCCTTTCAAG
 AAGCCCTGACGCTTGGGTGACCTGGCAGGCGACACTGGGAGTTTAAAGCGGCGGCGACCCAGGCGGCTGA
 TCTTGAAGCGCTGCTCGGAGCGGAGCGCTACTGCTTGGCGCGGCTGATGGCTGACGCCCTGCGCGCGT
 CGTGGCTGCTTTCGCGCGTGGTGGAGCGCGACGGCGAAGCTACTTGCAGCTGCAGGACTGCTGCGAT
 GGCTTCGAGCGGACCTGTGTGCTCGACTGCAAAATGGGCGTACAGACTTACCTAGAGGAGGAGCTGACCA
 AGSCCCGTGAGCGGCCCAAGCTGCGGAAGGACATGTACAAGAAAATGCTGGCGGTGGATCTTGAAGCTCC
 CACGAGGAGGAGCAGCGCAGCGCGCCGTACCAAGCCGCGCTACATGCAGTGGCGGGAAGGCATACG
 TCCAGCAGCAACCTCGGCTTCCGATCGAGGGCATCAAGAAAGCGGACGCGTCTCTGCAGCAGCAAGTCTA
 AGACTACGCGAAGCGAGAGCGGTGCTTTCGCGTCTTTGAAGATTGTGTGAAGAGGATGAGGAAGTCTG
 GAGGCGGTATCTGAACCGCTGACAGCAGATCCGGGACACCTGGAGGTATCCGAGTTCTTCAGGAGGAC
 GAGGTGATCGGCAGCTCGCTCCTCTTTGTGTCAGCATCACTGCCATCGCGCGCGCGTGTGGCTCATCGACT
 TCGGCAAGACCAAGCCCTCCCGATGGCCAGATCTTGACCAACGGCGGCCCTGGGAGGAGGGCAACCG
 CGAGGACGGCTATTTGCTGGGGCTGGACAATCTCATTTGGCATTCTGGCCAGCCTGGCTGAGAGATGAGG
 TGGACTCTGCTGCCCGCGGGCCGCTCACTGACATGTGACCTTGACGTTTGTGCCCATCTGTGATCGCG
 GCTTGAGACTGGAGCCCCGCGGTGACAGGCGAGTTCACCGGGCTCTGACGAGACAGGTGGCGGACCAATAG
 GGGGGGACCCCGCATGCCAGGGGTTTTCGCCACCCGGGCGCCAGCGTTCGCGAGCAGCAATGACACTAA
 CTTATAGAAGGGGAGGGGGCAAGGGCTTCTTCTCAGGCGAGCTTCTGAGGAGGCTCTGCCCTCTCC
 AGAGGTGCGCAGACCGCGAATTTATTTAGCAAGCCAGACCTTCCGGTCTAACGTCTCACACCCAGCAGG
 ATCCCTCTTCTAATAAAATCAAGACAAAA

>gi|38569399|ref|NM_002221.2| Homo sapiens inositol 1,4,5-trisphosphate
 3-kinase B (ITPKB), mRNA

GGAGCCGCGCGCGCGGCGAGCGCGGGACCCAGTACTATGGCTGTGTACTGCTATGCGCTATGCAATAGCCTGG
 TGATCATGAATACGCCGCAAGAGATGAAGAGCGCGCGCGGCCCGCAAGTGGCAGGACGAGCGCCCG
 GCCCCGAGGAGGCGAGTCTGAGCCCGCGCAGCGTTTTCAGCCCGGGAGAGGCGCTCTTTCTCTCTC
 CCCCCAGCCGAGTCTGCTGTCGCCCGAGGAGCCCGGAGCCCGGGGCTTGGCGGAGCGCGCCGCGAC
 TGAATAGTAGCAGCGCAGTGGCAGCGGCGAGCAGCGCGAGTAGCGTGAGCAGCCCAAGTTGGGCTGTGTCG
 CTTCTGAGGGGACCGCGAGCAGGTGGTGGCAGCCGGTACCTCTCCCGCCAGGGCCGAGGAGGCGCAAG
 AGGAAGCTGCGGATCTTGACGCGCAGTTGCAAGAAGCTGCAGGTGAACCGAGAAATGGGCATGTTTGAAG
 CGCACAATCCAGGCGAGCTCCGCCATTCAAGCGCCCGCAGCCCGCTTTGGGAGAGGCTCGCTCGCC
 CTCGCCGTGGCCCTTCCGAGCAGCAGTCAAGCCCTTGAAGGGTCTTGTTTCAAGGCGCCGCGAGCGAG
 GAACGGAGGACAAGTCTTGGGGGAGCAATGTCCAGAGACTTCAGGAACCGACTCCGGGAGGAAAGAG
 GGCCAGCCTATGCTCTCGCAGTGAAGAAAGGAATGCCACTCTTCCCGCCGGCTGCCCTTCAAG
 ATCAGAGGCTCAGGGTCACTCCGCTTTTGAAGGATGGAGAAGGGTATCCCTGCCAGTCCCGCTGTGGC
 TCACCCACAGCTATGGAATATGACAAAAGGGGCTCTCTACCCCGGGAACCTGGAGCTGCTAGCTCTCT
 CATTTGGGCTGTTCGAGCTAGCTTAAACGATGSCACGGAAGTGGCAGGAGATTACATCCAGCTGGCC
 ACACCTCCACAGGATCTTGGCCCTACTGAGCCGTCTGGAGAGGCGCGGTGAGCTTGAGGACCTGACGCC
 CAGAGGCCCTGTGTGAGAGGCGAGGGCAGTTTCTTGGCAGTGAGACAAGCCAGCCCAAGAAAGGGCG
 GGCCCGCGATGGAGAACCCTTGGGAAGATGGGAAAGGATATCTGCCCTGTGGCATGCCGGGCTCTGG
 GGAGCTGGAAGTGGGCAAAAGGCCAGAGGAGCAGCTGAGGCTGCAAAAGCCAGAGTCTCTGTGATCTT
 CTGAGCTGTGCCAGGCTGCCAGGCCCTTGGCTCCGTGAGGCTTGAGGAGGCCAGGATGCGGCGCCCC
 TGGGCGGGGCGCTTGGCAGCTCTCCGACAGAGTGGAGGAGGGTCCCAACCGCTGGGCTTGTCTGGGG
 CAGCCCTTGAGCAGCGCGGAGGACCGGGAATGTGGAGCGGGAATTTCTCTGCGAATGCTGAGGCCCT
 TTGCCCTGTGGGACGCTGCGAAAGATCTGAAGAAGCTCAGTGCCCTCTCTGGGACAGGGTGGGTGTG
 AGCCTGGGAAGCTCCAGGTTTGGCAGGCGACCATGGAGAAAGCGGTTTGGCTTGGACGCTGGCAGG
 GGTGCAATCAGGCGGCTTGGAAAGCCAGCGCGAGCAGAGTGAATGCCCTTCCAAGTCCGAGCTGCTA
 CCCCAGATCAGGACAAGCTTTCTTGAAGAGGCTGACGCGCCAGCAACATCATGCTGTCTATCTATT
 CAGACATGGGCAAGGAGGATGGGGCTTGGAGGAGCAGCAGGAAGCCCTCGGGGCAACCTGCTTCT
 GAGGAACTGTCTCTTCTCTGGCTCTCTCACGGGCTTCTCTCATCTACGAAGACTCAGAGGAGGAC
 ATCTCCAGTACCTTGAAGCAGCCCTGGACCCCACTCAGCTTCTTGCATACCTTGGACAGCAGAAAC

CTAGAGTGAGCAAAATCATGGAGGAAGATAAAAAACATGGTGCACCTGGCTCCCTTCGTATGTCCTTCAA
 GAAGAAGTACCCTTGGATCCAGCTGGCAGGACACGACGGGAGTTTCAAGGCAGCTGCCAATGGCAGGATC
 CTGAAGAAGCACTGTGAGTCAGAGCAGCGCTGCCCTGGACCGGCTGATGGTGGATGTGCTGTAGGCCCTTCG
 TACCTTGCTTACCTATGGGATGTGGTGAAGGACGGGGAGCGCTACAAACAGATGGACGACCTTACCTGGCCA
 CTTCCGACTCGCCCTGTGTGATGGACTCGAAGTGGGAATCAGGACCTACCTGTGAGGAGAGGAGCTACGAAG
 CCCCCGAAGAAGCCCACTGCGGAAGGACATGTACCAGAAGATGATCGAGGTGGACCCCGAGGCCCCCA
 CCAGAGGAGAAAAAGCACAGCGGGCTGTGACCAAGCCACGGTACATGCAAGTGGCGGGAGACCATCAGCTC
 CACGCCACCTCGGGGTTCAGGATCGAGGGAATCAAGAAAGAAGACGGCACCCTGTAACCGGGACTTCAAG
 AAGACCAAAACGAGGAGCGAGTACCAGAGGCTTCAGAGAGTTTCAAGAGGAACCAATTAAGCTCTCGA
 TCGCCTATTGGGACACGGCTGAAGGCCATTGCAACCACTCTAGAAGTTTCTCAAGTTGCCACAGA
 GGTCAATCGGAGCTCCCTCCTCTTCAATCACGACAGAAGAAGAACGGCCAAAGTGTGGATGATGACTTT
 GGGAAACACCGCCCCCTGCCTGAGGGGCAGACCCCTGCAGCATGACGTCCCCCTGGCAGGAGGGAAACCGGG
 AGGATGGCTACCTCTCGGGGCTCAATAACCTCGTGCACATCTTGACCGAGATGTCCAGGATGCCCCACT
 CGCCTGAGCTGCCACGCGCTCCTTGCGCCCGGCTGGGCCCTCTTCTCCTCCTGTGCTTCTTTCTC
 GTTCTTAACCTTTTCTTACTTACACCTGACTGACCTCCTGAACTGCATACAAAGGCTTTTGTAGAAG
 AGGAGATGAGATTTCTAGCTATTTTCTTAACCTCAGGGCTTGGAGGTGGATTTTGACATGCTTTTGTGA
 GAGAGGTCACCTACTAGAAGAAATGCCAGCTTTAGAGGTGGGTGAGTGTAGAAGTGGAGGGGGTC
 CTTGGCTGCTGAGGGACCTTACCAGATGAGCCCTGCGCTCTGGGAGCCCCTAGGAAGCACAGCCTGGA
 CCTACCACTCGCGGAGGCTCGCCCCCTGGCGGCCAGTGCTTTAGAGTGTCTGCCAAGCACAGCCCTTA
 TTTCTGCCGGGGCTCCTCCACCGAGAGCCACAGGGGGCCGGCCGGTTCCTGGTCCCTGGCTGGGAGCAG
 GGCCTTCTGTGTAGTTGGGGACAAAAACCATCTGGGGAACACATGTTGACTGTGAGCAAAAGTGTCTTCGGA
 TTAGAGCCTCAGGATGCCCTGGTGGCTCTTCCAGGGCTGCTCAGGCAAGGCCCCCCACCACTTGTA
 TGGAAACTCGCCGCTCCAGGCCAGACCAGGAGCCAAGAGAAGGCTGAAGCCAGCTTGGCTGTGTTCTC
 TGATCTAGGCTTCCCAGAGAGGCGGAGCAGAAGCTGTGCCACTTGGAAATTGCAACCCATGAGTTCAGAA
 GGCACACTCTGCCATCTGAGCTCCAAGGTGCTACCAGGGGAAGATGGGATCTATAGAGTCTCTGGGCC
 CTGGCCCCAGGAGGACACATTTTCTTGACCTCCTACCTTGTGTCTAGTTGGTCAACCTGCTCCTGCTG
 ATACATGGGCTCTGTCTGTGGGCCAGAGTCCCTTGCAGATATAGAAATAGGGGAGGAGCTCAGGCTGTG
 CGCCAGGCAAGGAAGGCGAGCTTCTGGCTTCCAGAGTGGCCGGTGGCCCTCTTGCAATCTTTGTA
 TTGCCCTGAAACAGCCTTACTGCCGTGAGGGCTTAGATTCTGCTTCTCCAATGTAGTGTGGGTATCT
 TGTAGGGTATGTGGTGGATGCCAGGGCGTGTCCAGGCACCTCTCTCTGAAGTCTCTGCATTTGGAGATT
 CGTGAGAAACCTATTTAAGCCCAATTTTAACTGAAAGCCAGTGAGTCTGATGAGGAAGATGTAAAAAT
 TTGCCCTGACTTCTTAAGAAACAAACCCCAAGCTCTGTGCCCATGCTCCTTGGGGCTTGCCACCACTCC
 TTTGCTGTGAGAGGTACAGGAGCTGGGAGAGTCCAGGAGCTAGGGACACAGAGGGAGACTATGACCAAG
 GTGTGTGTCTGGAGGAACCACTGCCCAACCCACCACCCCGGGTCTCTGGGGAAGTGTCAACCTGCC
 ACGGGACATGTACATTTTCCCTTTTGTGCTGGAAGTGTGAGTGACACTTGTGGGGTGGAGGGTGGGAC
 ACATGAGGATGTATAAGTACAGATTTAAAAAAGGAATCAACTTACCTTCTGGCTCTTGTTTAAAAAC
 AGTGGTGAGCTCTGTGTGGCGGCACCTTGTAAAGGTACACACCGCCGCGGCTGGAGCAGCAGAGACCTC
 GTGGCAGCATGTGATCTGGAAGGCAGGCAGGACGGGGCGTGGGGAGCCAAAGTCAACTCTTGGCCCTCT
 GGAGCTATAGTGACTTTTGGGCTAGAAGGGACCTTGGTGGTCTGTGCTTACGACCTTTCAGCGGAGGG
 CATCATTAATTACAGAGTAAAGATTCTATGAATATGGAATGGCCAAAAGTTTACTTACTCTCATCTGTGA
 AAGAAGATTGTGTAAGCAAAATCATGATATGAACAAAAATTACAGGGGACCTGTTTAAAGAGACAAAATGT
 TCCAAGCACTTTAGGAGACACACAGCTGTTTGAACAAATGTGCTAATATGCAAAATGATGTGCTTATTTAA
 AGGAGGCCCATGGGGCTCTTATTGGCAATACTTGGCTGTGGGTACATTAAGATGTGGAACATAGTAT
 AAGTAGCATCTTTAGGGTATTTCTGTACTTAGGGTTTGTGTTTCTGTTTCTTTTCTTTTCTTTTCT
 GTATTTACCTGTGTCTCTCTTACACCTACTCTGTCTCAAGCATTTTGGCAGCTCGCTTCCCTGCG
 CATCTGSCCTTCCCTTTGTCTCAGTGGGATAGATGGATTGTGAAATGGAATCTCCCAAGACCCCTGCC
 TGGCAGCTCGGAAGACCGTGCTCGCCAGCCCTCGTCAACACAGGAGCTCCTTGGGTCTCGGAGTGAT
 GTGCCAGCAGGACAGCAAACTCTGTGTAACCTGTGCAGTGAATGGGCGAGGCTCCTCTTGCCTGT
 CTTGCGGGGGGGCCCAACAGATTCTTGGCATTTCAGCACTGCTTAGCATCTCGGAAGGTTTCTTCAACTGC
 TCTGTTTCCCGAGCTTGCTTTAGTGTATGTAAGACATTTTAAAGTATATTTATTTTGTGTGGGTTTT
 AAAATTGCACAGAACACTAAGACCGAAAGGCTGGACTCTTGTGTTCTCTTGAAGAGCTTTGCTCTTGT
 GAACCTCTCTTCCCACTTGGTAGAAAGAGCCAGACCTCGACCCCTGGCCCTTGAAGATGACCTTTTCACT
 CTTCAAGTTGATTTAGCTTTGAGTTTCTTGCATCTGTCCACCCCATGTGTATCAACACCGCCCTTGGC
 CTCGGGGTGTCTACCTCTGTAGTGCCTTTTGTCTGGAAGGAGAGGACCCCGCCGCTGCCGAGAGCTC
 TCTCTGTTCTGCCACCTCTTCCCATGGGACTTGGAGAAACCTGAACCTGTTTACAACCCCTGACACG
 TGCTGTCAACAGATGCAACCTTCTGTAATAAGCCTTGGAGACCAAAAAAAAAAAAAAAAAAAAA

>gi|40254974|ref|NM_025194.2| Homo sapiens inositol 1,4,5-trisphosphate 3-kinase C (ITPKC), mRNA

GGGTCCGGCCGAAGCCGACCGAAGGAGCGGGCATGAGGCGCTGCCCTGGGAGCCTGAACGAGG
 CGGAGGCGCGGGCGCTGACCCGCGCGGCCCGCATGGGACTGGAGGCGCCGCGAGGAGCGGCGCGCGCA
 GCGCGGACAGCAGCGACCTTGGGCGCGCGCAGGGGCCCCGGCGGGGCGGCGCGAGAGGGGCGGCGCTGG
 GCCCGGACAGAGGGGTCAGCGCTCCACAGCAGGCTGAGAGGGCGCGCTCGGGCTGGCGCGGGGACAG
 AGAGTCCGAGGCAGAAATTCTGGACAGACGACAGACTGAGCCCGCGCAGCTGGCCTTGGAGTAGAGAC
 CAGAGGGCCCCAAGCAAAAGACGGAGCCAGACAGGTCAGGCTCCGAGCAGCATCTAGAATTGGAGCTGTGCTA
 GAGCTTGGAGACGACTTGTCTTCTTGGACGAGACCGGGACAGATGGCTTGGACTGATCCGACAGGTCGG
 ACCTCCAGTTTACAGCCCGAGGAGGCGAGCCCCCTGGACACAGCCAGGGGTGATAGGCCCTTGACACAGCT
 GGAAGTCACTGGGTCAAGCTCAGCCAGAGAGGGTCAAGTCTTGGGTGATACACTCTTGACCCACCAG
 AACAGTTCCAGCCTCCAGACTCACCAGAAGGAGCTGTCCCTCAAAGAGCCAAAGTGCTGATGGCTCTCT
 GGAAGAAATTGTATCTGATGGCTCCAGGACACAACAGGATATTGAAGGTCCCCTGGACAGAGCCATATAC
 TGATGGCTCCCGAGAAAAACAGGATACTGAAGCAGCCAGGAAACAGCCTGGCAGCTGGTGGTTTCCAAATA
 CAACAGGATACCTGATGGCTCCCTGGACACAACCTAGCAGCTGACGGTTTCCAGACAGCAAGCTGGGACAGACT
 GCCTCTTGGAGAGAGCTGAGGATGGCCATTAGAGGAACACAGCCTGGAGAAATTGCTGACTACCTTGTA
 CTCTCACTGAAGTGTAGCCCCCTGTGCCCTGTGCCCGCCTCATCTATTACCCTTGAGACCCCTGAGCCT
 GAGGCCAGCAGTGGGACCCCCCTCCCGGTTGAGGGGGGCGAGCGCGGCTTCTCTCTGCTCTTCTTT
 TCGAGGAGTCTGAGGATGACGTGGTGGCCGGGGCGGAGGTGCCAGCATCCGAGGACAGGCTTGGGAG
 CAAACCCCTGGAAGAGTCTGAAGACAGTTCTGAAGTATTCACCCCTTTGTGGTCTCCCTTCCGAAACACATAC
 CCTTTGGGTCCAGCTTCTTGGACATGCTGGGAACCTTCAGGCAGGAGGAGATGGTTCGGATTCTGAAACGTT
 TCTGTCACTGTGAGCAGCGCAGCTGGAGCAGCTGATGAAAGACCCGCTGCGACCTTCTGTGCTTGCCTA
 CTATGGCATGGTCTCGCAGGATGGCCAGACCTTCAACAGATGGAAGACCTCTCTGGCTGACTTTGAGGGG
 CCCTCCATTATGGACTGCAAGATGGGCAGCAGGACCTATCTGGAAGAGGAGCTAGTGAAGGCACGGGAAC
 GTCCCCGTCCCGGAGAACAGCATGTATGAGAAGATGGTGGCTTGGAGCCTGGGGCCCCCTACCCCTTGAGGA
 GCATCCCGAGGGTGCAGTACCAAGCCCCGCTACATGCAGTGGAGGGAACCAATGAGCTTCACTTATCC
 CTGGGCTTTCGGATCGAGGGATCAAGAAGGCAGATGGGACCTGTAACACCAACTCAAGAGACGCGAGG
 CACTGGACAGGTTGACAAAGTGTGGAGGACTTCTGTGGATGGAGACCAAGCATCTCCGCAAACTGACGT
 GGCATGCCTAGAAGAACTTCTGTAAGTCTGTGAGATCTCCCCCTTCTTCAAGACCCACGAGGTGGTAGGC
 AGCTCCCTTCTCTGTGTGACGACCCACACCGGCCCTGACCAAGGTCGTGATGATAGACTTTCGGCAAGACGG
 TGCCCTTGCCCGACCAACAGCAGCTCAGCCACAGGCTGCCCTGGGCTGAGGCGAACCGTGAGGACCGCTA
 CCTCTGGGGCCCTGGACAACATGATCTGCCCTCTGCGAGGGGCTGGCACAAGACTGAGCTGCTCAGCCACCA
 TCAGGTTAATTGGAAGGCGCCAGCTGGCTGGAGAGGCCCTGAGATGCCATGGGAGGCCCTGAGGTTGGCC
 ACGGGGGAGCTGGCCTCCAGGGACGGGAGAGATTGTGTCTATGTGCCACACGAGCAACCTGGGAAAGTC
 TGAAGGGCCTTGGGAGACAGGTAGCAGCTTGGCCCCATCATGATGCAAGGGGTTTGGGGAGCTTGAAGGA
 AGGTGATGAGGAGTGTGAGTCAGAAAAACAGAACGGGCTCCCGGATCTGCCGGGAAGGCTTCTGAGGGG
 CTGCCCTGAGAGCAATTACGTTTCACATGTCAAGGTTATGGTGTGACAGGGGTGCCCTGTGGACATGAATC
 ACTTTTAACTGCCCTCCCTGTGACGCTCCAGGCTGCCAGCTGGCTGAGGCGAGGAGCTGGGTGAGGCTCA
 TCTGTGGCGCCTCAGAGGGTCAAGCATCATTTGTTGAACAGATGCAGGCGCTCTGGACCATCTGGGGAGAG
 TGACAGTCCATGTCTTACCAGGAGCGCATTTTGAAGTCTGAGCGACAAGAGGCTCAGAGGGCATGACCCC
 ATGGGACTGGAATGCGGCGCTGAGGGCTGATACCGCTGGGCGGTATCCTGCCCTGCTGTGGCCCTGTGGGAT
 CCTCTGTGTCTCTCGCGGACATCTGTCTGACCTCCCTGCAGACCCAAACACAGCCAGCATCCCAAGCTTCTGT
 GCCAGCACTGTGACAGTACTCTGCTCTCTGTGACACAGATCCGGCCTCAGGACTTACACCTCTCTGCTCT
 ACCCCAGGCTTCTCTCTCTTCTCCAGCAAACTGCAGTGGCAGAAAGAGGTTTCAAGAGGCTGGGAAAG
 GTGGGCTCTCCCTTGTCAACTCAGAGCTGTCTGCACTCAGGAGGGCCCCATCCAAATCCGGGCCCCCTGCAAG
 GAAAAGCGCTGGGTGTGTGTGTCAGAGGCGCAGGGTGGGTGGGGCTGCCAGCCAGGACCTTGGCCTGCAGCC
 TGATCCAAACCAAGAGCTGTAGAACCCTGGGGTGTGGCTAACGGCCCCCTCAGACCCCATAGGCCAGCTGTCT
 TCTCGGCCCTTGAAGCTGGGCTGGCGGACAGGCACCTTACCTTTCCTTAAGCTGAAGCTCCACACTGCT
 TTCAGGGCTGAGGAGATGCTCTCTTTCTACTGACCATCTTGATACTTATTTATACGAGAGGCAAGTTG
 CTGGGCTAGTACTGGGAAGCAGGAGGAGAGAAATGCTCTGCTGAGCCTCTTACCCATGACACACCC
 CAATAACAGAACATTACAGCCAAAAA

>gi|4758697|ref|NM_002372.1| Homo sapiens mannosidase, alpha, class 2A,
 member 1 (MAN2A1), mRNA

GGCTCTCGCATCTTGTCTCTTTCCCTTCGCTTCTCTGACCTAGCTGCGCGGCCCGGCCCGGAGCT
 GCCGAACCCCGCCTCCCTTGGGTGAGGAGGACAGCCTGCCCTGTCGAGAAACATTTTCTGCCGACT
 CAGTTGGGCGGCGGTGGCAGGAAGTCGGGCAGCGACCTCTCTCCGCTGCCCGCGCGCCCTGCCGG

AGGTCGGCGCTGAGCTTTCGATCAAGTTTGTGGGGGCCCCCTTCCAGTTGCGCGGAGCTTCGCTCG
 AGAGGGGCGCCGACCCCGGGAGGGCGGCGAGGCCAGAGGCCGTTTGTGGCGCCGGAG
 ACTAGGTCGGGAGCAAGCGGGGACTCGCACCCGATCCGAGAGCGGGAGGCTCGCGAGCCCGGAGAA
 GGGAGGCTTCGAGCGGCTGCTTCTTAGAGTCCACAGTGCCTGTCTCTTTGGCTGAGGAGAGTGTCTGG
 CCCCAGTTCTTACGAGGAAAAATGAAGTTAAGCCGCGAGTTACACCGTGTTCGGCAGTGCATCTCTGTGT
 GGTGATCTTCTGCTCTACTCTGATGCTGGACCGGGTCACTTAGACTACCCAGAAACCCGCGCGGAG
 GGCTCCTTCCCTCAGGGCCAGCTCTCAATGTTCGAAGAAAAATAGACCATTTGGAGCGTTTGTAGCTG
 AGAATAATGAGATCATCTCAAAATTTAGAGACTCAGTCACTAATTGAGTGAGTCTGTGGAGGATGTGCT
 GAAAAGTTTCAGAAAGCAATTTACGCCAAGGTCTGGCTCACATCTTC TGCCCTCACAATTTATCCCTCTCA
 GTTGACACTGCGACAGTGTCTGTTTGTCTTCAAAAGTGAAGTCACAATTCAGATGTGCGAGATGTTGGATG
 TTTACAGTCAATATTTTGTGACAAATCCAGATGGTGGAGTTTGGAAAGCAAGATTTGACATTTACTATGA
 ATCTAATGAATGGGACACTGAACCCCTTCAAGTCTTTGTGGTGCTCATTTCCCATAAACGACCCAGGTTGG
 TTGAAGACTTTCATGACTACTTTAGAGACAAGACTCAGTATATTTTAAATAACATGGTCTCAAGCTGA
 AAGAAGACTCAGGAGAGAAGTTTATTTGGTCTGAGATCTCTTACCTTTCAAAAGTGGTGGGATATTATAGA
 TATTCAGAGAAGAGTGTGCTTTAAAGTTTAAATAGAAAATGGTCAGTCTGAAATTTGTGACAGTGGCTGG
 GTTATGCGCTGATGAAGCTACTCCACATTTATTTGGCTTAATTGATCACTAATTTGAAGACATGTTGAGT
 TGGAAAATAATATAGAGATGAACCTCGGTCCGGCTGGGCTATTGATCCCTTTGGACACTCACCAAAAT
 GGCTTATCTTCTAAACCGTCTGGACTTTCTCACATGCTTATCCAGAGAGTTCATTATGCACTTAAAAAA
 CACTTTGACATGCTAAAAACATTTGGAGTTTPTTGGAGACAGAATTTGGGATCTGGGAATGTTCACAGATA
 TTTTATGCCATGATGTGCCCTCTACAGCTATGACATCCCTCACACTTGTGGAGCCTGTGATCTAAAAATG
 CTGGCAGTTGATTTTAAACGCTCTTCTCGGAGGACAGATTTGGTTGTCTCGGGAGTCCGCCGAGAAACA
 ATACATCTGGAAATGTCCAAAGCAGGGCTCGGATGCTACTAGATCAGTACCGAAAGAGATCAAGCTTT
 TCTGTACCAAGTTCTCTCTGGCTCCACTAGGAGATGATTTCCCGTACTGTGAATACACGAATGGGATTT
 ACAGTTTAAAGAATTATCAGCAGCTTTTGTGATTATATGAATTTCTCAGTCCAAGTTTAAAGTTAAGATACAG
 TTTGGAATCTTTACAGATTTTTTTGTGTCGCTGGATAAAGCAGATGAACCTCAGAGACAGAGGCCAGT
 CGATGTCTCCGTGTTTAAAGTGGAGATTTTTCACCTTATGCCATCGAGATGATCATTTACTGGAGTGCTA
 TTTTACATCCAGACCTTTTACAACGAATGGACAGAATCATGGAATCTCATTTAAGGGCTGCTGAAATTT
 CTTTACTATTTTCGCCCTGAGACAAGCTTCAACAATACAGATAAAATAAATTTCTCTCATCATCTATTACA
 CGGCACTGACAGAAGCCAGAAGGAATTTGGGACTGTTTCAACATCATGATGCTATCACAGGAATGCAAA
 AGACTGGGTGGTTGTGGATTATGTGACAGACTTTTTCATTCGTAAATGGTTTGGAGAGAATAATTTGGA
 AATTCTGCATTTCTTCTTATTTTGAAGGACAAACTACATACGACTTCTACTCTCTGATCACTTCTCGG
 AGATGGATTTGAAACAAAAATCACAAGATTTCTTGCCACAAAAAATAATAAGGCTGAGTGGCGAGCC
 AAGGTACCTTGTGGCTATAAATCCTTTAGAACAAGACCGAATCTCGTTGGTCTCAGTCTATGTGAGTTCC
 CCGACAGTGAAGTGTCTCTGCTTACGGAACACCTGTGGAAGTTCAAGTCAGCGCAGTTTGGGATACAG
 CAAATACTATTTACAGAAACAGCCTATGAGATCTCTTTTCGAGCACATATACGCCCATTTGGGACTGAAAGT
 GTATAAGATTTTGAATCAGCAAGTTCAAAATCACATTTAGCTGATTTATGCTTGTATAGAAATAAAGTA
 GAAGTACCGGAATTTTACCATAAAGAAATGATAAATACTGAAGAAGGTATAAAGTACAGAAAGTCTCT
 TTGTTTACTTCTCGGTTTGTATCAAACTGGACTTTGTGAAGCAAAATGATGACTAAAGAGAGTGGTAAACACA
 TGAAGTAAATGTCAATTTTTCATGGTATGGAACCAATTTAAAGAGACAAAGTGGTGCTTACTCTCT
 TTACCTGATGGTAAATGCCAACCTTATGTTTACACAACACCGCCCTTTGTGTCAGAGTGACACATGGAAGGA
 TTTATTCGGAAGTACTGCTGCTTTTGGACATGTACTCATAGAGTCCGACTATACACATACAGGGAAT
 AGAAGGACAGCTGTGGAAGTTTCCAATATTGTGGACATCCGAAAAGTATATAACCGTGAGATTCGAAT
 AAAATTTCTCTCATATAAAGAGCCAAAAATAGATTTTATCTGACCTAAATGGGTACAGATTTCAACCTA
 GAATGACACTGAGCAAAATGGCTCTTCAAGCAAAATGCTATCCCATGACCACAAATGGCTTATATCCAGGA
 TGGCAAACTGTTTGTGACTGCTCTGCTCAGTCTTTAGGGGTTTCGAGTTTGAATAGTGGTCAATTT
 GAAGTTATCATGGATCGAAGACTCATGCAAGATGATAATCGTGGCTTTGAGCAAGGTATCCAGGATAACA
 AGATTACAGCTTAATCTATTTCGAATACTACTAGAAAAAGAGTGTCTTAAATACGGAAGAAGAAAGAA
 TCGCTGCTGAGTTTCTCTCTTCTTACCCACATAAATCTTCTCTCATGATCTCTCAGTCACTTCCAAT
 GCAAAATAGTTCTCACCATACCTTTGAGCTGCAAGGTGAATTTCTCTCCATGACGTCACTTTTGGCTTTGTG
 ACATTCATCTGGTTTAAATTTGAGAACAATACAGTCAAGGTGGGCAATCCCAATGAGGCGAGCCTT
 GATCTCTCACAGAAAAGGGTTTGAATGTCTGGTCTCTTAGCAAAAGGCACAGGGCTGTTTGTGTTCTACTACT
 CAGGGAAGATTTGGTACAGAAACTTTTAAACAAGTTTATTGTCGAAAGTCTCACACCTTCTATCATCTAT
 CCTTGTAGCTATCACTCCCGGCACAGAAATAGAGTGAGATCAACTTGAGTGAATGGAATGAGACGAC
 ATTTCCGAATCCAGTTGAGGTGAACCTGACTTTTCAATTTGGATTGAGAAATCATTTGGCTTTTATACCTTCT
 TTGGTTGACGTGCAATAAAGAACACATTAATTTAGCTCTGGCTACTGTGAGAACAATGAATCTCTGTA
 TTCTGTGGGTTTTTCTTTTCTTTTACCAGTACAGTAAG

>gi|5540099|ref|NM_006122.1| Homo sapiens mannosidase, alpha, class 2A, member 2 (MAN2A2), mRNA

GAGCAGCTCGGCCGACCTGGGCGCCGAGCGCGCGGAGGCCGCGGCGCTGACGGGTGTGTGTGGAGGCCAGTAA
 GAAGCTGAAGAAACAGGTCAGACGTGTGTGGGGCTGCCATCTTCTGTGGCAGTCTTCTCGCTCTACCTC
 ATGCTGGACCGAGTGTCAACACGATCCACCCGACACAGAATGGTGGGAACCTCCCCCGGAGCAAAATTT
 CTGTGCTCGAGAACCCTATTGACAGCTGGAGCAGCTTTTGGAGGAGAACCATGAGATTATCAGCCATAT
 CAAGGACTCCGTGCTGGAGCTGACAGCCAACGACAGAGGGGCCGCCCATGCTGCCTTACTACACGGTC
 AATGCTCTCTGGGTGTGTGCCACGGAGGCCCGGGCCAGCTTCTTCTCCATCTCCCCCGAGGACTGCCAGT
 TTGCTTTGGGGGGCGGGGTGACGAAGCCAGAGCTCAGATGTCTACTGTGTCCGAGGAAGTCGGCTTTGA
 CAACCTGATGATGGTGGTGTGTGGAGGCAAGGCTTTCACATCTCTACGACCCGACACCACTGGGATGCTGAA
 GACCTCAGAGGTGTATTGTGTGTGCCCACTCTCACAATGACCCAGGCTGGATCAAGCACTTCAAGATGT
 ACACAGAGCAGACCCAACACATCTCTCAATAGCATGGTGTCTAAGCTGCAGAGGAGCAACCCCGCGGCGCTT
 CCTCTGGGCAGAGGTCTCTCTCTTCGCGAAGTGGTGGGACAACATCAATGTCCAAAAGAGAGCGGCAGTC
 CGAAGGCTGGTGGGAAACGGGCAGCTGGAGATTGCGACAGGAGGCTGGGTGATGCCAGATGAGGCCAATT
 CCCATCACTTTGCAATTGATGTACAGCTCATCGAAGGACACCACTGGCTGGAGAGAAATCTTGGTGTCAAC
 CCCCCTCTGTGGTGGGCTGGACCCCTTTGGATACAGCTCCACCATTACCTGTGCTGCGCGCTGCC
 AACCTCACCAGCATGTCTGATTAGAGAGTGCACTATGCCATCAAGAAGCACTTTGTGCCACCCACAGCTT
 TAGATTTCATGTGGAGGCAGACATGGGACTCGGACTCCAGCACAGACATCTTCTGTACATATGTCCTT
 CTACAGCTATGAGCTCCCCATACCTCTGTGGCCAGATCCCAAGATCTGCTGCCAATTTGATTTCAAACGC
 CTGCTCTGTGGTGGCAGATCAACTGCCCTTTGGAAGGTGCCACCCCGGCCATCAAGAGGCCAGCTGGCAG
 AGAGGGCAGCCCTGTCTTCTGTACCAATACCGGAAGAGTCCAGCTGTTCGGAAGCAAGCTCCTCTGGT
 GCTCTTTGGAGTGAAGCTTCCGATATGACAGCCCGAGAGTGGGATGCCAGTTCTTCAACTACCAACGG
 CTCTTTGACTTCTTCAACAGCAGGCTTAACCTCCATGTGCAGGCCAGCTTTTGGCACTCTTCTGACTATT
 TTGATGCCCTGTACAAGAGGACAGGGGTGGAGCCAGGGGCCCGGCTCCAGGGTTTCTGTGCTGAGCGG
 GGATTTCTTCTCTATTCGCGACCGGGAGGATCATTACGTGACAGGCTATTACATCTCCGGGCCCTTCTAC
 AAGAGCTTAGACAGCTCTCGGAAGCCCACTCGCGGGGCGCAGAGTTCTGTACAGCTCTGGCTCGAGCTC
 AGCTCTGCCGCTCTGTGCTGTGCTGGCGGTACCCACTGTCTGATTTCACCTCTCTGACCGAAGCTCGCGG
 CACATTTGGGCTCTTCCAGCATACGATGCCATCACTGGCACGGCCAGGAGGCTGTGGTGGTGGATAT
 GGGGTCAAGCTTCTGCGCTCTCTGTCAACCTGAAGCAGGTTCATTCATTGCAAGCCCACTATCTGTGTG
 TGGGGACAAGGAGACCTACCATTTTGACCTTGAGGCGCCCTTCTTCAAGTTGGATGACATCTGCTTAAG
 TCACGACGGCTCCCAAGGCGCAGGGTGATCTCAGCTGGATTCTCGCCAGGTTTGTGTGCTATTCTCAAC
 CCACTGGAACAGGAGCGATTAGCATGGTGTCTCTGCTGGTCAACTCTCCCGCGCTGCGCTGTCTTTCCG
 AGGAGGCTCAGCCCTGGCCGTGACAGATCAGCGCACACTGGAGCTCTGCCACCAGGCGGTCTTGAAGCT
 CTACCAAGTGTCTGTGCTCTGCTGCCCTGCCAGCCCTGGGCTGGGCTGTGTCAGCTACAGCTGGGCTG
 GATGGGCACCCGACGCTGCCCTCTCTGTGCGCATCTACCTGCACGGCCGCGAGCTGTCCGTACGACGG
 ACGAAGCGTTTCTCTCTCGGTGTCATTGACTCTGGCACACGCGACTTCGCCCTCAGAACCCTGATACGTA
 GGTCTGTGTTCTCAGGCTCTTACTGGGCTCTCAAGGGGTCAAGGCTGTGTTTGTTCGACAGCATCTCGAAG
 GGTGTGATGAGGAGCAGGACAGGTCAGGTGACATGACAGTCTTGTCTATGGACCCCGTACGCTCAAGAG
 AAGAGTGGAGCTTACCTCTTCTCTGCCGATGGCAGGCGAAGCCTACGTCTCCCAAGGAGCCCGCGTGTCT
 GCGTGTCAAGGCCCTTCTCTCTCAGAGGTGGTTCGCTATATGACACATTATACAGACCAAGCACTTGA
 CTTTACAATCTGCCAGGGGTGGAGGGGCTGTCTCTGGACATATCATCTCTGGTGGACATCTCGGACTACG
 TCAACAAGGAGGCTGGCCCTGCACATCCATACAGACATCGACAGCCAGGGTGCAGCCCGACGGTATCTGA
 AGAAGCTCCGCTCTCAGGCCCAACTTCAACCCATGCCAGTCATGGCTATATCCAGGACGACACAGGAAGC
 CTTACGCTGCACATGCTCCAGGCCCTTGGGTGTCTTAGCTCTCAAGAATGGCCAGCTGGAGGTGATCTGT
 GACCCAGGCTGTATGTCAGGATGACAACCGGGGCTAGGCCAAGGGCTCAAGGACACAAAGCAAGCACTTGA
 ACCGTTTCCGCTCTCTGCTAGAGCGGCGAACCCTGGGCAAGTGAAGTCCAAGATAGCCACTCTTACCACTGA
 CCGATCTCTCTCTCAGCCACTGACCTCCATGTACCTGAAGCGCCCGCGCTCTGCTCTGCTCTGATGCCAG
 ATGACGCTCCAGCCCTGGCTGCGCTCATTTCACTCTCTGGCTTCTCACTGCTGCTGACTCTTCACTTCAAC
 TGCTCAACCTACGTACGCTCAAGCTGAGGAGGACACCTACCTCTCGCGGAGACCGCATCATCTTACA
 CCGCAGGGTTTGTGATCTGCGCTGAGGCGCAAGAACTTGGGCTCAACTCAGCCACCAAGCAAGGCAAG
 GTAGCCCTGGGACGCTTTTCCATGGCTGGATGTGGTATTCCTTCAAGCAACCTCTCTGACGTTTACTGT
 ACCCTCTGGCTCTCCCGCTCAACAGCACTGACGTCTATTGGAGCCCATGGAGATTGCTACTCTTCCGCT
 CGGCTTGGGTTAGGGCTCTTCTGTGGCTGAAGAGAAAGTTCATTACAGAGACTGCTCTTAAACATGAAG
 ATCATTTGACAAAGCCACACGGGTATCCATCTCCGATCTGCTCTCCAGCAACTGTGACACACTGGGCTCTGC
 CCTCATTTTCTGTTTATTGGCTGTGTGTGTTTTCGGCGCAACCCACAAACCTGATGTGGTAAATGAG
 GCAGACGCGAGTGAGATCAGGAGAGAAAGCCCTTGGTCAAGTGGGCAAGTGCAGGCTCTGCTTGGGT
 TGTGAGTGGACACCAACTGGGACAGGCTCAGGCACCCATCTCTTTTCCAAACAGGGAATAGAAGTGG

TGGAAGCAGACAGAAGAGGTAAAGGAGGCTAAAGTGGGTAAACAGCCAGCATCAGGGTCACTGTGGCAACA
 GCAGGCTCTAGGGGAATCTCTGGTATTATGTAGAGACTCCATGTCTCGTGTGATGAGCAGGATCAGAGTG
 ACTCTTGGGAGGACAGGGGTGGGAGCCAGAGATTAGCAGTGGGATGGAGCAGTAGAAGGAATCACTGTTT
 CTCCTTAGGAGTCTGAAGGCTCTGCTGCTTCTGTGATGGCTTTGCAGTAAAGTCCGCCCTTGGCCTGCATGC
 ATTGGCTAACAGAGCTCAGAAATGGCAGGAAGGACTCGCTAGAGATTGTCAATGGCCAGAGATCATAGGTCA
 CTTACAGGTAGCAAGCACTCGCAAACTGGGCATCTGGCCTATGTACTGATTGTGGGATGGTGGCAGGG
 GTGTGGGTCTCTCACCTTGCTGAAATCTCTTTGGCTCTGTGCTCTGTATGCTGCTGTCCCAAGGGC
 TCTTTCTTATTATGGCAGGAGTGGGGATTGGTCTACTTTCTCTCTGGAAAGGAAAGCCTCCAAGAC
 TCCATGTGCTTGGGCAGCTTGAGAAGCGTTCAGCACACCGCTAGCAGGACAGCTTGAAGCCTCACT
 TTAGTCTATCTGCAGAGGTATTACAGTTCTTGGCAGGGGACTAGGGGCAATGTAAGTATATGAGGAGGC
 AGTATGGGTGTGCAGGAGCTTCATTTCAGCTTCAATTAATAGGGAAGAACTTATGATAGCTCTATAGAT
 GCTGAAAAGGTATTTCGTAAGATTAAAAATCCATCCCTTATTAATAACTCTTAGTAAATTAAGTCTGGAAA
 GAAACACCCCTAATCTAGATAAAGGTCTGTTTCAGAAACCAACAGTAGTGCCATCTAAGAGTCAGACGC
 CACAGGCATTCCTCATTAAGTCAGAAACTAGCCAAGGCAAGCTATTATTACAGCAGTGTCCCGGCATCAT
 TAACCCCTGCAACAAGCCAGATGAGGAACATAAGGAAGAATTATAATTGTCAATTATTGTAGACAAATAA
 ACTGCTACTCTGTAAAA

>gi|10835172|ref|NM_000620.1| Homo sapiens nitric oxide synthase 1
 (neuronal) (NOS1), mRNA
 AGAGCGGCTCTTTTAATGAGGGTTGCGACGCTCTCCCTCCCCACCCATAAACACAGTCGGGTTGGACGTC
 ACTGTAAATCTGTTTCAGTGATGATAGGATAAAGGAGGGACATTAAGAAATTAATTCCTCCCTACGACCC
 TCGCTGAAGCTCAGGGCTCAGTCCCTACATATTATGCGCGGTTTCCAGCCGCTGGGTGAGGAGCTACTTA
 GCGCGCGGCTCTCCGAGGGGCGGCCGGGACGCGAGCAGCGCGGAGCGGAGCGGCTCATATGATGCTCA
 GATCTGATCGCATCTAACAGGCTGGCAATGAAGATACCCAGAGAATAGTTACATCTATCATGCGTCAC
 TTTCAGTACAGGCCATCAGACGCATCTCTCTCCCTTTCTGCTGACCTTAGGACAGCTGCCACCGGCTCT
 CTTGACGCTGCTGCTGTGCAACATCACTTCTTTAGAGAATAAGGAGAGAGGCGGATGCAAGGAAATCATGC
 CACCCAGCGGCCACCAAGCATAGTGGGTGACGCTGAGCTGACGCTCAAGACAGAGAGGGGCTGAAGCCTT
 GTACGACCTGTGACCCCGGCTCTGCTCTCCGTGTAGGCTGAAGCGTGAAGCTCTCTCTGGTAGCAATCATC
 TTGGCTGATAGCATTTGTGAGGTTCTCAGACAGGACCCCTCGGAAGCTAGTTACCATGGAGGATCACAAT
 TCTGGTGTTCAGCAAAATCCAGGCCAATGTCAATTTCTGTGCTGCTCTTCAAGCGCAAAAGTTGGGGGCTG
 GATTTCTGTTGAGGAGCGGGTCAGTAAGCGCCCGTGCATCTCTGACCTGATTTCTGGGGGCGCGCC
 AGAGCAGAGTGGCTCATCCAGGCCGGAGACATCACTTTGCGGCTCAACGGCGGGCTCTTGTGGAGCTG
 AGCTATGACAGCGCCTGGAGSTACTCAGAGGCATTTGCTCTGAGACCCACGCTGGTCTCATCTTGAGGG
 GCCCTGGAAGTTTACCACGCACTGGAGACACCTTTACAGGTGATGGGACCCCCAAGACCATCCGGGT
 GACACAGCCCCCTGGGTCCCCCACCAAAGCCGTGGATCTGTCCACCAGCCACCGGCCGGCAAGAACAG
 CCCCCTGGCAGTGGATGGGGCTCTGGGTCCCGGGAATGGGCTCAGCATCGATGATGATGGGACGAGG
 CTGGCTCACTCCCCCATGCCAACGGCTTGCCCCAGGCCCCAGGCCAGGACCCCGGCAAGAAAGCAAC
 CAGAGTCAGCCTCAAGGACAGGGGAGAACAAATGAATGCTCAAGGAGATAGAGCCTGTGCTGAGCCTT
 CTCACCACTGGGAGCAGAGGGGTCAAGGGAAGGGGCACTGCCAAGGCAGAGATGAAAGATATGGGAATCC
 AGGTGGACAGAGATTGGACGGCAAGTCACACAAACCTCTGCGCCCTCGCGCTGCGGAGACGACGATCTT
 CAATAGCCTATGGGGGAAGGGCAATGTGCTGTGCTCTCAACAAACCATATTACAGAGAAGGAGCAGCCC
 CCCACCTCAGGAAAAAGTCCCCACAAAGAAATGGCAGCCCTTCAAGTGTCTCACGCTTCTCAAGGTCA
 AGAATCGGGAGCTGAGGTGGTTCTCACTGACACCCCTAACAGACCATTTGGAAACGGGATGCAC
 TAGATACATCTGATGGGCTCCATCATGTCATCTTCTCAGCATGCAAGGAGGCTGAAAGATCGCGACA
 AAGGACAGCTCTTCCCTCTGCGCAAGAGTTATTGATCAATACTATTCTCATTAAGAAAGTATGGCT
 CCAAGGCCCATATGAAAGGCTGGAAGAGGTGAACAAGAGATCGACACCCTAGCACTTACCAGCTCAA
 GGACACAGAGCTCATATTGGGGCAAGCAGCCCTGGCGGAATGCCCTCGCGCTGTGTGGGAGGATCCAG
 TGGTCCAAGCTCGAGTATTTGATGCGCCGTGACTGCACACCGCCAGCCGGATGTTCACTACATCTGTGA
 ACCATGTCAAGTATGCCACCAACAAAGGGAACCTCAGGTCTGCCATACCATATTTCCCCAGAGGACAGA
 CGGCAAGCAGTACTCCGAGCTTGGAACTCCAGCTCATCCGCTACGCTGCTGCTACAGAGGCTGACGGC
 TCCACCTTGGGGAGCCAGCCAAATGTGCACTTACAGAGATATGCATACAGCAGGCTGGAAAGCCGCTCA
 GAGGCGCTCTGATGCTTGGCGCTCTGCTTCAAGGCCAACCGCAATGACCTTGAGCTCTTCCAGATTCT
 TCCAGAGCTGGTGTGGAAGTTCCCATCAGGCACCCCAAGTTTGAAGTGTCAAGGACCTGGGGCTGAAG
 TGGTACGGCTCTCCCGGCTGTCTCAACATGCTCTAGAGATTGGCGGCTGGAGTTCAGCGCTTCTCCCT
 TCAAGTCTGGTACATGGGACAGAGATTGGTGTCCGCGACTACTGTGCAACTCCGCTCAAAATATCTCT
 GGAAGGATGGCCAAAGAGTGAATCTAGACATGAGGAAGACGCTCTCTCTGGAAGGACAGGCGCTG
 GTGGAGATCAATATCGCGGTTCTCTATAGCTTCCAGAGTGACAAAGTGACCATGTTTGACCATCTCCG

CCACCGAGTCTTCATTAAAGCACATGGAGAATGAGTACCCTGCCGGGGGGCTGCCCTGCCAGCTGGGT
 GTGGATCGTGCCCCCATGTCCGGAAGCATACCCCTGTGTTCACACAGGAGATGCTCAACTACCGGCTC
 ACCCCCTCCTTCGAATACACGCCCTGATCCTCGGAACAGCATGCTCGGAAAGGCCACCAACGGGACAGCA
 CAAAGCGCGAGCCATCGGCTTCAAGAAGCTAGCAGAAGCTGCAAGTTCTCGGCCCAAGCTGATGGGCA
 GGCATTGGCCAAAGGGGTGAAGCGACCATCTCTATGCCACAGAGACAGGCAATTCGAAGCTTATGGC
 AAGACTTGTGTGAGATCTTCAAACACGCCCTTGATGCCAAGGTGATGCCAAGGAATATGACATTG
 TGCACCTGGAACATGAAACTCTGGTCTCTTGTGGTACCAGCACCTTTGGCAATGGAGATCCCCCTGAGAA
 TGGGGAGAAATTCGGCTGTGCTTTGATGGAAATGAGGCACCCCAACTCTGTGACGGAAGAAAGGAAGGAC
 TACAAGGTCGAGTTCAACAGCGCTCTCTCTACTCTGACTCCCAAAAATCATACGGCAGTGGGCCGACCT
 CTAGAGACAACCTTTGAGAGTGCTGGACCCCTGGCCAAATGTGAGGTTCTCAGTTTGTGGCCTCGGCTCAGG
 AGCATACCTCACTTTTGGCCCTTCGGACACGCTGTGGACACCTCTGGAAGAATGGGAGGGGAGAGG
 ATCTTGAAGATGAGGGAAGGGGATGAGCTCTGTGGGACGGAAGAGGCTTTCAGGACTGGGCGAAGAGG
 TCTTCAAGGCAGCTGTGATGTCCTTCTGTGTGGGAGATGATGTCAACATTGAAAGGCCAACAACTCCCT
 CATCAGCAATGATCGCAGCTGGAAGAGAAACAAGTTCGCCCTCACTTTGTGGCCGAAGCTCCAGAATC
 ACACAAGGCTATTCCAATGTCCACAAAAGCGAGTCTCAGCTGCCCGGCTCCTTAGCCCTCAAAACCTCC
 AGAGCCTTAAATCCAGTCGGTCAACTATCTTCGTGCGTCTCCACACCAACGGGAGCCAGGAGTGCAGTA
 CCAGCTGGGGACCACTGGGTGTCTTCCCTGGCAACCAGGAGACCTCGTGAATGCCCTGATCGAGCGG
 CTGGAGGACGCGCCGCTGTCAACCAGATGGTGAAGTGAAGTCTGTGGAGGACGGGAACACCGCTTTAG
 GTGTACTCAGTAACCTGGACAGCAGAGCTCCGCTCCCGCTGCACCATCTTCCAGGCTTCAAGTACTA
 CCTGTGACATCACCAACGACCAACGCCCTCTGACGCTGACGAGTTTGGCTCCCTTAGCTACACGCGAAG
 GAGAAGCAGCGTCTGCTGTCTCAGCAAGGGTTTTCAGGAGTACGAGGAATGAAGATGGGCAAGAACC
 CCACCATCGTGAGAGTGTCTGAGGAGTTCCTATCTATCCAGATGCGCGCCACCTGCTCTGACCCAGCT
 GTCCCTGCTGACGCCCGCTACTATTCCATCAGCTCTCTCCACAGATGATCCTGATGAAGTGCACCTC
 ACTGTGGCCATCGTTTCTACCGCACTCGAGATGGAGAAGGACCAATTACCACGGCGTATGCTCCTCCT
 GGCTCAACCCGATACAGGCTCGCAACTGTGCTCCCTTTTGTGTGAGGAGGACACCGAGTCCACCTTGGC
 CCGGAACCCCAAGTCCCTGACATCTCTGTTGACACGGCAGCGGATTTGCCCTTTCTCGAAGCTTTCTGG
 CAACGCGGCAATTGTGATATCCAACACAAGGAATGAACCCCTGCCCATGGTCTGTGTTCTCGGTTGCC
 GGCACTTCAAGATAGATCATATCTACAGGAAGAGACCTTGCAGGCCAAGAACAGGGGGTCTTCAGAGA
 GCTGTACACGGCTTACTCCGGGAGCCAGACAAACAAAGAAGTACGTGACAGGACATCTGCAGGAGCAG
 CTGGCGGAGTCTGTGTACCGAGCCCTGAAGGAGCAAGGGGCGCACATATACGTCTGTGGGGACGTACCA
 TGCGTGTGATGTCTCCTCAAAGCCATCCAGCGCATATGACCCAGCAGGGGAAGCTCTGCGCAGAGGACCG
 CGGCGTATTCATCAGCCGATGAGGGGATGACAAACGATACCATGAGGATATTTTGGAGATCAACCTCGCA
 ACGTACGAAGTACCAACCGCTTAGATCTGAGTCCATGCGCTTATTGAAGAGAGCAAAAAGACACCG
 ATGAGGTTTTTCACTCCTAACTGAGCCCTCTTGCCAGCGCGCTGCAAGTTTGTGAAGCGCGGACAGACA
 CTGCTGAACCTTTCTCTGGGACCCCTGTGGCCCTCGCTGCTGCTCTGTGCTGTGACCTTGG
 TTTCTCCTCTCGGGCTTCTCGCCCTCAGTGGTTTCTCGGCCCTCTGGGTTTACTCTGTAGTTTTC
 TGCTGCGATCGAATCGTTTCTAATCTGCACTGCTCTTACAAAATCTGTGTCCTCCCTCTCTGGC
 GACACGGGCAACTCAGGGTCACTGAACCACTGGCCGTGCTGTGCGGGGTTTTTTCTCTGG
 GTTCTCCCTGGAAAGGCTCAGGAACCTAGGCACAAGCTCTCTGAGCCAGTCCCTCAGCCACTGAAGTCCC
 CCTTTCTCCTTTTTTATGATGACATTTTGGTGTGCGTGTGCTGTGTGTGTGTGTGTGTGTGTGT
 GTGTGATGGGCCAGGTCTCTGTCCGCTCCTCTTCCCTGCACAAGTGTGTCGATCTTAGATTGCCACTGCTT
 TCATTGAAGACGCTCAATGCCAAGAAACGTGTCCCTGGCCCATATTATCTCCTCGTGTGTCATAAATTAG
 GGTCCACGCCCATGTACCTGAAACAATTGGAAGCCCATAAATTGTCTTGAAGAGGTTTCAGGCGAT
 GGGGAGAGGAGTGGGAAATGTAATTAAGGGGCTGTCTCCAATGAAGAGGCAATCCCAAGAAATTGCTGC
 ATTTAGATTTTGAATACCACTGAGCAGAGCCCTCATGTGACATGAACCATCAATGAGATTGTGCACAACT
 CCTCCCCAAACCCACCCATACCAGCTAGAATCACTTGACTTTGCCACATCCATTGACTGACCCCTCTCTC
 CAGCAATAGCATCAAGGGGCTTGAAGTTATGTGTTTCAAGAAGCCTGGTGGCAATTAAGGATCTTCCC
 ACTTTGCCACTGATGATCTTTGGATGGGTCACTTGCTCAGTTTTCCTGATTTTCTGATCTATCAACGA
 CTAAGAATATGAATGGATTAAATGTTAAAGCTTTGGTGCTGGAAACAATATCAAGTAAACATATGATT
 ATTTATTTTATTTATCTCCCAAGCGGGCTTGCTGCTTCAACCTTGGGATGAAAATGAAGAGTGGTTA
 AAGTGGATGAGGTTGAAAGAGTTGCCATTAATGAGGTCCACGCTGGCTTCTTCGATAGGAGCCACCACT
 GGGGTGGGAAGAATTTGCTCCTCAGGCTTGTGTGCCCTCTGCAAGTTGATCTCCAAGTTTAAACCTGTTA
 AATTAAATTTTGACAAATAAGTTTACCCTCAACTCAGATCAAAAATGGGCGAGCAAGTCTTCGTAAGGAAT
 GGAGCCGGTGTAAATCTCTCCCTAAGAGGCAACCTGTGTAATTACTCTCTCCAGATTAATGTGTGGGAAG
 GATCCCTTTGTATACCTTTTAAATACTACAAATAGTGTGAGGAGTCCAGAAATGAAGAGCAAGAACT
 CTAGTGGCCTCCAGACTGCAAGGTCCCAAGGATGGAAGGGGAATGTTCTGTGTTCTACCTGTGTTG
 TTGTGTCCTGTATACAGAAAACACATTTCTTTTATATCTGTACGTGGGCATATCTGTGTGTCAGT

TTGGGTGTCTGCTAAAGAGGAAGTGCACCTGGCCCTCTTTGAAAGGGCTTTACAGTGGGGGCACCAAGACC
 CCAAAGGCCACGGCCAGGAGACTGTTAAAGTGAAAAGGCAATCTATGACTCACCTTGCTCTGCCATCCCT
 GGCAGCCCCCACCGGGTCTCGTTTCCTGCCACATGGAGCTTGACTTCATGCCAGCTATAATCTCCCTGCG
 CTCTCTTTAACTCCAATTTCCCTGCTCACTCTTCCACAGATATAAAGAACAAACACTTAGCATCCCA
 CTACCCCTCTTAATAGCTGAAGGGAAGCCCATCTAAACTCCTTTCTCGCAAAACCCATTTCAGCTCCTA
 GTAGCTTTCTCTCCAAAGGCTTTCTTTCCAACTCTTATAGCTTTGGAGACGCTCCCAATTCGCCAGG
 GAAGGAAACTGTTGTGTCCAATCCCCATTAAAGACAAATTGATCAGTGCTTCCC

>gi|37540251|ref|XM_291315.2| Homo sapiens hypothetical protein
 FLJ23309 (FLJ23309), mRNA

GGCCGGGCTGTGCGGGTTGGGGCGGTTGGGCTGGCAGCTGAGGCTCGTGGCCATGGAGTGGGGTTCTG
 AGTCGGCTGCTGTGAGGCGGCCACCGCGTCGGAGTAGAGCGTCGAGAGGGAAGCGCGCGCGCCACCGCC
 GGAGAGGGAGGCGCGAGCGCAGGAGCCTCTGTTGATGGGTGTCAGCGCGCGCGGGAGGACGCGGAAGAG
 AGCCCCGGGGTAGCGCGCGCGAGCAGGGGCGCGGGGACCGGCTGTCTGAGGTGCGCGCGCGCTGG
 GGCCTGCGCTCTACCTGATCGCGCTGCGGACGCTGGTGCAGCTCTCGCTGCAGACCTCGTGTCTACGCG
 GGCCTCTGCACCGCGGGGAGTTCGAGCGCGCTCCAAGCCAGGGATTTATCTTGAACACATAACCTCACT
 GGCCTCAGGACTACAGGAAGTCCAGAAAATGAAATTCGACCGTGCACCTACCTTTTGAACAGATTAAAC
 TGATTGAAGTCAAAAGCAACAGCCTTCATAAGATTTCAGTAGATGTACAACGCCCCACAGGCTCTTTTAG
 CATTTGATTTCTTGGGAGGTTTACAAGCTATTATGACAACTACCAATGTTTGGTAAAGCTGGAACCC
 AGAGATTGAGCCGACCATGCTGCTCTTGGCTAATTGTCATTTCTGACTCAGTAGCAAACTCACCAGTGCCA
 TGATGATGACAGTTAGCTGCTCAGTGATGCTGGAAGTCTTTGCGCTCTTGTCAACATCTTTCAGAAAGCTT
 GCATCATGCTGATATTTCTCTTTAATGGTGCTGAGGAAAATGCTTTCGAAGCCAGTACATGGTTTCATT
 ACTCAGCACCCCTGGGCTAGCTTGATTGCTGTCATTCATAACTAGAGCGACAGGTTGAGAGGGAAG
 AACTTGATTCTCAAACAGGTCTGAAAATCCTTGGTTGGTTCAAGCTTATGTTTCAGCAGCTAAACACCC
 TTTTCTCTCTGTGGGTGGCTCAGGAGGTTTTCAGAGTGAATCATTTCTTCAGATACTGACTTTTCGTAT
 TACAGGATTTTGGGAACATCCAGGAATAGACTTAGCTTTTATTGCAATGGATACATTTATCACCA
 ATAGTATGACACCGGACAGAAATTCAACAGATTCCATTACAGAGCAGGTGACAACTTTAGCAGTTCT
 TAAGTACTAGCTACATCTGATATGCTGGCTGCTGCTTCAAGTATGACATGCGAAACATGGTCTCTCT
 GATGCTGCTGGGCTGTTTGTCTATTCCTACCCCTCTCGTATTGGCTCAATCATAACTACATGGTGTAA
 TGGGTGTTGTTTGTACTGGGCAAAAAATTTTGCAGCCCAACATAGAGCTGTGAATCTACAAGAAGGA
 CTCTCTGTGTGGACTTGGCATCACTTTGATCAGCTGGTTCAGTACGCTTCTACCTTCTCATTTATAGA
 GTGTTCACTCTCTTATGGACAGTCTCTCTCATGGTATAACCACTTCTATGCTCCGTTTGTCTGTATG
 GAACTGCAACTGTAGCAAAAAATACTATTATACATACTCTTGCAGAAAAGATTTCATTACATGAATGCCAG
 TGCCAGTATCTGGGAGAAGTATTTTGGACATTTGCTGTTTGTCCATTGCTGTTTCTTGTATCCCTC
 ACTTACCAAGGACTTTGCTCGGCGTTTATTAGTGCTGCTGGGTAGCATTTCCCATTGCTCACAAAGCTCT
 GTGTGCATAAGGACTTCAAGCAGCATGGTGCCCAAGGAAAATTTATGCTTTTACCTTTTGGGGAGTGT
 TATTCCTTATCTTTATGCAATTGTACCTCATCTGGGACATATTGAGATGTTTACCCCTTATCTCTGGGAGA
 AGTGGTCTCGAATCCCACTGATGTTGTGCTGGCATCACTTTTGGCTGGCTGTCAAGATGATCTCTCTGCT
 CCTATTTTATTAACTTCACTTACCTTGCCAAAGGACAAAAAAACATGCTAACTTTAACTTTGGTATG
 TGCAATTACATCTCTCTGTTTTCAGTGGAACATTTTTCATATAGCTCCAATTGCTCTAATCCGAAG
 CCAAAGAGAGTGTCTTTCAGCATATGACTAGAACATTCCATGACTTGAAGGAAATGCAGTTAAACGGG
 ACTCTGGAATATGGATCAATGGGTTGATTATACTGGAATTTCTCACATAACCCCTCACATTTCTTGAGAT
 CAATAGATATCTCCGAGCTCACTGTAGGAGAATGCACCTCTTTGGTGTGTTCTGTTGATCTTCAGATG
 CACTTTCTGATCGAGAAAACTGGTATCTTCTCGCCCCAGAAGTTTCTCCAAGAAATCTCTCATATTTC
 GACTCATCTCAAAGAACACACCTTTGGGATTCATAAAATTTGACTTTGAAGCAACAGGACCAAGCCA
 TAGTCTCTTCTATGTTGAGGCCCAAAAGGCTCAACACTTTCTCAGTGGTCTCTTGGCAATGGCACCCCA
 GTCAACAGTAAAGGAGGAGACTACTTTGCTTTTACTCCCATGGACTCGAGGCTCTGCATGGCAGTTCT
 GGATGAAGTGCAGGTTTCAAGAAACATCTTGAAGGAATGGTCAACCGTGGCATTTGCTGCCCATCTCT
 GCTCTGGGAGAGCAAGAGATCCCCTCAACTGGATGCTCTGAAGGAAAAGTTCACGATTGGACATTTCCC
 TCTGCTGGGTGTCACCTACGATCTCTTTGATTTTAACTTTGGATGAGCTCTAAGTACATGCCAG
 TGGATACTCCATGTGACATGGTTCTCCCTATGTTACGTGGATGTTTGTAACTAGTCAATGAATTTTA
 ATGATCATATGTTCAAAGAGCTTTCTGGGTTAACGCTTTTCAGGCCCAAGCATATAAGGTTTATGCTGT
 GCGCGACGTGATGCTATGGCTTTGACACTTGAATAATGGCAGCTTTTGGCACTTCAGCATATGGGGTAC
 TGCCACTACACACAGCTGATTTTATGACCTTAAGGACAAAGCCAAATTCACATTCAATAGTCTGCCCC
 TTTTAGGATCAAGAAGATGCATCTGACGTGTCAGAGCATGTTAATGAGACAAAAGTTGTTTCCAATTAAAGC
 CCAAACCATTTGTTGATTTAGTGGATGGTGGGTAAAATATCATTCAGTGGGTAAATGATCCCCCTTGAG
 AATATAACTCTGTGTAGGTCAGTGAAGTGATTGCCATAGGCGTGGAGAGAAGCATTTGCACCTTTGAG

GCTGTAGCCTGTGTCAAGCTGTTTCTTCAAGCAGCCTCTCAAATGTGCTTTGTCTCTCTGTGCTGAGGCC
 TGGACCCCTGTGCTGAGCTGGTGACTACTGCTCTGACAAGTGGACACACAGATGCACTGCTGTGCTGCTT
 TCTTGAGGTGGTGTTCATATGCTGTTTCTCTGTAACATGCTGTTTACCCCTCTCCATCTTACCAAGTT
 GAAAAGGGGAATATTTGGCCACATACCCCTCTGGTTCGTAGGTTCTTTGGTTCAGAAATATGTTTGT
 CGGCATACATGCTTTAACTTCTTCTCAGAGCACTGAGCTGCCATCTGGGCTATCTCGGGGTAGAAGG
 AAGCTCGGAGTGGTGGGAATTTATAAATATTTATCTCTTTTCTTTGTTTTCATAGGATCTTGTGTTA
 TACAAGGTTAGTCTTTCATGGTATAATCTTACTGATGCATCGGCCCTATCTTTTGTGTTTCCAGCAGATT
 GAATAGATTAGTGTTCCTCAGTAACCTACTATCCAGCAGACTGGCTTTCTCGAGACTTGAGGTTGTGGCT
 TATATCTGGAATGAGACCACTGTACGTGAGGTGGTTCAGATCTCGTAATGGCAGCATGAGGCACTTAA
 AGGTGGTGTTCATTTTGGAAGATGGCTATGTAGCTTGTAAAGGTGATACACAGCATACCTCTCATGCGCTTT
 TTGGTTTCCAGCAGTGGAGGCTATGGTGAGATCAATGGTAACCTGTGCAAGCTTCTTTTATCTCATTAGGA
 AATGTGAACGCTGGACAAATTTGAGTTTAAACAAGGACAAAAGTTGAAAGAAAAGGCACAGTTAAACA
 AAAAGGGTGGCTAGATTATCTTGGGTGATGGAGGAAATGAGAGAGGAATGCTCTTGAAGGTTGGTCTG
 TGGATCTGTCTGAATAGAAAAGACACAGTAAGTATGCATTGCCGGAGAAAAGCTCTTGAAGCTGCTTGT
 CTCATGTGATATGATGTGCTTTTAAATCATGCCCTCGTTGCCCTGCTTAATCTGTGATCCCTCAAAAACCT
 AACTGGGCCCATGAGTGGGCTGCAACCAGAGCTGAATAACATGTTAGGCTCACACATGACATCAGCAGC
 TGCACACTGGAATCATTGCTCTTCTGGACTTTGTAGAAATCAGTCTCAAGTGCTCTCAAGATCTGCTGCT
 CTGCTACTTTTATCTGTGAGGTAGCACATAAGGTTTGCAGGTTTATATTTGTATAGAATACAGATTGT
 GGAGAAAAGTAAATAATTTCTCAATGAATTTAAAAATGGGCCATTTTCTATCCCGTGGTTCATCTGA
 TATAATTAGTGTTCCTCTGTAATCTCCCCCTCTATGGGAAGGATGCCTTTACTCTTTTATCAGTAATAA
 TTATGACTGTTTTCATGCTGCTTAGGGTTATTTCCCTGTGTAACCATTTGCTCTTTTGTTTTGGTCTTCT
 TTAGCATTTAGAGCTTTGGTATTGTACAAGGTCACTAGTAAAGATGCTCAGTACTCTCAGGGCTTGTGTA
 ATATTCTGGGAGGTCAATTTAAATGCCAGAAATGGTCAAGCAATATACACAGTATTTATGACTCTGTATA
 GCATACCGTTTGTCTGTACATTAGTAGATTCTGAGATTAAAAAAATTTTAAAGAGTGATCTTTAA
 TAATTTCTAAAAGGGTCTTTTCAAGCTCTAAACAAAGTCACTAAACAAATGCATTATTTCTACAGAAATTAG
 ATGTTAGTAGTACAGTACTGCATATCTAGGGAAGGTTGAGGAAATTGATTTCACAAATAGTCTGCTCTT
 GTGTTTGAACCTAAGAATGATGTGCGATGAAGTGTGTGTTTTCACAGTTTAGCATATAAACAAACATG
 ATAGATTACCTTAAAGTGTTCACACCAGGGGGCCACAAGCCAGCTGCTCTCAGGAAGCTGTGAAG
 GAGTGTTTGTCAATTTCTGTCTAGTGTGTGCTGACTTACTGAGGATTAATGTTGCCTTACAATGTTAC
 TGAATAAACCTGTTTAAATAT

>gi|21361381|ref|NM_007171.2| Homo sapiens protein-O-
 mannosyltransferase 1 (POMT1), mRNA

CCCGAGGCTCGGTGAATCGAACGTTGAGCAGGGCGGTGGGTGGTGGAGTGCCGAGCGGCCATCCCC
 CAACCGTCGGCCAGCTCGGACGGTTCGAGGGCGTTGCCGGAGCCGGCCGCGCTCTGTGTGACATCGGA
 GAAACGCGGGGCGCTGCTCGTAGGCCGCTTTTCTACAAGATGTGGGGATTTTTGAAGCGCCCTGTAGTGG
 TGACGGCTGACATCAACTTGAGCCCTGTGGCCCTGACTGGGATGGGTTACTTGCCCGGCTGTGGCAGCT
 CACCTACCCCGGGGCTGTGGTTTGTGACGAAGTATATTTAGGGCAGTACATCTTGTGTTTACATGAACAA
 ATCTTCTTCTGTGATGACAGTGGGCCGCCATTGGCCACATGGTGTGGCCCTGGGAGGTTGTTTAGGAG
 GATTTCGATGGCAATTTTGTGGAACAGAAATGGAGCAGAATACAGTACGAACGCTGCTTGTGTGGTCCCT
 GCGCCTGCTGCCAGCACTCGCGGGGGCTTGTGCGTCCCATGGCTTACCAGATAGTGTGGAGCTCCAC
 TTTTCTCATGTCGCCCATGGGAGCTGCTCTGTTGATGCTTATCAAGAAATGCTCTCATCTACTCAGTCAA
 GGCATATGCTTTTGGAAATCAGTGTTAATATTTTCAATCTATTGGCCGTGTGTGCTTACCCTGAAGTTCTT
 CAAGTGCCAAAAGCAGCCCTTTTCTCTGAGCTGGTGGTCTCGGCTAACCACTGACAGGGGTGCTGTTGT
 TCCCTGTCAGTGGGCATCAAGTACATGGGTGTGTTTACGATGCTGCTGCTGCTGGGTGTGACAGCTGTC
 ATGCTTGGCACCTGCTTGGAGACCAGACTTTGTCCAATGTAGTGCTGATGTCAGATGCTGATGAGGCC
 GGCTGTGATGGGGCAGATGGGATGTACAGGGGGTCTGTGTGCTGCTACTTGTCTGCTGCTGAGCAGATG
 GCTTTGTGCTGTCATCCCGGTGCTCTGTACTTACTGTTCTTCACTGCTGCTTCACTGCTTCACTTCTCGCT
 CTGGGCCCCAGCACAAATCATGTCTCAGTGCCCTTCCAGGCCAGCTTGAAGAGGAGCATAGCTCGGATCAC
 CAGAGCTCAGCCTCAGGAGTGGGCTTTGGGTCCAGGTCACCTCTGAGGAGGCTCTTTGGGAACCTGTG
 CCTGCTGGCTTCACTCCACCAGGACACCTACCCCATGATATATGAGAAGCCGCCAGGCAGCTCCACC
 AGCAACAGGTGACCTGTATCCCTTCAAAAGAGCTCAATAACTGGTGGATTGTAAAGAGCTCCAGGAGCA
 CAGCTGGTGGTGAGCAGCCCTCCGAGACCTGTGAGGCACGGGGACATGGTGTGACGCTGTGCTCACGGCATG
 ACCACCCGCTCCCTGAACACGCATGATGTTGACGCCCTTCAAGCCCATTTCAAGAGAGGTCTCCCTGCT
 ACATGACTATAACATCTCCATGCCCGCCAGAACCTCTGGAGCTGGAAATGTGAACACAGAGGATCTGA
 CACAGAGCTCTGAAGACCATCTCTCAGAGGTCCGCTTTGTGACAGTGAACACTTCCGCTGTCTTAAAG
 CTGAGCGGGCTCACTTCCCTGACTGGGGTATCGCACTGGAGATCGTGGGAGAAAGCTGTCCCGGG

GCTACCACGGGAGCAGCGTGTGGAACGTGGAGGAGCACCGATACGGCGCAGCCAGGACGAGGGAGCG
 GGAACGGGAGCTGCACCTACCTGCGCAGGTGGACCTCAGCAGGAACCTCAGCTTCATGCGCAGAGATTCTCG
 GAGCTGCACTGGAGGATGCTGGCGCTGAGAAGTGATGACTCGGAACACAAGTACAGCTCCAGCCCACTGG
 AGTGGCTCAGCTTGGACACAATATTGCCCTACTGGCTGCACCCAGGACAGCGCTCAGATCCCACTTAT
 TGGAAACATAGTGATCTGGGTTCGGGCAGCGCTCGCTCTGGCCATCAGCCCTGCTGTCTTGTGTGAT
 CTCTCCGACGGCGAGAAATGTCATGACCTCCCTCAGGATGCTTGGCTGCTGGGTGCTGGCTGGG
 CGCTGTGTGCCGTGGCTGGGCAGTGAACCTACCTCCCGTCTCTCTGATGAGAGAAGACACTCTTCCCTTA
 CCACTACCTGCCCGCACTCCTTCCAAATCCTTCTGCTCCCTGTGGTCTTCGACACATCAGCGACCAC
 CTGTGCAAGTCCCGAGCTCCAGAGGAATCTTTTCAGCGCCCTGGTGGTGGCCCTGTACTCTCCCGCTGCC
 ACGTGTCCAAACAGCGCTGCCGCCACTCACCACGGGGACAAGTCACTCTCCGCACATGAATCAAGGCCGT
 TCCTGTGGAAGTCACTGGGACATCTTGATCCGAAACACTAGAACAAGATGTGGCAAAAGAACACCCGT
 GCTGGGGTCGGGACAGGTTGAAGGCTCTTGGTCAATGATACGTAATGAGCAGGGTGGGCCCACTGGGA
 GGACACGGGCTGGGCTGAGCAGGGCTCTAGTGGAAACATATGGGGTCTCATTTGAAAAGCTCTTGATG
 AGCACTCCTTTTGTGCAAGTTAATTTTTCGACAATAAAGATATTCAGTGTCTTACCCCTGAACT
 AAGACACAGGGAGTATTTCAGAGGCCAGCTAGGAGTCACTGACAAACGAAAGCCGAGAACCAGGGCCA
 CAGTGGAAAGCTTAAGCAAGAACAGGGCTGGTCTTGCTAATTGCTGAGGTGTGAGGTTTGATCTGGC
 AGACCCGATCTCCTTCATGAACACCAGCAACTGAGCAAGTCCGGCCCTGCCCTCAGCAGACCCGGC
 AGGCGTCCGGGACAGCTCAGTGTGGAGGGCCACTGGAACCAAGCAGCAGGGCTGGGGCTTGATGTCTCA
 TTGTCTATGACAGCGTCAAGACTGCCCTTGGCACCGTGCTGTGTGGAAACCTCCCTCTGAGACTCCAC
 TGAGACGTGGCTGAGTGAATCTCTCTGCTCAGTGGTCAAGGTGTGTCATCCATACAGCTTCATGCCCTT
 GCTCTTTTAAATGTAATTAATAAAGAACCAACTGGCGTTTGTAAAAAATAAATAAATAAATAA

>gi|18860905|ref|NM_002846.2| Homo sapiens protein tyrosine
 phosphatase, receptor type, N (PTPRN), mRNA

CGGCCAGCCCGCCTCAGCCCTCTGGCAGGCTCCGCCAGCGTCTGCGGGCTCCGGCCCGGAGCGCA
 GCGCCCGAGCTCGGAAGAAGTGC GGC GCCCGCCGCGCGGCTCTGGGGGTCTCGGGGGATCCGGGGTCTCCGG
 CTGCTCTCTTGCCTCTCTGCTGCTGAGCAGCGCCCGGGGGGCTGCAAGCGCTTGTGTGCCACAGCGTCTC
 TATTTTGACCGCAGGCTCTGCTCTCACTTGAAGTCTGTATTCAAGATGGCTATTGTGGCAGCTGCGAGGT
 GGAAGTGGGGCAGGCCCGGCCCTTTTGAAGTCACTTCCCAAGTTCTTCAAACGCTTACAAGGTGTGCTC
 GCACAACCTCAGTCCCAAGGATTGTCTTGGCAGGATGACCTCACCAGTATGTGATCTCTCAGGAGATGG
 AGCGACTCCCAAGCTTCCGCCCCAGAGCCCCGTCCAAGGGACAGGTCTGGTCTGGCACCAGGAGACC
 TGGTCTCTGCTGGAGAGCTGCTTTTACAGGACATCCCACTGGCTCCGCCCTCTGCTGCCAGCATCGGCTT
 CCACAACCACCACTGGGCAAGGTGGAGCTGGGGCCAGCTCCTCTCTGTGCCCTCTCTGAGGCTGAGTGTG
 TCCCCCTCTCTTTGGAGCACTGTGCTGCCCCACAGCTCCCAACCTTCACTGAGTTACGAACCTGCT
 CTGTCTGACGCCCTACCTGTTTCCACAGTTTGGCTCCCGTATGGCTCCAGGGTCTCAGAGGGCTCCCA
 GGGATGGTCAAGTCTCGGCCCTCCCTGCCAAGGCTGAAGCCCTGCCCTCTTTCAGCAGAACTGCCTCCAAGG
 GCATATTTTGGGGACACCCCTGGCCACTCTTACGGGGACCTTCCAGGGCTCTTCACTTGGCCAGCTTTTCA
 AGACTCTGGGCTGCTCTATCTTGGCCAGGAGTTGCCAGCACCCAGCAGGACCGCCAGGTGCGCAAGGCTGCCA
 GAGCAAGGGAGCAGGACGCCGGGCAGAGGACTCCCAAGAGGGCTATGAGAAGGAAGGACTAGGGGATCTGGT
 GAGAGAAGCCTGTCTCCCAAGCTGTGCAGCAGAGTCCGGCTCTGCAGAGCTGGCCGCTGTGCTGCTGGCG
 CTATGGGTTAGAGCTGCGTCAGCTGACCCCTGAGCAGCTCTCCACACTCTTGACCTGCTGACGCTACTG
 CCCAAGGTTGCAGGAAGAAATCCGGGAGGGGTTGTAATGTTGGAGCTGATATCAAGAAACAAATGGAGG
 GCGCGCTGGAGGCCGAGAGACAGCAGAGCTTCCAGCCCGACATCCCACTGCTGGACACCACTCATGCTG
 CAGCCCTACCTCTCAGTGAAGTCCAGCAGGTGCCAAGCCCTGCTCTCTGAGCTCTCCAAAGCTGCCAGA
 CCCCCTGTGACACTGTCTGCTGTGAGAAGAAAGGCCCACTGGCCAGCAGCCAGCCACCGCTGGCAGGAG
 AGCCCTCAGCCCGCCAGCAGCAGAGGAATATGGCTACATGCTCACTGATCAGAAGCCCTGAGCCTGGC
 TGCAGGAGTGAAGCTGCTGGAGATCTTGGCTGAGCATGTGCACATGTCTCAGGCACTTCACTCAACATC
 AGTGTGGTGGGACAGCCCTCACTTCCGCACTGGGCACAAATGAGCAGAACTGTCTTTGGCTGATGTGA
 CCCAACAGCAGGGCTGTGTGAAGTCTGAACTGGAAGCAGACAGCAGGGCTCCAAATCTTGCAGCAGGAGT
 GGGACAGAGGGAGGAGGAGCTGCACTGCTTCCCAAACTGGCAGCAGCTCACCCTACAGCTGCTCAGTG
 CTGCTCACTCTGTGTGCCCTGGCAGGTGTGGCTGGGCTGTGTTGGCTCTGGCTGGCTCTGTGTGTGTC
 GGCAGCATGCGCGGACCAAGACAAGGAGCGCTGGCAGCCCTGGGGCTTGGGGGCCATGTGTGTGACAC
 TACCTTTTGAGTACCAAGACCTGTGCCGCCAGCAGCATGGCCACGAAGTCTTGTTCAAACGGGCAGAGGGT
 CCACCGGAGGCTTCAAGGCTGAGCAGGTGTCTCTCCAGTTCAGCGAGCAGCCAGCGCCAGCCCACTG
 CCCACAGCAGCAACCCGCTGCTTGGTGGAGGAGCCGCCCAAGCAACATGACATCTCCACGGACACAT
 GATTCTGGCATACATGGAGGATCACTTGGGAACCGGACCGCTTGGCAAGGAGTGGCAGGCCCTCTGT
 GCCTACCAAGCAGAGCAAAACACTGTGCCACCGCGCAGGGGAGGGCAACATCAAAAAGAACCGGCATC

CTGACTTCCTGCCCTATGACCATGCCCGCATAAAACTGAAGGTGGAGAGCAGCCCTTCTCGGAGCGATTA
 CATCAACGCCAGCCCCATTATTGAGCATGACCCTCGGATGCCAGCCTACATAGCCACGCAAGGGCCCGCTG
 TCCCATACCATTGCGAGACTTCTGGCAGATGGTGTGGGAGAGCGGCTGCACCGCTCATCGTCACTGTCAGACC
 CGCTGGTGGAGGATGTGTCAAGCAGTGTGACCGCTACGCCAGATGAGGTTGCCCTCCCTCTACACCGT
 ATATGAGGTGAACCTGGTGTGGGAGCACAATTGCTGGTGCAGGAGCTTTCTGGTGGGAGGATTTACCTGAAG
 AACGTGCAGACCTGAGAGCGCAGCCTACGCGAGTTCACTTCTCAGCTGGCCGCGAGGGAGCACAC
 CGGCTCCACGCGGCCCTGCTGAGACTTCCGCAAGGAGTGAACAAGTGTACCGGGGCGCTCTGCCC
 CATCATCTGTCACCTGACAGTGAATGGTGGGGAGGAGCCGGCACCTACATCCTCATCGACATGGTCTGAA
 CGCATGGGCAAGAGGATGCAAGGAGATTGACATCGCTGCACCTGGAGAGGATGGGTAGCAATCTAC
 CGACAGCCTCTCTGCTGCCATACATTCCTTGCCCTGGCTTCTCTGTAGCTCTCTCGGGGTCTGGGAGTTC
 CTGAACATCTGTGTGTGCTCCCTTATGCTCCAGTATGAAGAATGGGTGGAGGTCGCCACACCGGCT
 CCCCCTGCTTCTCAGCCCGGGGCTGCTCTGACTACACATTTGGCGCTCTGCCCCTCCCTGGCTACAG
 CAGCCTCCTCCACACCTCCACCATGCGCTGCTCAACCTCTCTCTCTTGGCGAAGAGCAATTT
 CTAGAAAAAACTACTTTGTACCACTGTGAATAAAGTTAGTGTGTGTCTGTGACGCTGCAAAAAAAA
 AAAAAAAA

>gi|19743910|ref|NM_002847.2| Homo sapiens protein tyrosine
 phosphatase, receptor type, N polypeptide 2 (PTPRN2), transcript
 variant 1, mRNA

GCCTCCCGCGCCTCCCGCGCGCCATGGACTGAGCGCCGCGGCCAGGCGGGGATGGGGCCGCCG
 TCCCGCTACTGCTGCTACTGCTGCTGCTGCCGCCACGCGTCTGCTGCCGCCCTTCGTCGCTCC
 CGCGGCCGCGCAGCTCCGGGGCGCTCTGGGCTGCTGCTCGAGGAGGGCCCTCTCGGAGCGCTCGAGGCG
 TGTGTGAACGATGGAGTGTGTGAAGGTGCCAGAAGGTTCCGGCAATGGACTTTTACCGATACGAGGTGT
 CGCCCGTGGCCCTGCAGCGCTGCGCGTGGCGTTGCAGAAGCTTTCCGGCAAGGTTTCACTGGCAGGA
 TGACTATACTCAGTATGTGATGGACCGAAGCTTGCAGACCTCCGAAAACTTACCTGAGGCGCTCGAA
 GCATCCAGCCGACGACAGGCCCTCAAACAACAGCGCTTGGCAGCGAGAGAGGTACCTGCGGAGGGCGGT
 CTGCCCTGGCCAAAGCCCTTCCGACGCCACCTGCCCTTCTTGAAGGCCCTGTGCCAGGCCCAAGCCTCAGA
 CGTGCTCGCCAGGACCCATACGGCGCAGGACAGACCCCGCTGAGGGTGATGACCGCTTCTCCGAGAGC
 ATCCTGACCTATGTGCCCCACAAGTCTGCGCTGACCTACCCTCCCGGGCCCGGAGCCAGCTCCCGGAGG
 ACCCTCTCCCGCGACCTTCGGCCAGCTCCAGCCAGATGAGCTCAGCCCTAAGGTGGACAGTGGTGTGGA
 CAGACACCATCTGATGGCGGCCCTCAGTGCTTATGCTGCCAGAGGCCCTCAGCTCCCGCCGGGAGGGC
 AGCCTGGAGGCCAAGTACCTTCTGCTGTCACCTCAAGAATGCCAGGCCCTTGTCTGGCAGCAGCCGCC
 CCGAAGTGGCTTACCTTCTGGGAGATTCCGAAGACCCCTCCAGCACAGGCGAGTGGAGACAGGATCTA
 TACCCTCTGAAGGACCTCGAGAGGCAAGCCGCTGAGGTGAGGGGCTGAGTGGCTGGAAGCTGACGGC
 ATGGCTGAGCTGATGGCTGGCCCTGATGCAAGGCTGGAACATGGAGTAGCTCTGAGGACGCCCTGGGAGAG
 CGGCCCTGGGAGAGTCTGGAGAACAGGCGGATGGCCCAAGGCCACCTTCCGTGGAGACAGCTTTCAGA
 TGAGGAGGTGCAGGAGCAGAGTATAGACTTACCAAGAGGTCATCGTCTGAGTGGACACACTCGGGGGC
 CTCTCTGAGAGCCAGGCTCTCGACTTCTTACCTGGAGCCCTCCCTTTGCAAGGCCCTCTGACATGGAGA
 GGAAGAAGTCCGAGCAACCTGAGTCTTCCCTGTCTTCAAGAAGGAGAGCTGCCGGAGTGGAGAAGCTCAA
 GACCAGACGTATTTCAAGAATCTGCTGGGCGAGCAGCCGCTTGGAGGCCCGGGGCGCTGCTGTGGG
 GAGCTCCAAACACAGATGCTTGGGCCCTCGAAGGAGGAGCAGAGCCTTCACGGGGTGTCTCAGGAGCCG
 TCAGCGAGCGGCTGCAATTTGAGAGTCCAGCCTTCCGAGGAAGAGGCGCGGGCTACATCGTGACAGCAG
 AGACCCCTTCGCCCCCGAGGAAGGAAGCGGCTGGTGGAGGACGCTGCCGCCCTCTCGAGTGGCCAGC
 AGTGCGTCTGCTGACCTGGAGGTTCTCGGACCAAGCAGTGACCTTCAAAGTGAGGCGCAATGTCTCAAACAG
 TGACCACTGAGGATGTGGAGAAGGCCACAGTTGACAACAAAGACAACTGAGGAGAACTCTTGAATGAA
 AATTCTTCAAACCGGAGTGGGTGAAAGCAAACTCAAGTTCTTCTGCTCTCTAGGCGGAGCAAGAAGAC
 TCCACCAAGTTTATCGCGCTACCTGGCTTCTTCTGCTGCTTCTGGGCGCTCTCTGCTCTGCTGCTGCT
 TCACTTCTGCTCTCCGCTATGCTCTCAGCACAGGCTGAAGGAGAAGCTCTCGGAGCTAGGGGGCGACCC
 AGGTGCGAGATGCCATGCCCGCTACCAGGAGCTGTGCGGCCAGCGTATGGGCCAGGGCCACGAGCGCA
 CTTGAGGCGCGCAGACACTGACGATCAGCAGCAGCTTCTTCCAGTTTACGAGCAGGGCGGCTTCCGAGC
 CTTCCGCAAGCAGCAGCGCTCATCTTGTTCGAGGAGGCTGTGCAAGTCAACATGGACATCTCCACCGG
 CCACATGATCTGTCTACATGGAGGACCACTTGAAGAACAAGAACCAGGCTGGAGAAGGAGTGGGAAGCG

CTGTGCGCCTACCAAGCGGAGGCCAACAGCTCGTTCTGCGCCAGAGGAGGAGAACGTGCCAAGAACC
 GCTCCCTGGCTGTGCTGACCTATGACCACTCCCGGGTCTGCTGAAGCGGAGAACAGCCACAGCCACTC
 AGACTACATCAAGCTAGCCCCATCATGGATCAGACCCGAGGAAACCCCGGTACATCGCCACACAGGGA
 CCGCTGCCCGCCACCGTGGCTGACTTTTGGCAGATGGTGTGGGAGACGGCTCGCTGGTGATCGTCAATG
 CTACACCCCTCGGCGGAGAACGGCTCCGGCAGTGCTACCACTACTGGCCGGATGAGGGCTCCAACTCTTA
 CCACATCTATGAGGTGAACCTGGTCTCCGAGCACATCTGGTGTGAGGACTTCTGTGTAGGAGCTTCTAT
 CTGAAGAACCCTGCAGACCAACGAGACGCGCACCGTGACGCAGTTCCACTTCTCTGAGTTGGTATGACCGAG
 GAGTCCCTTCTCTCAAGGTCCCTCTTGGACTTCCGCGAGAAAAGTAAACAAGTGCTACAGGGGCGGCTT
 TTGTCCAAATAATTTGTTCTATGTGACGTGACGGCCGAGCGGACCTGACTCGCTGTATCGACATGGTT
 CTCAACAAGATGAGCCAAAGGTGCTAAAGAGATTGATATCGCAGCGACCTTGGAGCACTTGTAGGGAGCAGA
 GACCCGGATGGTCCAGACGAAGGAGCAGTTTGAAGTTGCGCTGACAGCCCTGGCTGAGGAGGTGAACGC
 CATCTCTAAGGCCCTTCCCCAGTGAGCGGCAGCTCAGGGGCTCAGGGGAGCCCCACCCACGGATGT
 TGTCAGAGATCATGATCTGACTTTAATTGTGTGCTTCTATTATAAAGTGCATAGTAATAGGGCCCTTAGC
 TCTCCGATAGTCAGCGCAGTTTAGCAGTTAAAGAGTGATTTTGTTTAACTAAACAATAATAAGAGAGA
 TTTTGTGGAATAACCCGTTACGGGTGAGGGGAAATCGGTTTCATCAATTTTCAGCTTGCTTAAAAAAAATAC
 TTTTGTCTTAAAGCACTGTCTACCTTCTTGGTTGAAGTTGTGTAAACAATGAGCTAGCCAGCAGCTGTGA
 GCGCGTTTTCAGGAAGAGTGTGCTTGTCACTTGCCACTTTCGGGAGGTTGATCTCACTGTGCGAGGATGG
 CGGGGAAGCTTGGCAGCACTCAGTGAGGCCGCCGCCGACACAAAGGCAGTTTGGCATTTCTCTTTGAGAG
 AGTTTATCATTTGGGAGAAGCCGCGGGGACAGAACTGAACGCTCTGCAGCTTCCGGGCAAGTGAGACAAATC
 ACAGCTCTCTCGCTGCTCTCCATCAACACTGCGCCGGGTACCATGGACGGCCCGCTGAGCCACACCTGTG
 AGCCCAAGCAGAGCTGATTCAGGGGCTCCCCGGGGGACAGACCTGTGCACCCCATGAGTAGTGCCCACTT
 GAGGCTGGCACTCCCTGACCTACCTTTGCAAAAGTTACAGATGACCCCAACATATGAGATGTGTTTTTA
 ATGTTAAATAATTTGATTTCTACGTTATGAAAAACAGATGCCCCGTGAATGCTTACCTGTGAGATAACCAAC
 AACCAGGAAGAACAATCTGGGCATTGAGCAAGCTATGAGGGTCCCCGGGAGCACAGCAACCTGCCAGG
 CCCCCGCTGGCTCTCTCAGGACAGCTCCCGGACCTGTGGGGCCCCAGAGAGGGGACATTTCCCTCTTGGGA
 GAGAGAGGATTCAGGCAACTCGGAGAGGGCTGCGAGCATTTCCCTCCGGAGAGGAGATCAGGGCGAC
 CTCGACGCACTGTGCTAGAGCGCTGGAAGGGGAAGTGAGAAACAGCCGACCGGCCCTGCCCTCTTCCCGGG
 ATCACTTAATGAACACAGCTGTGTTTGACATCATGTAAACCTTAAGCAGCTAGAGATGATTCGGATTGTGACAA
 AATAACATTTGAGATATCCGATTCGCCATCAACCCCTACCCAGAAATAGGACAATTCACCTTCAATTGACCA
 GGATGATCACAATGAAGCGGCGCGCAGAGGCAGCTGTGTGGGCTGCAGATTTCTGTGTGGGTTTACCGCT
 AGAAACCGCACTTCAATCCGCCCTTCCACAGCACTTCTCCATTTAGATAGATGGTCACTTCCAAAGG
 CCTTACCAGAGGAAACAGGGCTACTGAGCGGACAGAATGATGCCAAAATATTCCTTATGCTCTTCAATG
 GTATTGTAATGAATATCTGCTTTAATATAGCTATCATTTCTTTTCCAAAATTACTTCTCTTATCTGCGAA
 TTTAATTAATCGAAATGAATTTATCTGAAATAGGAAGCATATGCTTACTTGTAAATTTCTAACTCCCTAT
 GTTTGAAGAGAAACCTCCGGTGTGAGATATACAAATATATTTAATTGTGTCATATTAACCTTCTGATTCA
 AAAAAA

>gi|4507334|ref|NM_003895.1| Homo sapiens synaptojanin 1 (SYNJ1), mRNA
 GAGGAGGAGCGGAGGAAGAGGGCTGCCTCCGAAGAAGGAGAAATGGCGTTAGTAAAGGATTCGGCAT
 TATCAAAATTTGATCCCCCACTTTACGCTTCATAGTGAAACTAGGCAATAGGAAGAATGCTCTCATGT
 TCGAGTCTGGGGCTGTGCTGTGCTCTCATCTGCAGAAAAAGAGGCAATCAAGGGTACATATCCAAAGT
 ACTGGATGCATATGGACTCTTAGGTGTTCTGCGGTTAAATCTTGGTGATCATATGTTACATTATCTGGCT
 CTAGTCACTGATGATGTGCTGTGTTGGAAAAATCAAGAACTCGAAGTTTCCGAGTTCTTCCACTGAGT
 TTATATCACTGCGAATCGATTCTTCAGATGAGGATCGCAATTCAGAAGTGGCGAAGGTTTGAATTGAG
 AAACCTTTATTTGATGATGCTGCTATCTGCACTCAGTTTGAAGTTTGAAGTTTGAAGTTTGAAGTTTGAAGTT
 CAAGAACAGACCACTGATAATAGATTTTCTGGAATCAGTCTTTCATTTGCATCTCAAACATCTAGGCT
 TGAATTTGTGATGCTGGTTATTACGTTCTTATGTGTGAGGAGTAGAAATCAAGAACTTTATGCTGTCTCA
 TAAACAGCGCAAGGCTTGCTCTCAATTAAGCTTGAACGAGCTGGGACAGGTTTAAATGTCGG
 GGAACAATATGATATGGTATGTTGCCAATTTTGTAGAAACAGAACAGTTGTGCTACTTATGATGACTCAG
 TTTCTCTCTATCAACAAATGAGGATCTGTTCCATTTGTTGGGAGCAACAGGGTGTCAAGTGGGATC
 TCATCGTGTCCGATATGTCAGGGGATTGAAGCCAAATGCACCTGCTTTTGAAGGCAATTTTGAAGCAT
 AAGAATCTATATGTTAGCAAAATAATAGTAAATTTGCTTGGATCAAGGAAGTTGAACATCTGTAGTA
 AAGCTTTCCAGAGCTAATTTGAAAGCTTCTGAACATGCTGTGATATCCAGATGGTGAATTTTGACTATCA
 TCAAAATGGTTAAGGAGGAAAGGAGCAAAAAATACATAGTGTCTTAAACCTCAAGTGTGAGAAATTTCTA
 GATTAATGATTTTATTTTCAATGGAAGTTGAAGTTTCAAGATGCCAGAGTGGTACAGTTGTCAACAAAT
 GCTTGGATGTCTTGTAGAACAAATAGTGTGACGGCATTTCTGGCTTAGAGATGCTAGCTTAAACAGTT
 GGAAGCTCTTGGTTTAGCTGAAAAGCCTCAGTTGTGTGACTGCTTTCAAGAAGTTTTCGGTCAATGTGG

TCCGTGAATGGTGATTCAATCAGTAAGATATATGCGAGAACTGGAGCTCTTGAAGGGAAAGCGAAGTTAA
 AAGATGGTGTCTGCTCTGTTACCCGAACAATTCAGAAATACTTCTTTGACAGCTCCAAGCAAGAGGCCAT
 TGATGTTTTCGTACTGGGAAATACTCTGAATAGTGATTAGCTGACAAAGCTTCGAGCACTTTAACTACT
 GGAAGTTTGGCGTGGTTCTGAGCAGACATTACAGTCAGCATCTCTTAAAGTACTAAAGACAGTGTGTGAGA
 ATTTCTACAAATATCAAAAGCCTAAGAAAATTCGAGTATGTGTGCGGAACCTGGAATGTGAAATGGTGGGAA
 GCAATTTCCGACGATAGCTTTTAAAGATCAGACACTCAGTACGTGGCTCTTTGATGCAACCAAGTTAGCT
 GGCATCCAGGAGTTTCAAGATAAAAGAAGTAAGCCAACCTGATATATTTGCAATTTGGTTTGAAGAAAATGG
 TAGAATTTGAATGCTGGAACAATTTGTGAGTGCAAGCACAACAAATCAGAAGCTCTGGGCTGTAGAAGTTCA
 GAAGACAATCTCCAGAGACAACAAGTATGTGCTGTGGCTCTGTAACAGTTGGTGGGCGCTGTGTTTGT
 GTTTTATCTCAGACCCAGCATGCTCCTTTTATCAGGGAATGTGTCAGTTGATAGTGTGAAGACTTGAATGT
 GAGGTGCAACTGGAATAAGGGAGCAGTTGCAATCCGAATGCTCTTCCATACAACAGCCTTGTCTCGT
 CTGTAGCCACTTTGCTGCAAGGCGAGTCACAAGTCAAAGAAAAGAAATGAAGATTTTATAGAAATAGCACGA
 AAATTTGAGTTTTCCTATGGGAAGGATGCTATTTTCCCATGACTATGTATTTTGGTGTGGTGATTTCAACT
 ATCGAATCGATCTCCCTAACGAAGAAGTTAAAGAGCTCATAAGACAGCAAAATTTGGGATTCCTTTATAGC
 AGGAGATCAACTATCAATCAGAAAAATGCTGGACAGGTTTGTAGAGGATTTTGAAGAGAAAGGTAACCT
 TTTGCTCGCAATATAAGATTGACTTGTTTTCTGACGACTATGACACAGCTGAAAGAGTGGCCGACCCCTCC
 CCTGACAGAGCTGTGCTTTTGGAGAAGGAGAAATGGCCCTTTTGTATAGTACAGCTGAAGATCTAGATCT
 TCTAAATGCTAGTTTTCACAGTGAAGCAAAATTTCTGTACGTGGACTCCAGGCACTTTGCTGCACAT
 GGAAGAGCTGAGCTGAAGACTTCTGACCACAGGCCCTGTGCTTGCCTGATTGATATAGATATATTTGAAG
 TTTGAAGCTGAAGAGAGGCAAAAACATTTATAAAGAAATTAATGTCAGTTTCAGGCGTCCACAGATGGTACAGT
 ATTGGTCTCAATCAAAAGTTCTTTACCAGAAAAATAATTTTGTGATGGCTTGTATTTGATGAGCTCTG
 CAGCAGTTTTCAGAGTTTGGTGAAGTTATACCTTATAAGATTGTAGAAGATAAAATGGGTGTACATTTT
 TGGAGGGAAGCTCTGCCCTTGAATGTTCTGAGCTAAATGGTAAAGAGTTATTGCAATCGCATATAACTAT
 TGCTTTAAAAAGTCCAGACTGGATCAAAAAATTTGGAAGAAGAAATGAGTTTAGAGAAAAATTAGCATTCGA
 TTGCCATCATCAACAAGCTTACCTGCTTGTGTAAGATACGAGAGTTCGACGAGATTTTGATATGTGAAG
 GTGATTTGATGACTATAGTCTGAAGTGGAGGAACCTTCTCTCAGCATCTCCAGCCATCTTCAAGTTTC
 CGGCTTGGTACTTCCCCAGCTCTTCAACCCGAACTAGTCCCTGCCAGTCACTACAATATCAGAGAGTCTG
 CTTGTACCTTCCCTTCCCATCAGCCAAGCCGAGCACCCTCAAGAATCTCTGGGCTCCGAGTGGCAGGA
 GTTCTCCTATTGACGCGCAGCCAGCAACGCCCTCTGCCGAGAAAGACCCGCCAGCCCTTGGAGCCCA
 CGGGCGGGCGGGCCCGCCGGTCTGCCCTTCCACACGCGCCGGCTCCCCACAGAGACCTCTCCCGCT
 TCAGGGCTAGGAGTCTCGACCCACTAGAAAGGAAATTTGGAGGTATTGGAGCCCTCCGAGCTCTGGG
 TAGCTAGGAGAGAGATGGAAGCACCACAAAAGCCCTGGAACAACAAGGAAAGATAATATAGGACCGAGTCA
 GCCTTACAGCTCAAGCAGGACTTGCAGGCCCAGGACCTGTGGATACAGTACAGCCAGACGACGATTCCT
 CCTCGTGTGGAGTTATCAGTGCCTCCAGAGCCACGCGGGGATCTGTCTGGAAGACTGACTCCTGAA
 GCCAAAGCAAAACATCAGAAACGTCGAAAGGTTCAACTTTCTTCTGAACCACTGAAGCTCAGGCTGC
 TTTTCTCCCGCAGTCTTCTTTGGCCCGCTGCTCAAAGGTTGCAAGAGCCTCTTGTCCCTGTGGCAGCA
 CCTATGCTCAGTCTGGGCCCCAGCCAAATTTGGAACCCCAACCAACCACTCTGAAAGAGGTTCACT
 CCGATGCTTGGCTCTCAGAGCTTCTTCAACCCGAAATGAAACAAATGGAATCTCTGTAGGCAAAAG
 AGAATCACCATTAAAGATTGACCCATTGGAAGATCTGTATTTAACTGTCTGTATCAAGAGCTCAG
 CTATCTGTTCAAAGCTCACTGTTCACCCAGACCCAAAGAGGTTGATTTCAGTGTCTCTGCAACGC
 AAAGTAATGTTAACTTTGAGTCTGTAAAGTTGCATGCCAACATGCTTCAATTCAGCTCGGAGTCA
 ATCCCAAGAAAAATATGCAAGATTCTCAAAACCACTTTATTACTGGCTTGACCGAGGACAAATCTTTCACT
 GACAGGACTGCTGCTCTCGAAACCCATTTTAGAGCCAAGTCTGAAGAATCAGAGGCAACTTCACTGTTCT
 CCAAGAGAAGGCCCGTTACTATCAGTCTTTCCCTTCTGTGACGCTCTTGGTCAATAACAAAGCAGGG
 TTCACTTTGACTGTATGGCTTTAAGGACAGTTTGTATCTACAGGCGCAGCTACATTTAAAAATTAGCAAC
 CCGAAAGGATGGTAACTTTCGAGGAAGAAGAGGATTTTGGTGTGAAGGGAAGTCAAAGTCAAGCTTGTT
 CAGACTTACTGGGTAATCGCAAGTTCAATTTCTGGCTCAACCTTGACATTTGAATGATGACTGGAATAA
 AGGACAAATGCTTCTCTGTGTGTGCGGTCAAGAAGACCTTCTCACTCTCTGTCTCTCTGCTCCG
 CCGGCAACAGCCCTCCAGTAGATCTTTCACGACCTTGGCCTCTAAGGCTTCAACCCACACTGGACCTTTA
 CAGAAGATAACGCCAGCCGG

>gi|26190607|ref|NM_003898.1| Homo sapiens synaptojanin 2 (SYNJ2), mRNA
 GGCACGAGGCGGGGAGCTGTGCGGGGAGCGGCCCTCGGAGGACGTGGCCCGGCCCGCCCGCAGT
 GGGCCGACCTCTACGGCCCTGAGCAAAAGGGCTGCGGCTGCTGGGCGCCCTGGGGCGGAGGGGAGTGT
 AGCGTGTCTGGAGGCGCGCGGCCGCGACGACTGCTGTGTGTGAGGCGCGCAGCTGGTGGCCAGCTGG
 CTCCAGAAGAAAAGGAAGTCATTAAAGGACAGTATGGCAAGCTCAGCGACGCGTACGGCTGCTGGGGGA
 GCTGAGGCTGAAATCTGGTGGCACGCTCTGAGCTTCTGGTGTGGTGACAGGCTGCACATCTGTGGG

AGAATTCCAGATGCTGAAATCTACAAAAATCACTGCCACTGACTTTTACCCCTTTCAGGAAGAGGCCAAGG
 AGGAGGAACGCCCTCATAGCTTTGAAGAAAAATCTCAGCTCGGGGGTGTCTTATTTCTCATGCGCAAACGA
 TGGGCTCGCTTTGACCTGACTGTCCGCACGCAGAAAGCAGGGGGATGACAGCTCTGAATGGGGGAACCTC
 TTCTTCTGGAACAGCTGTTGCACGTGCCCTTGAGGCAGCACCAGGTGAGCTGCTGTGACTGTCTGTGA
 AGATCATCTCGCGGGGTGTTACACCTCCGCACCGGTATGCTCTCCACAGCAGGCCAAGGCCCTGCCCTGT
 CTCCTGCCGTAGGTGTGAGCGCACAGGCACTGCTTCCACACCCGTGGCGTGAACGACGACCGGCCATGTG
 TCCAACCTTCGTGGAGACAGAGCAGATGATTACATGGACGATGGAGTGTATCTTTTGTCACAGATCAGAG
 CCTTCGTTTCGCCGTGTTCTGGGAACAGCCAGGGCTTCAGGTTGGCTCCCATCATCTGAGACTCCACAGAGG
 CTCTGGAAGCCAATGGCCCCGTCTTCGACAGGCACATGTTGCTTCTGAAGGACGAGTACGGGCAGCAGGTG
 TGTCTGGAACCTTCTGGGAAGCAGAGGCGGAGAGGAGGTGCTCAACAGAGCCTTCAAGAAAGCTGCTCTGGG
 CTCTCTTCAGCCAGCGGCACAGCCCTATGATCAATTTTGACTTCCATAGTTGCCAAAGGTGGGGAAGCT
 AGAGAAATTTGAGACCCCTCTTGAGGCCACAGTTAAAGCTGCATGGGAAGACTTCCATGTGTGTTCAACAAAG
 GGGGGAACGTCAGTCCACGTTTTCAGAAAGGCACCTTTGCGGATGAATGCTCTTGACTGCCCTGGACCGAA
 CCAACACTGTGACAGACTTTCATCGCGCTCGAGGTCTTGCATCTGACGCTCAAGACCTCGGGGCTGAGTTC
 AAAACCCATCGTTGACCGCTTTGTGGAGTCTTCAAGGCCATGTGGTCTTGAATGGCCACAGCCTGAGC
 AAGGTTTTCACAGGCAGCAGGCCCTGGAAGGGAAGGCCAAGGTGGGGAAAGCTGAAGGATGAGCCCGGCT
 CCATGTCTCAAGCCATCTCAGTCCAACCTTCTTCGACGGGTGAAGCAGGAGGCCATCAAGCTGCTGCTGTG
 TGGGACGCTCATCGCGAGGAGGTGGCAGACAAGGGGGTGTGCTGCTGACAGCAGCAGCGCTCTCGGTG
 ACTTCCAGGATCTGAAAGCTATGACTGAGCGCTAGTCCGAATTCACAAATTTCAAGCGGATCCGGATTG
 CTAATGGGACCTCGAAGCTGGAACGAGGAGAAAGCAGTTCGGAGCAACGTGCTCAGGACGGCGACGCTGAC
 AGACTGGCTGCTGCTGCTGCTGCGCCAGCTCTCGGGAGCTACCGACTCCAGGATGACAGCAGCCAGCTGAC
 ATATTGTCTGTGGGGTTGAAGAGATGGTGGAAATGAGCGCAGGGAATATTTGTCAATGCCAGTACTACCA
 ACAAGAAGATGTGGGGTGAACAGCTTCAGAAAGCCATCTCACGCTCTCATAGATACATCTCTGTGGACTTC
 GGCACAGCTGGTGGGCGTCTGTCTTTATATCTTTGTACGTCCATACCATGTCCCGTTTCATCAGGGACGTA
 GCCATCTGCACAGCTGGAAGACGGGCATGGGGGGCAAGGCGGGGAACAGGGGCGCGCTCGGCATCCGCTTCC
 AGTTTCCACAGCAGCAGCTTCTGTCTTCATATGTAGTACCTTGACGGCGGGGACGTTCCAGGTGAAGGAGCG
 CAGTAGAAGACTACAAGGAGTACCCAGAAACCTTGCTTCCCAATGGGGAAGAAATGTTTTCTCTCATGAT
 TATGATATTTGGTGTGGCGGATTTCAACTACCCACTTGATCTTACTTATGAAGAACTTTTCTATTTTGTATA
 AACGCCAAGACTGGAAGAAACCTTCTGGAATTTGATCAACTACAGCTACAGAAATCAAGTGGAAAAATTTT
 TAAGGACTTTTCAAGGAGGAGCCATTAACCTTTGGACCCACCTACAAGTATGACGTGTGGCTCAGCCGCCAT
 GATACAAGCGACAAATGGCGCACCCCGCTTGGACAGACAGGGTGTGTGTGGAGGAAGAAACATCTCTT
 TTGATAAACAGCTGGAGAACCTCAACCTCTTAGACAGTGATCTAGATGTGACACCAAGCTCAGACACAC
 CTGGTCTCTGTGCTGCTGCTGATTTATGGTGTGTCGCGAGCTACAAGCGCTTGATCAGACAGCTGTGCTG
 CGGATCTGGAGGTGGAAGTTCAGGAAGTCTGATGTGGGTGCTCGGAGAGGGTTTTCAGGAAGGTGCTCT
 CTTTCCAGGGCCCCCTGGATGCCACTGTGTGATGAACCTTCAATCACCAGCTTTAGAAGAGAAACACGA
 GTTTCAGAGGACCTCGCTGACTGAGCTCATGACAGACTTGGGGAGTTATGGGACAAATTTGTTCTGTACAG
 ATCAACCAAGGGCAGATGCTGTGTAACCTTTGACAGACAGTCACTCGGCTCTCAGTGTCTCGGACGTGGAGC
 GTAAGAAGTGAAGAGCAGCAGTGAAGATTAGACCCAGAGCAAGGACTGGCTGAAAGGTTTGGCAGAGA
 GGAGATCATTCGGAACAGACAGCATGGCCCCCGTGTCTCCCACTGCCAAGCTCTGTCTTGTGGAGGAA
 AACCTTGACTTCAACAGTTTGACTATGAGTCAAGAGGGGATATCTTGAAGCAGTGAAGACACTTTGG
 TGGATGAATTCATACGCTGGAGTCTCGGACAGTGAACCTCGGGGAGACGACCTCTCTGATGTCCCCGG
 CCCCACAGCACTGGCTCTCTCCCAAGATGCACTGCTCTCACCAAAAAGAGCAGCATCCACAGCTACAAAC
 GATGACGGGAGCTGTGTGGAGCTCAAGCGGAGCTGGAAGCGCTCGGGAGTTCGCCACCTGTTCTCCGA
 CAGAGTCTGTGTGCTGCCAACCGGCTCGGCCACCTCAACCCCGCAGAGACCCCCCTCTCAACCCGG
 TTTATGTGTGAAGGTCGGCTTCAGATGCTCCATCTCTCTCGGCACCATGGACAGATGTCATTTCAATTTG
 CAGACGGCAAGACTTCTACCAGGAGCACCTCAGCAACCTCCCAAGGCTCGACTGGAATAAGTAAACCTT
 ATAATGTCAAGCAGATCAAAACACCACATGCCAGGAGGAGAGCAGCAATCCGGTGTCTCTTGGAAAG
 CAGAGGAGGAGCTCTCGAAGAGCCCTTAAGTGCCTGGGCCCAAGGACCTTCTGAAGCACTCTTGGAACCA
 GAGCCCAACCGGGGCGACGCAAAACAGAGACCCCAAGCGGCCCTCTCTCTCCCTCGGGCCCCAC
 CCAGAGTCTCTGCGCATCTCCGAAGCCAACTTGAGAAGGACAGAAAGCCCTGTGACCCGGAAGACAGTT
 TGAGCAACAGACTGTCCATTTTACAATCGGGCCCCCGGAGACAAGCGTTGAGGCCCTCTCTGTCTGAC
 GCCCTCGAGTCCCTCTGTTCCCAAAACAAAGAACATTTAGCCTGGGAAGCTGACAGAGAGGCCAAGCC
 ACAGGAAGCCAGCATCAGACAGAGCCCTCTTGGGGCAGAGGAGCTCTGTGCCACCACTCTGAGGGCGCC
 GCCTCTGTGCTCAAGCACTCCCGGAGGAGGAAGATGACGCCCGCGAGCTCTCACTCGAGGTCTCTG
 CAGACCAACAGCCAGCTTCTCTCAGGCGCTCACTTACAAATGACAGTGACAGCCCTCTGGGCAACCTG
 CCGCGGGCAGCGTCTTCCCAACAGGGGACTTCTTCAGCACTTCATCTGCTACAAGCCCCGACAGCGATGG
 CACCAAGCGATGAAGCCAGAGGACAGCCCACTTCTTGGTGAATATCAGGACCCCTCTTGGAAACCTTCTT

CACCACCCATAACTGTTGAATAACACTTGGCTTTCTAAGAGCTCAGACCCCTTGGACTCAGGAACACGGA
 GCCCCAAAAGAGATCCCATAGACCAGTGTGACGTGGCGCTTACAGTGCACAGGCAGAGCTGCCACCAGCA
 TCATGAACCAACAAACCTTAGGTCTACTGGGTGACAATCAGTGACCAGAAAAGGAGCAGCATCGCAGGTG
 TTTGACCACCTGGCAAAAACATGACTGAGCAGCTTTGAAGGCTGCAGTCTATAGAACTGCATACCTTTCTCT
 CCTCTAGACATCCCTCCACCAGAAGAGACATCTATTAAAGGCACACTGGCCAAAACGCTTTGGTCATCT
 GCTACTCTCTGTGTAGTTTACAAAATCTGTGCTCTTTATTAGTAAGATGGTTACTCAGGCACCAAAATAT
 ATTTCACTCAAGGCTTGTACATCTGAAGTTTGTCTTCAAGGAATGGGAACCTTTCGTGTTAAATTCGGTG
 TATGGATTTTAAGAAAGGAACTAGCCCAATGAGGTCCAAAGATTCTCACCATTGAATTTTAAATGGC
 TGTTCAGTCTTGTGTACGTGTGATGGAGATTTGTCTTTTGTTTTATTTGCACTTTTACAGATTTGGGTATAA
 CATTTTGGGGAGCCACCTGAAGGTTGATGTATAAAGTAAGGATTAGAGAAAAGAGGTCGTTTGTGACCAATTA
 ATAGCTGTCTCGCCGCTTCAATAACAGGTTACAAAATCAGAGTCCGAAGCAGCAAAATAGGTCTCAACCT
 AATGACTAGACTGTACATTCCTCATGAGCCTTCATGTTTAAAGTGTGTACATGTGCGTTAACTGTATGATG
 CTGTAATCCCGAGGGAGCCGGTGGCATAACCCGTAGCTTAACTTAGCTTAACTAGCTGAAAGGCTCTT
 GTGCCATGTCTTAGACATTTGCATGCCCTATCAATTAATCTATAATCCTGAGCATGGTGTGCTACTGAAACC
 AATTTTATTCACCATCTAGTCCTTATTAATGAACCTCACGGATCTTTGTTCGCTTATATTTTCATG
 CATACCATCAACAGACACAGTGCAGAAAACCTTCTGTGATACCGAGATTTGATTTCTATTTGTAGAAATA
 TGGAGAGTGTTCAGCCTCGTCTGTCCGGCTGGAGCTTCGGGATGGAAAGTGTATGTGTCCTCTGCATAT
 AAGAATCACCAGGCCAGTGTCTTCTGGTCTTGTCTATATGTTTGTCTATATTTTGGCTATACAT
 TTTCCACCTTTTCCAACAGCAGCTTCTCACCATTCAATAAC TGAAAAGACATTACCATAGTGTCTTACA
 TTTTAAAGTAATGTTACAGGCTCGGAATCCATTGGGAGCAGATACCGTGTTTTCGCTATTTAATAAGA
 AGTTCAAGTAGTAAATCTTACTGTACCGCTGTGTATCTTGGGAGCCTCTGTACAGAGGCTCGCACAGCAG
 TGATCAAGTGTCTACCTTACGTGACTGGGGGATGTCTGTCTTAAAGCTGACTGCTAGGATAGTAAGGA
 TCACTTGGCTGGGCTATGGCTACTGTCTTGTACCAATTAGACATCTGGAATTTTCATAATTAGTTTTCAT
 TGTCACTGTCAAGATATATTGCAGATTACTTAAATATGGCCATCAAAAACAAAGTTACAACACGTATCTC
 TTTTCTATCTGAAAACATAATACCTGGAAAAGGATAAAAAAAGGAATCTCGTACGCCACAGAGCTAGAC
 AGATAAGATGCTACTAGTTGTACCACTGATCAAAAAGCGGCTTTTAAAGTGATCAGGATGCGCTTGGTGGCAT
 ACGTGGTTTATATGATTTTACCTCTGTAAACAAACACAAGAAATAAACAGAAATGGTCTCTTAAACAGAGTTT
 GGGGGAGAGGACGAAGATGGGTCTTGGAGAAGCTGATTTGCCAAGATGCACATCTGCTTAAACAGCCAG
 AGTCAATAATGAAATGAAATGAAGAAATTCATCTAAATGTCTCTTTTCCCTATAACCTCTTTTCTACCAA
 AAGAGAGATAAATTTGAAAACAGATAAATGTAAACACACAGTCAAGAAGCAGGGGAAAAGTAAGCTCTC
 CAAAGTTGCTTGTGAGCTGGGAAATAGATCTCAATTTTAGGTTTCTCTGCTTACAGTACCTGCAATTA
 TGGGACAGAGATAAATAATTTTGTAAATAATGTGCTCATCTCCTAAGTAGCTCTTCAGAGCTTGACCGT
 AAGTAAAAACACACAGAAATTTGTGTGACTGGGGGAGGTGAATCAAAAAAGTTACGAGGATTTAAGAG
 TTAATATATATTGTATCTGTGCTGTCAAAATTTAGTGAACACATAGATTGGATTGGAGTTGGTAGTAGAAG
 TAGTGTCTCATACCAAGAAATCTCTT

>gi|37556102|ref|XM_209367.2| Homo sapiens similar to dJ680N4.2
 (ubiquitin-conjugating enzyme E2D 3 (homologous to yeast UBC4/5))
 (LOC284767), mRNA
 ATGGCGCTGAAACGGATTAATAAGGAACCTAGTGATTGGCCCGTGACCCCTCCAGCACAAATGTTCTGCAG
 TGCCAGTTGGGGATGATATGTTTCACTGGCAAGCCACAATATATGGGACCTCATGACAGACCATATCAAGG
 CGGTGTATTTTGGACAAATTCGTTTTCTACAGATCACCCCTTCAACACCATTAAGGTGCAATTTGACA
 ACAAGAAATTTATACCCAAATATTAACAGTAATGGCAGCATTTTCTTGACATTTCAAGATCACAGATTG
 CGCTGTCTTAAACACTTCTTAAAGTTCTTTATCTCATTTGTTCACGTGCTATGTGATGATCAAAACCCAGATGA
 TCCCTTAGTGCCAGAGATTGACGAGTCTATAAACAGACAGAGATAAGTACAACAGAAATATCTCGGGAA
 TGGACTCAGAAGTATGCCATGTGA

>gi|19549332|ref|NM_015983.2| Homo sapiens ubiquitin-conjugating enzyme
 HBUCE1 (LOC51619), mRNA
 GTGCAGCTTGGTGGCGCTGAGCCGGCAGCGGGCCGCTCAGGCAGCCCCGGCCGGCCGCCCGGGTCC
 CGGCAGCGGGGTAGGATGGCGCTAAAGCCGGATCCAGAAGGAATTAACCGACTTGCAGAGGACCTCTCTGT
 CCCAGTGTCTGCAGGACCTGTCCGGTGTGATGCTTGTCCACTGGCAGGCCACCATAGCTGGGCCGAATGA
 CAGTCTTACCAGAGGAGGTTTCTTCTCTGACCATCCACTTTCTTACAGATTACCCGTTCAAGCCCCCA
 AAGGTTGCTTTCACAACCAAAATTTATCACCCATAATATCAACAGCAATGGCGAGCATCTGCCTTGATATCT
 TCGGCTCTCAGTGGCTCCAGCATCTGACGTGTGTCAAAAGTCTCTGTGCTCATCTGCTCGCTCGCTGCTGCA
 CCCCACCCCGATGACCCCTGGTGCCAGAGATGACACACACCTACAAGGCCGACAGAGAGAAGTACAAC
 AGACTAGCAAGAGAGTGGACACAAAAATATGCTATGTAAAGTGCCTTGGAGGTTTACATGAGACACTGTC

CAAGAGAAGCTGGCAGAGAGGCTCTCCCTTAAAACTTTGGGCTGTGGCTGAGCCATTCAAAGAGCATCA
TCTGTTCTTCAAACAAATGTTGGTCACCCACTCTCTCCAGCTGCAGCATGTTGGTGCCATTTTCAGCAAT
TACGGCTTTGACAGTGCCACCTCTTTGATGCCAAATCAGCAACCATTTGTTGTTATGACTCTGCAGTCTTCC
TGGTGACACTGGAATCTCTCTCTCTGCCGCTCAGTTTGTCTGTTGCTTTGGGGGGCCAGGCGCTCG
ACGTCTCTCTACCCGCTCTCAAAATGGTGCTTCTGCCCATGATGGTACCACACCCAGGGCTCTCAGCTTGGC
CCCTCACCACCACTCCCTTTGGCTTTTAGAACTCAGTGCCATCTGGGTGCCAGGCAGAGCAGCTTTG
TTCGCACCTCATCTGCTGCAGAACACATCTCTGAGGAGTCTCAGCTTATCTCTGGAGGAAATTTGGGAACAG
TGTCACCTGGGAAGTGAGGCCCTAGCCCTGTGGCTTCCACCAAGTCTCTCTCTGCAGTGCCACAGTGGTGGA
TTTCTCGCTCACCACCAAGAGCAGCAAGTGGAAAAATTCAGGATACAAAGCACATAACCCACCCATAGA
GATGATATGTTTTTAGAAAGCAAGAGCAAAATATGAAACCTCTAGAGATTTGGGTGATGTTTACTTCATT
TGATGAAGATTTCTCACTACCCCGCTCTCTCCCATAGGAGCTTACACTAAGTCTCAAGTGTAGGACCTTCA
CAGACTAGAACACAAGGAGGAGAGACTCTTAAACGTAAATAAAATGCAATTCACCTACAACCTCT

>gi|33188457|ref|NM_003339.2| Homo sapiens ubiquitin-conjugating enzyme
E2D 2 (UBC4/5 homolog, yeast) (UBE2D2), transcript variant 1, mRNA
GCTTCGCAGCGTCACGCCCTCCGGGCGGTGGCGGCACGGCGTGCAGTCTTACTCACAGGGCGGCC
CGTATCCCTCCGCGCGCGCGGCTCGGCCCTCCCTCCCTGGCCGCCAATCCCGCGCTCCCGACG
TGCCCTCGGTGGGCGCCACCCGTGCTCCGACGCGCCACCCGCGCGCGCGCGCGCGCGCGCGG
TCCCTTCGGTCCACCTGCAGAGGAGGAAGACAGGCAATCCCTCCGGCTGTCCGACCAAGAGAGGCGCGC
CGAGCCCGAGGCTTGGGCTTTTGGCTTCTGGCGGAGGAGTCTGCGCGGTTTAGGAGGGCGCGCTGATCT
TGGGAGGAAGAGCAGCTACGCGCGCGCGCGCGGTGGCGGTGGCGCGCGCGCGAATAAAGGGCGCGCG
CGGGTGATGCGGTGACCGCTGCGGCGAGGCCAGGAGCTGAGTGGGCGCGCGCGCTCAGCCGCTCCGCTA
GGACCCGCTTCTCTCAACTCTCCATCTTCTCTCTGCCAGCCAGATCGCCGAGGCGGCTCAGGCTCCGCTA
GCCCTTCCCGCTCCCTTCCCGCGCGCGTCCCGCGCGCGGGGCGCGCGCCACCCGCTCCACCATTGG
CTCTGAAGAGAAATCCACAAGGAATGAAATGATCTGGCACGGGACCTCCAGCAGAGTGTTCAGCAGGTCC
TGTTGGAGATGATATGTTCCATTGGCAAGCTACAATAATGGGCGCAATGACAGCTCCCTATCAGGTTGGA
GTATTTTCTTGACAAATTCATTTCACCAAGATATCCCGTTCAAACACCTAAGGTTGCAATTACAACAA
GAATTTATCATCCAAATTAACAGATATGGCAGCATTTGTCTTGATATTCTACGATCAGTGGTCTCC
AGCACTAACTATTTCAAAGTACTCTTGTCCATCTGTTCTCTGTGTGTATCCCAATCCAGATGATCCT
TTAGTGCCTGAGATGCTCGGATCTACAAAACAGATAGAGAAAAGTACAACAGAAATAGCTCGGGAATGGA
CTCAGTATGATCGGATGCTGTAATTAAGAAATTTATGGATAACCTCTACAATAAAGATAGGGGAACCTGA
AAGAGAAAGTCCCTTTTGATTTCCATTTGACTGCTTCTATGAGCCACAGCTCATCTCCCTCTGTGCACA
TGTTTACCTGATACAGCAGTGCTGCGGTGTGTACATACTTGAACAACAAACTAGAAAATAGCTTCTCT
GTACCAACATTGCTCCTTAGCAGAGAAGTGTGTGTGTGACAAGCCAGTTTACAGGCATTTACCTAGGTGT
GAGACTAAAAGCTTTTCTTATTGACTTAAATTTGATTAACAGCAAGGTGTGAGGGGTTGGTGGGTATGG
TCTGCTTTGGATGGGGAAGAAAAGGCTCCACTCACTATAGGAGATTAATTTAAGTGAATCCATTTA
AACTCAAAACAGTTATGAAGAAAGCAAGGTGAAGAATGAAGCTGTGTCTGTATCTATTTTATTCGCAAG
AGCTACAGCTTTAGGTGAAAGTTATGACCAACAGATTAACCTACCCACCTCTGCATTTTAAGTCTA
AGTTTAACTGGTCAACATTTAAATGGATTGGAGCTATTAGTACATCAAGTGTGATGGGCTTTGTTCCCAA
CTCTTTTACATCTCTCCACCTTCAACCTTTGGCGTTTTCAGCCCTTCTTTCTTCCATATCTTTTGT
GTTTGTATGTGGTTTCTCAGTTAATACATAGCTAATAGCTCTTATTTTCTTATGTTTTTAAACGCTTAG
GCTATTTTGGATGTAGGTTGAAATTCATTTGATGAAATCTTGTGTATTTTAAAGACCCCAATTGCT
CTCTTGGAGCTTGACTTTTCAAGAATGATTAATCTGTGTATAAAGCTGGTTACTACAGCTTACATATA
ATTTTGTGTGAATAGGCTTTTTCATTTTAAAGAAGTTGTCTAGCTGAGATTAGTGGTGGATTTTCTCCC
ACTTCTGAAATGTTTCAATTTATCTGGTGTGATTTTAAAGATCATGAAACAAATCCAGTTACATGTAAAAA
GGATATCTTACGAGTAAATTTTATGAACAAGTTAGAGGCATAAGCTTAAAGACATTTCCATGAAACAA
CATGCAGCATTCAGGAACCTTGATTTGTTAAATTCATAAGAAATTTGCTTTTATTAATGAACATAAGCTGC
ATTTCTACAAAACCTTTGACATCTCCCTTGGTATATAGGACATAAGACATAGGAGCATTTGCTATTTGGTA
AGTTAAGCTCTCTGTGATGTAATATAAAGAGCAACATTGACAAAACCTGGGAAACAAGAGCACAGCTGT
TCTTGGAGAGTCTACATATAATTTACTTTGCACTAACATTTGCAGGATGTTCAACAAATTTAAATGTACT
GTATGTGGCTTTTGAAGTCTTCCCTTGACCTAGTAAATATAGCTTGAAACTGTAAACAACTGTGTT
TGCCAGAAACATCATTCATGTGAAGTACGCAAGTTACCTTTTTCGCCCTCTTTTCTCTTAATGTAAAC
TAGGCCAACCTGAAAGCCATGGCTGATGCTCTAGGCCATCAGGTCTTTCAAATGCATCTTTTACTACTCTTG
CACAAAGTTAAGGAATAAATGTCCTACTGCTTTTGGTTTAAAAAATAAAAAA

>gi|33149308|ref|NM_003340.4| Homo sapiens ubiquitin-conjugating enzyme
E2D 3 (UBC4/5 homolog, yeast) (UBE2D3), transcript variant 1, mRNA

ACCAAGTAGGAAATCGGGGACGCTGTGGGGAGGGGCGTGGGGCTGGATCGCGCAGCGGCTGCTTCCTT
 TACCTTCTCCCATGGTCTCCTTCCGGTCTCGATGCTTCTCTGAGCCTAAGGGTTTCGCCCACTCGTTC
 ACCCTCCCCCGCTCATGATCTTCTCCTCCCCCGCCCTCCTGGTCCAATCTCCGATCTGTTTAGTAA
 GAAGTGCTGCTTCCGAGAAGAGAAGGAAAGGGCTTGACACGATTACATCGGCCCGGACGTGGGAAG
 CAAGCGCTCGGCTTCGGCTCACATCGGTCTCTGCTCGGGACGGCGGCTGTGGCGAATGATCCGCGG
 CGGTGAAGAGCGGCTGTGCTCGCAGAGCTGGTGTGAGACGAGACAATCTCGCCGCCCGCGGGATAA
 TCAAGAGTTTGGCCGGACCTTTGAGCATACACCGAGAGAGTGAGGAGCCAGACGACAAGCACACATAT
 GCGGCTGAAACGGATTAAATAGGAACCTAGTGATTGGCCCGTGACCCCTCCAGCACAATGTTCTCGAGGT
 CCAGTTGGGGATGATATGTTTCAATTGGCAAGCCACAATTAATGGACCTTAATGACAGCCCATATCAAGGCG
 GTGATTTCTTTTGACAATTAATTTCTTACAGACTACCCCTTCAAACCACTTAAAGTTGATTTTACAAC
 AAGAATTTATCATCTCAAAATATTAACAGTAATGGCAGCAATTGTCTCGATATTCTTAAGATCAGAGTGTGCG
 CCTGCTTTAACAATTTCTAAAGTTCTTTTATCCATTGTGTCACTGCTATGTGATCAAACCCAGATGACC
 CCTAGTGCCAGAGATTGACGGATCTATAAAACAGACAGAGATAAGTACAACAGAATATCTCGGGAATG
 GACTCAGAAGATTGCCATGTATGCTTACCTTAAAGTCAGAATAAATCTGCATTATAGCTGGAATAAACTTT
 AAATCATGTTCTTTTGTATTTCTTATCCGGCTGCTCCCTATCAGACCTCATCTTTTAAATTTTAA
 TTTTGTGTTTACCTCCCTCATCTTCAATTCATGCTCATCTGAGAAGACTTAAAGTTCTTCCAGCTTTGGAC
 AATAACTGCTTTAGAACTGTAAAGTAGTTACAAGAGAAGACAGTTGCCAAGACTCAGAATTTTAAAAA
 AAAAAATGGAGCATGTGATATTATGTGGCCAATGTCTTCACTTAACTTGGTTATGAGACTAAAAACCATTC
 CTCAGTGCCTTAACATGCTGAAGAAATCATCTGAGGGGAGGGAGATGGATGCTCAGTTGTACATCAAA
 GGATACAGCATATTCTAGCAGCATCCATCTTGTTTAAGCCTTCCACTGTTAGAGATTGTAGGTTACAT
 GATATGCTTTATGCTCAATACTGATGTGGCTGGGAATTTGGTATGAAATTTATAGCATCAGCAGAAACAGA
 AAATGTGATGATTTTATGATGTCAATAAAGGAATGACCTGTTCTTGTCTACAGAGATAAGAAATGG
 AAGTCAACACCCCTTTGTATTCCAAAATAGGGTCTCAAAACATTTTGAATTTTCAATTTAAATTTGTAGGA
 GGCTTGGAGCTATTAGTTAATCTATCTTCCAATACACTGTTAATATAGCACTGAATAAATGATGCAAGT
 GTGTAATGGATGAGTGATCACTCAATATAGCTCTGCTAGTAAATGATTATTTTCTTCAATAAAGTTGAT
 AAACCAATGAGTTAGCTGCCCTGGATTAATCAGTATGGGAACAATCTTTTGTAAATGCAAAAGCTGTTTT
 TGATATACTGTTGGGATTTGCTTCAATGTTTGACATCAAAATGATGATGTAAGTTCTGAAAGAGTGAATA
 TTTTGCATGTTTCAAGTTAAAGTGACAGCTCTGTTACAGTTGACACATGCTTGACCTGATTTATGAGAGA
 ATTAATAAGCTATTTGGATAGTGAGCTTTAATGTGCTGCACATGATACTGGCAGCCCTAGAGTTTCATAG
 ATGGACTTTTGGGACCCAGCAGTTTGAATATGTGTTATGGAGTTTAAAGAAATTTTATTTCCAGGTGCAG
 CCCCCTGCTCAACTGAAATTTCTTCACTTGTACACTTGAGAGTGGAAAAAACAACATGAGATGAAT
 AATGGGTCAAAAATTTGCAAAAATAAGTACTGTTTGTGTTGGGAGTTGCTATGAGGCTGTGTTGAAGTGA
 CTTATCTATGTGGGATTTGAGTATCCATTTGAAATGGATTGTTACGCCATTTACATTAATGAGCAATTA
 AATGCAACAGATATCATTTACAGGTGACTTAACATGAATGAATAAAGTCAATGCTATTGGAAAAA
 AAAAA

>gi|37539364|ref|XM_353788.1| Homo sapiens similar to dopamine beta-
 hydroxylase-like (LOC378372), mRNA
 ATGGCCCCAGACCTTCTCTTCAGGCTTTTTCACATTTTGGCCCTGGGAGTCCCCTTACAAAGCAACCGCC
 TTGGCCCCACATCTCGCCCTGCGGTATTCAGGTTCCCTAGATCCTTCTAATGTCAATTTCTCGCTGGGA
 CTTTGACCTTGAGGCTGAAATCATCAGTTTGTAGCTCCAGGTCCTGACAGCTGGCTGGGTGGGCTTCGGT
 GTCAACAAATCGCTACACCAAGTGGGAAGTGATCTGGTGTGGAGGAGCTTGCCCTAATGGCAATGTCT
 ATTTCTCGGATCAGACTTTGTGGAGGAAGACACTGGAAGGAGATGGGAGCCAGGATGCTGAGCTGCT
 GGGCTGACGGAAGATGCTGTCTACACCACCATGCACTTTTTCAGGCCCTTTCGCTCCGCGACCCCTCAT
 GACCTGGATATTACGAGCAACACCGTGAGGGTGTGCGCCCTATGGCTGGATGACATCTGAAAGTGT
 ATCGGGAGCGTACTTTGTGAAGTCCATCTTTCTGCTACAAGTCGTCCACCCTGAGATCTGGATGTGCC
 TGAGAGACCACTACATCATGACTTGGAGATCACTAATTTCTCATTTCCAGAGGATGACACCACGATTTGCC
 TGCACTTTCTTCTCTCTCTTATTGTGAGCGAGAAGCATCACATTTACAAGTTTGAAGCTTAAGTTGTGCT
 ACCACAATGAGACAACGGGTGATCACATCTGGTGTACGGCTGTGGCAATGCTAGCGTTCTCCCCACAGG
 CATCAGCAGTATCTAGGGCCGACCTTGCTTCTTCTTGTCTACAGCTCATCTGGGCTCGGCTGTG
 GGGGGCACACTGTGCAAAATAGCACAGGATGTCCTCAGCTGGGCTTCTTCAAGCTTTCACATTCAT
 TCCCCCGGGCGCTGAGTCTTATGCTCATGCGGCTGTGTAGGACCGGAGAAGTTTGGAGAGTGAATGG
 AGCTCTATGCTTGACATCAGGTGTATGGCTACCTGTCGACACCCACTTGGCTGAGCGGGCTTCGAA
 CGAGTGCAATACAGGAATGGAACACAATTCGAAAAATCTGTAAGAGCAATTTCTATGACTTTCAACCTGC
 AGGAGACTCGAGATTTTGCCCTCTAGAGTGGAGATCAAGCCGGAGAGTAATTTGCTGGTAGAATGTCTACTA
 CCAGACACTGGACCGTGAATCCATGACATTTGGAGGGCCCGACACCATTAATGAGATGTGCTCATCTCT
 CTCTTCTACTATCCCCAAAATAACATCTCCAGCTGCATGGGGTACCTTGACATTTATCTACGTGGCCACG

AGCTAGGGAGGAGGCATCAGAGTGA

>gi|24308084|ref|NM_015529.1| Homo sapiens monooxygenase, DBH-like 1 (MOXD1), mRNA

TTTCCAAGGAAGAAAGGCACACAATGGTATCAAATGTTTCATTCATCCATCTCTTGATGCTCTACGATA
 TTATCAGTCTACACATGCTTTCTGTAAAGGCCAGAAGTTCAAAGATGGCATGAGTTTCACGAGCATGTA
 TTCCCCAGATTGGAATACTCCAGGCCCTTGGAAATTCGCCGGATTATATAAAATAACTCTAGACAACAAGAC
 TTTGTCTTTAAAGGTCCTATGAATCTTTTCTCTCTGTATTTAGGTATCTCGATTTTCTTTTCCATATT
 TTCCACAGGATTAATTTTACAAATGCAATAGAGAGTTGAAAAAGATGCTCAGCAAGATTACCATCTAGA
 ATATGCCATGGAAAAATGACACACACAATAATTAATTTACCAAGAGCTGCATACATGTTGAGACATAAAT
 GACAAGAGTATAACCGATAGCAGCTGTGAGAGTGATCTGGGCCCTACCACCATGAAGATGCAGGAGAAGCTG
 GTCCCAAGTACCATGACTCCAATAGGGGCCACCAAGAGTTTGGCGTTATTTGAATCTCTGAGAAAACTAGTGT
 GCTATCTACAGCCTTACCATACTTTGATCTGGTAAATCAGGACGTCCTCCATCCCAACAAAGATACAACA
 TATTGGTGCCAAATGTTTAAGATTCTGTGTTCAGAAAGACATCATGTAATAAAGGTTGAGCCAGTGA
 TACAGAGAGGCCATAGAGACCTGTGTGCACCACATCTCTGCTCTATCAGTGCAGCAACAACCTTTAACGACAG
 CGTCTTGGAGTTCGGCCACGAGTGCTATCACCCCAACATGCCCAGTGCAATTCCTCACCTGTGAAACTGTG
 ATTTTGGCTGGGCTATTGGTGGAGAGGGCTTTCTTATCCACCTCATGTTGGATATATCCCTTGGCACT
 CATTAGATCCGCATTAATGTGCTCTAGAAGTCCATTATGATAAATCCCACTTATGAGGAAGGCTTAATAGA
 TAATCTGGACTGAGGTTATTTTACACAATGGATATAAGGAAATATGATGCTGGGGTGATTGAGGCTGGC
 CTCCTGGGTGAGCTCTTCCATACCATCCCTCAGGGATGCTGAGTTCACAGTCTGAGGGTCACTGCACTT
 TGGAGTGCTTGGAAAGGGCTCTGGAAGCCGAAAAAGCCAAGTGAATTCATGTGTTGTTCTCTCTCCA
 TGCTCACCTGGCTGGCAGAGGCATCAGGCTGCGCTCATTTTCGAAAGGGAAGGAAATGAAATTTACTTGCC
 TATGATGATGATTTTGAATCTCAATTTCCAGGAGTTTCAATCTCTAAAGGAAGAACAAATCTTACAG
 GAGATAACCTAATTACTGAGTGTGCTACAACACGAAAGATAGAGCTGAGATGACTTGGGGAGGACTAAG
 CACCAAGGAGTGAATGTGCTCTCATACCTCTTTTATACCCAGAATTAATCTTACTCGATGTGCAAGT
 ATTCAGACATTTATGGAACAACCTCAGTTCAATGGGGTTAAGAGACATCTACAGACAGTACAGACCTGGC
 CTTTCATTATCAAAAGTCTCAAGCAATATAAAACCTTTCTTTCATGGATGCTATGAATAAGTTTAAATGT
 GACTAAAAAGGAGGCTCTCTCTTCAACAGCTGGTCTCAGCCTGCCAGTGAATGTGAGATGTTTCTCAAG
 ACAGACAATGCTGAGTGTCTGATTCAAGGAATGACAGCATTACCTCCAGATATAGAAAGACCTATAAAG
 CAGAACCCTTTGGTGTGGCAGCTCTTCTTCTCTCTCCCTGCACAGAGATTTTCTCCATCACTTGCTTGT
 TTGCCCTCTGCTACTCAGCTCAGCTGAGCACAAAGAGCTTGTGATCAAAATCTTGTGTGAGACTTGACAA
 GTGTTTCTATGATCTGAACCTGTCAATTTGAAGTACAGGTTAAAGACTGTGTCCACTTTGGGCATGAAGAG
 TGTGGAGACTTTTCTCCCACTTTTCT
 AGGTTCT
 CTTAAGATAACCAATTTAAAAAATGGGCTGTCTATGTGGGAATAAAAGAAATTTCTTCTTCTCTACTACAT
 TCTGTTTATTTAAATCACTTATGTTGCTATTTCACTTTTGTACTGCTTTTATATTTCTTTAAAAAAT
 TCTCTCTTTTAAAAAATATAAAAGGGACTACTGTTTCAATCCAGTTTCTCTCTCTCTCTCTCTCTCTCT
 GTGAGTCTTTTCAAGGTGAACAGCCATTTCTCTGACTTTTAAATGTGCAAGTCTGGTCTTTCTCTGTA
 ATTACCACTGGGCCCCCTTACCTCAATGCTTTTGTGATGCCACTCTGGTTCCTCTGTTTATCTAGAGT
 TGTGTGTACCCCAATGACCCCAACCCATYTTAAAGTCACTTTTTCACCTCTCCCTGTTTATGATCTGGC
 CAGATGAGTTTTTCTAGAGCTCTGTCTATCTGAAAAGAAAGAGGCTATGGGAAACATAGAAATGGTA
 TGTAATTAATACGTATCATAGGCTGAGGAGAAAAATGATAGCTGGCTGCAGAACCCAGTGTCTGTAGGTGA
 CTTATAGAGGTTCCAGATCAAAAGACAGGCCGTGTGAGCCAGCTGAGAGGGGTGAAGTTCTGAATGGTT
 CCTTCTGCTACTTTTGGGTGACACATGTACCACATCTGGCTCAGTTTAAAGTCATGGTTCTATGTAGATTT
 ATTTTATATAGTTTAAATAGACTTTAAATTTGTACCAATGAAATCTTGTCACTCTTTTGGTTTCT
 TTTATATAGCTCAGCCAAATCTCTGTTTATGTCTGTCTCATCTCTTAAAGTAAATCTGTTTGGATCA
 TATTAAATAACCTCTGGCCG

>gi|40254422|ref|NP_000594.2| nitric oxide synthase 3 (endothelial cell) [Homo sapiens]

MGNLKSVAQEPGPPCLGLGLGLGCGKQGPATPAPEPSRAPASLLPPAPEHSPSPSPLTQPPEGPKFPR
 VKNWEVGSITYDLTSLAQAGDQGPCTPRRLGLSLVFPKRLQGRPSGPPAPBQLSQRDIFINQYSSIKR
 SGSQAQERLQVEVAEVAATGTYLQRESELVFGAKQAWRNAPRCVRGTPQWKGLQVFDARDCKSAQEMFTY
 ICNHLKYATNRGBNLSAITVFPQRCPGRGDFRIWNSQLVRYAGYRQDQGSVRGDPANVEITELCIQHGW
 PGNRGFDVLPLLQAPDDPPELFLPPELVLEVPLEHPTLEWFAALGLRWYALPAVSNMLLEIGGLEFPA

APFSGWMYSTEIGTRNLCDPHRYNILEDVAVCMDLDRTRTSSSLWKDKAAEINVAVLHYSQYLAQKIVTDH
HAATASFMKHLENEQKARGCCPADWAWIVPPISGSLTPVVFHQEMVNYFLSPAFRYQDPDWKGSAAKGTGI
TRKKTFFKEVANAVKISASLMGTVMAKRVKATILYGSETGRAQSYAQLGLRFRKAFDPVRLCMDEYDVVS
LEHETLVLVVVSTFGNGDPPENGESFAAALMEMSGPYNSSPRPEQHKSYKTRFNSISCSDDPLVSSWRKKR
KESSTNTDSAGALGTLRFRCVFLGSRAYPHFCFAFARAVDTRLEELGGERLLQLQGGDELGGCEAFRGWAQ
AAFQAACETFCVGEDAKAAARDISPKRSWKQRQRYRLSAQAEGQLLLPGLIHVHRKMFQATIRSVENLQ
SSKSTRATILVRLDTGGQEGQLYQPGDHIGVCPPNRPGLVEALLSRVEDPPAPTEPVAVEQLEKSGPGGP
PPGWRDPRPLPCTLRQALTFFLDITSPSPQQLRLLLSTLAEPEPQQEALQLSDQPRRYEEWKWFRCPT
LLEVLQEPFVSVALPAPLLTLQLPLLQPRYYSVSSAPSTHPGEHLTVAVLRYRTQDGLGPLHYGVCSWTWL
SOLKPGDPVPCFIRGAPSRFLPPDPLPCILVGPGTGIAFFRGFWQERLHDIESKGLQPTMTLVFGCRC
SOLDHLRYDEQVAFQQRQVGRVLTAFSREPDNPKTYVQDILRTLAAEAVHRLCLERGHMFVCGDVTMSA
TNVLQTVQRILATEGDMELDEAGDVIGVLRDQQRHYHEDIFGLTLRTQEVTSRIRTQSFSLQERQLRGAVP
WAFDPPGSDTNSP

>gi|4506061|ref|NP_002724.1| protein kinase, AMP-activated, gamma 1
non-catalytic subunit; AMPK gamma 1; Protein kinase, AMP-activated,
noncatalytic, gamma-1 [Homo sapiens]
METVISSDSSPAVENHEPQETPESNNSVYTSFMKSHRCYDLIPTSSKLVVFDTSQVKKAKFALVTNGVR
AAPLWDSKKQSFVGMILTITDIFINILHRYYSKALVQIYELEEHKIEWTREVLQDSFKPLVCISPNASLFD
AVSSILIRNKIHLRPVIDPESQNTIYLTHKRILKFLKLFITFEPKPEFMSKLEELQIGITYANIAMYRTT
TPVYVALGIFVQHRVAGLPPVDEKGRVVDIYSKFDVINLAAEKTYNNDLVSVTKALQHRSHYFEGVLKCY
LHETLETIINRLVEAEVHRLVVVDENDVVGKIVSLSDILQALVLGTGEEKKP

>gi|33186925|ref|NP_057287.2| protein kinase, AMP-activated, gamma 2
non-catalytic subunit; H91620p protein [Homo sapiens]
MGSAYMDTKKKKLDVSSPGSGGKKNASQKRRSLRVHIDLSSSFAMPFLDGDLEGSGKHSSRKVDSPFGPG
SPSKGFFSRGQPPRPSSPMSAPVRPKTSPGSPKTVFPFSYQESPPRSPRRMSFGGIFRSSSSKESPSNPN
ATSPGGIRFFFSRSKTSGLSSSPTPTQVTKQHTFPLESYKHEPERLENRIYASSSPPTDQGRFCPSFSQ
SPTRPPLASPTHYAPSKAAALAAALGPAEAGMLEKLEFEDEAVEDESSEGVYMRMRSHKCYDIVTSSKL
VVFDTTLQVKKAFFALVANGVRAAPLWESKKQSFVGMILTITDIFINILHRYYSKPMVQIYELEEHKIEWT
ELYLQETPKPLVNI SPDAISLKDVAVSLINKIHLRPVIDIPISGNALYLTHKRILKFLQFLMSPMDKPAF
MKQNLDELIGIGTYHNIAFTHPDTPIIKALNIFVERRISALPVVDESSEGVVYISKFDVINLAAEKTYNND
DITVQALQHRSQYFEGVVKCNKLEILEITVDIRVRAEVHRLVVVNEADSVIGIISLDILQALILTPAG
AKQKETETE

>gi|8394044|ref|NP_059127.1| protein kinase, AMP-activated, gamma 3
non-catalytic subunit [Homo sapiens]
MEPGLHALRRTPSWSSSLGGSEHQEMSFLQENSSSWSPAVTSSSERIRKRRAKALRWTRQKSVEEGE
PPQGEGEPRSPRAAESTGLEATFPKTTPLAQADPAVGVTPTPTGWDCLPSCDTASAAGSTDDVELATEFP
ATEAWECELEGLLEERPALCISQAPFPFLGWDDLRKPGAQIYMRFIEEHTCYDAMATSSKLVIFDPTML
EIKKAFALVANGVRAAPLWDSKKQSFVGMILTITDIFILVHRYYSRPLVQIYEIEQHKIETWREIYLQGC
FKPLVYSIPNDLSFEAVYTLINKRIHLRVLPDVPVSGNVHLILTHKRLLKFLHIFGSLLRPSFLYRTIQD
LGITGTRDLAVLEATPILTALDIFVDRRVLSALPVNCECQVGVLSYVHLAAQQTYNHLMDSVGEA
LRKRTLCLLEGLVSCQPHESELGEVIDRIAREQVHRLVLVDETQHLLGVVLSLDILQALVLSGAPIDPSGPE
KI

>gi|24041029|ref|NP_000616.3| nitric oxide synthase 2A isoform 1; NOS,
type II; nitric oxide synthase, macrophage [Homo sapiens]
MACPKWFLFKTFPHQYAMNGEKDINNVEKAPCATSPVPTQDDLYHNLSQQNESPQLVETGKKSPES
LVKLDTPLSSPRHVRIKNWGSGMTFQDTHHKAGILTCRSKCLGSIPTPKSLTRGPRDKNPTPDELL
PQAEIFVQYQYSGFKEAKIEEHLARVEAVTKEIETGTGYQLTGDELIFATQAWNRAPICRIGIQWNSLQ
VFDARSCSTAREMFHEICRHVRYSTNNGNIRSAITVFPQRSDDGKHDFRVNWAQLIRIYAGQMPDGSIRGD
PANVESTQCLIDLGWPKPYGRFDVVPVLVQANGRDPELFEIPDLVLVEMAHKPYEWFRELELKWYALP
AVANMLLEQWGLEFPCCPGFNWYMGTEIGVRDFCDVQRYNILEEVGRMRGLETHKLASLWKDAQVAVEINI
AVLHSGFQKQVNTIMDHSAASFSFKYMQNEYRSRGGCPADWIWLP PMSGSIITVPVHQQEMLNYSPPFY
YQVEAWKTHVWQDEKRRPKRREIPLKVLVKAVLFACMLMRKTMASRVVRTITL FATETGKSEALAWDLGAL
FSCAFNPKVVCMKYRLSCLSEERLLLVVSTFGNGDCPGNGEKLKSLFMLELNKFRYAVFGLGSSM

YPRFCAFAHDIQKLSHLGASQLTPMGEDELSGQEDAFRSWAVQTFKAACETFDVRGKQHIQIPKLYTS
 NVTWDPHHYRLVQDSQPLDLKSSMHAKNVFTMRKLSRQNLQSPSTSSRATILVELSCEDGQGLNLYLPG
 EHLGVPCGNQPALVQGILERVVDGPTPHQTVRLLEALDESGSYWVSDKRLPPCSLSQALTYFLDITTPPTQ
 LLLQKLQAVATEEPERQRLLEALCQPSSEYKWKFTNSPTFLVLEEFPSLRVSAGFLLSQPLPKPRYSI
 SSSRDHTPEITHLTVAVVYTHTRDGQPLHGHVCSTWLNLSLKPQDPVPCFVRNAGSFHLPEDPSHPCILI
 GPQTGIAPFRSFPQQLRHDSSHQKGVGRGRLTVFGCRRPDEDHIQVEEMLEMAQKGLVHAHVATYSRLPG
 KPKVYVQDILRQQLASEVLRLVHKPEGHLYVCGDVRMARDVAHTLKQLVAAKLKLNEEQVEDYFFQLKSKQ
 KRYHEDIFGAVFPYEAKKDRVAVQPSSELSMAL

>gi|4504789|ref|NP_002211.1| 1D-myo-inositol-trisphosphate 3-kinase A
 [Homo sapiens]
 MTLPGGPTGMARPGGARPCSPGLERAPRRSVGELRLLFEARCAAVAAAAAAGEPRARGAKRRGGQVPNGL
 PRAPPAPVIPQLTVTAEEPDPVPTSPGPPERERDCLPAAGSSHLQQRRLSTSSVSSTGSSSLLEDSEDD
 LLSDESRSRGNVQLEAGEDVGQKNHWQKIRTMVNLVPIPFKKRYANVQLAGHTSGFARQSTGLILKR
 CSEPERYCLARLMADALRGCPVAFHGVVERDGESEYQLQDLLDGDPGCVLDCKMGVRYTLEELTKARE
 RPKLKKMVKMLADVEAPEEHEHAQRAVTKPRYMQWREGISSSTTLGFRIEGKADGSCSTDFKTTR
 SREQVLRFVEEFVQGDDEVLRRYLNRLQQRIDTLEVSEFFRRHEVIGSSLLFVHDCHCRAGVWLIDFGKT
 TPLPDQGLDHRPWEENREDGYLLGLDNLIGILASLAER

>gi|38569400|ref|NP_002212.2| 1D-myo-inositol-trisphosphate 3-kinase B;
 IP3 3-kinase [Homo sapiens]
 MAVVYCALNSLVIMNSANEMKSGGGPGSPGSETPPPPRRAVLSPGVSFSPGRGASFLFPFAESLSPEEPR
 SPQGWRSRRRLRSSSSGSGSGSSVSPSWAGRLRGDRQVVAAGTSLSPGPEEAKRKLRLQRELQN
 VQVQNKVGMFEAHIQAQSSAIQAPRSPRLGRARSPSPCFRRSSQPPGRVLVQGARSEERRTKSWGECQP
 ETSGTDGSRKGGVSLCSSQVKKGMPPLPGRAAPTGEAQGPSAFVRMEKGIAPSPRCGSPPTAMEIDKRGFL
 PTPGTRSLAPLSGLPGASLTMATEVAARVITGPHRPQDLALTEPSGRARELEDIQPPEALVERQGGQL
 GSBTSAPERGGPRDGEPPGKMGKGYLPCGMPGSGEPEVGKRPETTVTSVQSAESSDSLSWSRLPRALAS
 VGPPEARSGAPVGGGRWLQSDRVEGGSPTLGLLGGSPSAQPGTGNVEAGIPSGRMLEAGLPCWDAAKDLKE
 PQCPGDRVGVQPGNSRVVQGTMEKAGLAWTRGTGVQSGEQTWESQRQSDALPSELLPQDQDKFFLRLKA
 CSPSNIPIAVITDMGTQEDGALTEETQGSPRGNLPLRLKSSSSASSTGFSYSEDSEEDISSDPERTLDPN
 SAFPILTDQKIPRVKSHKSRILKNMVHWSFPVMSFKKYPWIKLAGHAGSFKAANGRIKLKKHSEQRCL
 DRLMVDVLRFPVPAYHGVVDKDERYVQMDLLADDFDPCVMDCMKGIRTYLEELTKARKKPSLRKDMY
 QKMEVDPEAPTEEEKAQRAVTKPRYMQWRETISSTATLGFRIEGLKEDGTGVRFKKTKREQVTEAF
 REFTKGNHNLIAIYRDLKARTTLEVSFFFKCHEVIGSSLLFIHDKKEQAKVWMDIFGKTTPLPEGQTL
 QHDVPWQEGNREDGYLSGLNNLVILTEMSQDAPLA

>gi|18643383|ref|NP_079470.1| inositol 1,4,5-trisphosphate 3-kinase C
 [Homo sapiens]
 MRRCPCRGSLNEAEAGALPAAARMGLEAPRGRRRQPGQQRPGGAGAPAGREPGGGPWARTEGSSSLHSE
 PERAGLGPAGTGESPOAEFWTDGQTEPAAGLGVETERPKQKTEPRDRSSLPTHLEWSWELETCLWNET
 GTDGLWTDPHRSDLQFQPEEASPTQPCVGHWPTELETHGSQTPPERVKSADNLWTHQNSSSLQTHPEG
 ACPDSKEPSADGSKWELYTDGSRQDDIEGPWPTEYTDGSKQKQDTEAARKQPGTGGFQIQDQTDGWSWTQ
 STDGQTPAGPTDCLLEPEDGPLEEPEPEGELLTHLYSHLCKSPCLCPVPLRLIETPEPEAGQPVGPPEPSVR
 EGGSGGFSASSPDESEDVAGGGGASDPEDRSGSKFWKKLTVLKYSPFVVSFRKHYPVWQLSGHAGN
 FQAGEDGRILKRFCQCEQRSLEQLMKDPLRPFVAYYGMVLQDQGTFFNQMEDLLADFEGPSIMDCMKGRS
 TYLEELVKAREPRPRKMDYKMWAVDPCGAPTEEHAQGAUTKPRYMQWRETMSSTSTLGFRIEGLKKA
 DGTCTNFTKQTALQEQTKVLEDFVDGDHVLQKYVACLEELREALEISPFKTEHVVGSLLFVHDHTG
 LAKVNMIDFGKTVLADPHQTVLSHRLPWAEGNREDGYLWGLDNMICKLQGLAQAS

>gi|4758698|ref|NP_002363.1| mannosidase, alpha, class 2A, member 1;
 mannosidase, alpha type II [Homo sapiens]
 MLKSRQTFVFGSAIFCVVIFSLYMLDRGLDYPNRPREGSFPPQQLSMLQEKIDHLERLLAENNEIIS
 NLRDSVINLSVESVEDGPKSSQNSFSQAGSHLLPSQLSLSDVTADCLFASQSGSHNSDVQMLDVYSLISF
 DNPDEGGVWKQGFITYESNEWDTEPLQVVFVPHSHNDPGWLKTFNDYFRDKTQYIFNMVLLKLEDSSRG
 FWISLKYLSKWDIIDIQKDAVKSLIENGQLEIVTGQWVMPDEATPHYFALDILQIEGHQWLNNIIGV
 KPRSGWATDPFGHSPMTAYLLNRAGLSHMLIQRVHYAVKKHFALHKTLEFFWRQNWDLGVSVDILCHMMP
 FYSYDIPHTCGDPKICQFDFKRLPGRFGCFGWGVPETIHPGNVQSRARMLLDQYRKKSLFRTKVL

APLGGDDFRYCEYEWDLQFKNYQQLFDYMNSQSKFKVKIQFGTSLDFFDALDKADETQRDKGQSMFPVLV
 GDFFTYADRRDDHYWSGYFTSRPFYKRMDRIMESHRAAEILYYFALRQAHKYKINKFLSSSLYTALTTEAR
 RNLGLFQHHDAITGTAKDWVVVDYGTRLFHSLMWLEKIIIGNSAFLILKDKLTYDSYSPDTFLEMDLKQK
 SQDSLQPNIIIRLSAEPRYLVVYNPLEQDRISLVSVVYSPTQVFSASGKPEVQVSAVWDATANTISSET
 AYEISFRAHIIPLGLKVKYKILESASSNSHLADYVLYKNKVEDSGITFKNMINTTEEGITLNSFVLRFDC
 QTLGKMKQMKTDEGKHIEVYNQFQSWYGTITIKRDKSGAYLFLPDGNAKPYVVTTPPVFVRVTHGRIYSRFT
 FFDHVTHRVRLYHIQIGIEGQSVSEVSNIVDIRKVVYNREIAMKISSDKSQNRFTYDNLNGVQIQFPMRTLSKL
 PLQANVYPMTTMAYIQDAKHRLTLLSAQSLGVSSLSNSGQIEVIMDRRLMQDDNRGLEQGIQDNKCDITANFL
 RILLEKRSVANTVEEEKSVSPYSLLSHITSSLMNHVPIMANKFSPTELEQDGEFSPQLQSCLDHLNVNL
 RTIQSKVNGHGSNEAALILHRKGDFCRFSSKGTGLRFCSTTQGGKILVQKLLNKFIVESLTPSSLSLMHSP
 GTQNTISENLSPMEISTFRIQLR

>gi|3123244|sp|P49641|M2A2_HUMAN Alpha-mannosidase IIX (Mannosyl-
 oligosaccharide 1,3-1,6-alpha-mannosidase) (MAN IIX) (Mannosidase alpha
 class 2A member 2)
 MLKKQVTCGAAIFCVAVFSLYLMLDRVQHPDTRHQNGGNFPRSQISVLQNRIEQLEQLLEENHEIISH
 IKDSVLELTANAEGPAMPPLYTVNGSWVVPPEPRPSFSISPDQCQFALGGQRQKPELQMLTVSEELPF
 DNVDGGMVRQGFDISYDHPHDMAEDLQVFFVPHSHNDPGMIKTDFKYYTEQTHILNSVMKVLQEDPRRR
 FLWAEVSFFAKWWDNINVKRAAVRRLVGNQGQLEIATGGWMPDEANSHYFALIDQLIEGHQWLERNLGA
 TPRSQWADVPFGYSSTMPYLLRANRLTSMILQIRVHYAIKKHFAATHSLEFMRQTWDSSTSDIFCHMMP
 FYSYVDVHTCGPDPKICQGFDFKRLPGGRINCPWKVPVPRAITAEANVAERAAALLDQYRKKSQLFRSNVL
 VPLGGDDFRYDKPQEWDAQFFNYQRLFDFFNSRPNLHVQAQFGTSLDSDYFDALYKRTVEGEPARPGFPVLV
 GDFFSYADREDHYVTGTYTSRPFYKSLDRVLEAHLRGAELVYSLAAAHARRSGLAGRYPLDFTLLTEAR
 RTLGLFQHHDAITGTAKAEVVVDYGVRLRLSLVNLKQVYIIAAHYLVLDGKETHYHDFEAPPLQVDDTRL
 SHDALPERTVIQLDSSPRFVFLFNPLEQERFSMVSLLVNSPRVRVLSSEGGPLAVQISAHWSSATEAVPD
 VVQVSPVRLPALGLGLVQLGLDGHRTLPSSVRIYLHGRQLSVSRHEAPPLRVIDSGTSDFALSRYM
 QWVSGLTGLLKRIRRVDEEHEQQVDMQVLYVGTRTSKDKSGAYLFLPDGEASPTSPRSPCCVSLKALS
 SQRWLRMTSTFTRRSQFTICQGRGCLWTVHPMWTSGTSTRSWPCTSIQTSTARVQPRYLLKPLQAN
 FYMPVMAYIQDAQKRLTLHTAALGVSSLDKGQLEVLDRRLMQDDNRGLGQGLKDNKRTCNRRFLLE
 RRTVGESEVQDSHSTSPYSLLSHLTSMYLNAPALAPVARMQLPGPGLRSFHPPLASSLCDPDLHLLMLRTLQ
 AEDTLPSAETALILHRKGDFCGLAEKNLGFNCTTSQKQVALGSLFHGLDVLPQTSLTSLPLASPSN
 STDVLEPMEIATFRLRLG

>gi|10835173|ref|NP_000611.1| nitric oxide synthase 1 (neuronal) [Homo
 sapiens]
 MEDHMFVGQIQPNVISVRLFKRKVGGLGLVFKERVSKPPVVISDLIRGGAAEQSLGIQAGDIILAVNGR
 PLVDLSYDSALEVLIRGIASETHVVLILRGPGEFTTHLETTFTGDGTPKTIRVTPQLGPPPTKAVDLSHQPP
 AGKEQPLAVDAGSGPNGQAHAYDDGQAGSLPHANGLAPRPPGQPAKKAATRVSLQGRGENNELLEKIE
 PVLSSLLTSGSRGVKGGAAPAKAEMKDMGIQVDRDLGKSHKPLPLGVENDVRFDNLGQGNVPVVLNPNYS
 EKEQPTSGSKVSPTKNGSPKSCPRFLKVKNWETEVLVDTLHLKSTLETGCTEYICMGSIHMPSSHARRP
 EDVRTKGQLFLAKEFIDQYSSSIKRPFGSKAHMERLEEVNKEIDTTSYQLKDTELIYGAHAWRNASRC
 VQRIQWSKLQVDFARDCTTAHGMFNYICNHVKYATNKGRLSAITIFPQRTDGHKDFVRVWNSQLIRIYAGY
 KGPDGSLTGDPAVNPQFTEICIQGQWKPGRGRFDVLPALLQAGNDPELFP1PELVLVPIIRHPKFWEFK
 DLGLKWLGLPAVSNMMLLETIGGLEFSACPPSGWYMGTEIGVRDYCDNSRYNTLEEVAKKNMLDMRKTSSLW
 KDQALVEINIAVLVSFQSDKVTIVDHSATESFIKHMENEYRCRGGCPADQVWTVPPMSGSTPVPFHQEM
 LNYRLTPSFYEYQDPDWNTHVWKGNGTNGTPTKRAAIGFKKLAEAVKFSAKMLQQAAMAKRVKATLLYATETGK
 SQAYAKTLCEIFKHAFDAKVMSMEEDIVHLEHETVLVVTSTFGNGDPPENGEKFGCALMEMRHNSPV
 EERKSYKVRFNKNSVSSYSDSKSSGDGPDLDNDFESAGLANVRVSPFGLGSRAYPHFCAGSHADVDTLLEE
 LGGERILKMRGDELCGQEEAFRTWAKKVFKAACDVFCVGDVNIKANNSLISNDRSWKRNKFLRTFVA
 EAPLELTQGLSNVHKVASALLSRQLQSPKSSRTIFVRLHTNGSQELVQYQGDHGLVFPGNHEDLVN
 ALIERLEADAPPVQMKVVELLEERNTALGVISNWTDELRLPPTCTIFQAFQYLLDITTPPTPLQGFQASL
 ATSEKEQRLLVL SKGLGEYEEWKGNKNPTIVEVLEEPPSIQMPATLLLTQSLVLTQRYYSLSSSPDMYP
 DEVHITVAIVSYRTRDGEGPIHHGVCSSNLNRIQADELVPCFVRGASPFHLPRNPQVPCILVGGPTGIAP
 FRSFVQQRQFDIQHGMGNPMPMLVFCGRQSKIDHYYREETLTQAKNKGVPRELYTAYSRPPDKPKVYQD
 ILQEQLAESVYRALKEQGGHIVYCGDVMTAADVLKATQIRMTQQGKLASADGAGVIFSRMRDNRNYHEDIF
 GVTLRTEYVNTNRLRSESIATFIESKDKTDEVFSS

>gi|37540252|ref|XP_291315.2| similar to KIAA1815 protein [Homo sapiens]
 MEWGSESAVRRHVRGVVERREGAAAAAPPPEAREAAQEPLVDGCGSGGRTRKRSPPGSGSGASRGAGTGLSE
 VRAALGLALYLIALRTLQVLQLLQQLVLRGAAGHGEFDALQARDYLEHITSIGPRTTGSPEINILLTHYL
 LEQIKLIEVQSNLSHKISVDVQRPPTGSFSDIFLGGFTSYVDNITNVVVKLEPRDGAQHAVLANCHFPDSVA
 NSPGASDDAVSCSVMLLEVLRLVLTSSSEALHHAVIFLFGAEENVLQASHGFIQTQHPWASLIRAFINLEAA
 GVGKGELVFTQGPENPMVLQVAVYSAAKHPFASVVAQEVFQSGIIIPSDTDFRIYRDPGNIPGIDLAFITENG
 YIYHTKYDTADRILDTSIQRAGDNLAVLKLHATSDMLAAASKYRKHGNNMVFVDVLGLFVIAVPSRIGSII
 NYMVMGVVLYLKGKFLQPKHKTGNYYKDFLCLGLGITLISWFTSLVTLVIAVFSILIQSLSWYNHFFV
 SVCLYGVHTAVAKIILHTLAKRFYYMNASAQYLGEVFFDISLFFVHCCLPLVTLTYQCLCSAPFISAVWVAF
 LLTKLCTVHAGDQKQAGKFIAYLLGMFIPYLYALYLIAWFEMFTPLIGRSGSEIIPDDVLAISILAGC
 TMLLSYFINFITYLAKSTKTKMLTLTLVCAITFLLVCSGTFPPYSSNPANPKPKRVFLQHMTRTFHDLEG
 NAVKRDSGIWINGFDYTGISHITPHIPEINDSIRAHCEENAPLCGFPWYLVPHVFLIRKNWYLPAPVESPR
 NPPHRLTISKEQTPWDSIKLTFEATGPHSMSFYVRAHKGSTLSQWSLGNQTPVTSKGGGVFFVYSHGLQA
 SAWQFWIEVQVSEEHPEGMVTVAAAHYLSGDEKRSPLQDALKEKFPDWTTPSAWCTDYDLFVF

>gi|21361382|ref|NP_009102.2| protein-O-mannosyltransferase 1 [Homo sapiens]
 MWGFLKRPVVVTADINLSLVALTGMGLLSRLWRLTYPRAVVFDEVYQYISFYMKQIFLDDSGPPFGH
 PLLALGGYLVGLGDFGNFLWNRIGAEYSSNPVWSLRLPALAGALSVPMAQIVLELHFHSCAAMGAALLM
 LKINALITQSRLLMLLESVLIFNNLAVLSYLFKFNCKQHSFFSLSWFWLTLTGVCACSAVGIKYMGVPT
 YVLVLGVAAVHAWHLGGDQTLNSVNGADVQCRCMRPACMGQMRMSQGVCFCHLLARAVALLVTPVVLVLLF
 FVYVHLTVFRSGPHDQIMSSAFQASLEGGELARITQGGPLEVAFGSGQVTLRNVFQKPPVPCWLHSHQDTYPM
 IYENGRGSSHQQVTCYFPKDVNNMWIVKDPRRHQVLVSSPPRPVRHGMVQVLVHGMTTRSLNTHDVAAP
 LSPHSEQVESYCIYDYNISMPAGNLWRLEIVNRGSDTDVWKTILSEVRFPVHVNTSAVLKLSGAHLPDWGYRQ
 LEITVEKLSRGYGHGTSVNVVEHRYGASQEQRERERELHSPAQVDVSRNLSPFMARGSELQWRMLALRSD
 SEHKYSSSPLEWTLDTNIIAYWLHPRTSAQIHLGNIVIVWVSGSLALAIYALLSLWYLLRRRRNVHDLPO
 DAWLRWVLAGALCAGGAVNVLPPFLMEKTLFLYHYLPALTFTQILLPVVLQHTSDHLCRSOLQRNSFSA
 LVVAYNYSACHVSNTRLPLTYGDKSLSPHELKALRWKDSWDILIRKH

>gi|4506321|ref|NP_002837.1| protein tyrosine phosphatase, receptor type, N precursor; islet cell antigen 2; islet cell antigen 512; islet cell autoantigen 3; protein tyrosine phosphatase-like N precursor [Homo sapiens]
 MRRPRRPGLCGSGGLRLLCLLLLSRPGGCSAVSAHGCCLFDRRLCSHLEVCIDQLGFQCGQVGVQAR
 PLLQVTSVPLQRLQGVLRQLMSQGLSWHDDLTYVVISQEMERIPRLRPPEPRPRDRSGLAPKRPAGEL
 LLQDIPGTSAPAAQHRLLPQPPVGVKGGAGASSSLPQLAELLPLLEHLLLPQPPHPSLSYEPALLQPYL
 FHQFGSRDGSRSVSESGPMGVSVGLPKAEAPALFRTASKGIFGDHPGHSYGDLPGLSPQAQLFQDSGLY
 LAQELPAPSRARVPLPEQSGSSRAEDSPGEYKEGLGDRGEKSPASPAVQPDAAQLRLAALVAGYGVGLR
 QLTPELSTLLTLQLLQPKAGRNPGGVNVGADIKKTMGEVPEGRDTPALRVPARTSPMPGHPTSSPSSSE
 VQVQVSPVSSEPPKAARPPVTPVLLKESPLQSGQSTVAGQPSARPAEEYGIYVTDQKPLSLAAGVKLL
 ELIAEHVHMSGSGFINISVVGPAITFRIRHNEQNLSADVTQAGLVKSELEAQTLGLQTLQGVGQREEA
 AAVLPQTAHSTSPMSVLLTLVALAGVAGLLVALAVALCVRHARQDKERLAAQLGPEGAGHDDTTYEQD
 LCRQHNRKTLFNLRAEGPPPEPSRVSSVSQFSDAAQASPSHSSSTPWCCEPAQANMDISTGHMILAYME
 DHLRNRLAKEMQALCAYQEPNCTCATQOGEGNKKNRHPDFLPYDHARIKLVKVESPPSRSDYINASPI
 IEHDPMPAYIATQGPLSHNTADFWMQMVWESGCTIVIMLTPLVEDGVKQCVDRYWPDEGASLHYVVEVNC
 SEHIWCEDFLVRYSYFKNVQTEQTRTLTQFHLFSWPAEGTPASTRPLDFFRKVNKCYGRGSCPIIVHLS
 DAGARTGTYLIDIMVLRNRMAKGVEIDIAATLEHVRDQRPGLVRSDQDFEALTVAAEVENNALKALPQ

>gi|11386149|ref|NP_002838.1| protein tyrosine phosphatase, receptor type, N polypeptide 2 isoform 1 precursor; protein tyrosine phosphatase receptor pi; phogrin; tyrosine phosphatase IA-2 beta; IAR/receptor-like protein-tyrosine phosphatase [Homo sapiens]
 MGPPPLPVLALLLLLLLPRLVPAAPSSVPRGRQLPGLRGCLLEGLCGASEACVNDGVFGRCQKVPAMDFF
 RYEVSPALLQRLRALVKLSGTGTWQDDYTYQVMDQELADLPKTYLRRBPASSPARPSKSLVSGSERYS
 REGGAALANALRHLFFLEALSQAPASDVLARTHTAQDRPPAEGDDRFSESILTYVAHTSALTYPGPGR
 QLRELDLPTLGLQPDDELSPKVDGSDVRHMLMAALSAYAAQRPAPPGEGSLEQPYLLRAPSRMRPLL

APAAPQKWPSPLGDSDESPSTGDGARIHTLLKDLQRQPAEVRGLSGLELDGMAELMAGLMQGVHDGVARG
 SPGRALGESGEQADGPKATLRGDSFPDDGVQDDDDRLYQEVHRLSATLGLGLQDHGSRLLPGALPFARP
 LDMERKKEHEPESLSSEETAGVENVKSQTYSKDLLGQQPHSEPGAAAFGELQNMGPSPSKEEQSLPAG
 AQEALSDGLQLEVPQSEEEARGYVITDRDPLRPEEGRRLVEDVARLLQVPSAFADVEQLGPAVTFKVS
 NVQNVITTEDVEKATVDMNKDLKEETSGLKLTQTGVGSKSKLFLPPQAEQEDSTRTALTFLVSLACILQVL
 LASGLTYCLRHSSQHRLKEKLSGLGGDPGADATAAYQELCRORMATRPDRPEGPHTSRISSVSSQSGDG
 PIPSPSARSSASSWSEEPVQSNMDISTGHMILSYMEDHLKNKNRLEKEWEALCAYQAEPNSSFFVAQREEN
 VPKMSLAVLTYDHSRVLLKAENSHSHSDYINASPIMDHDPRNPAYIATQGPLPATVADFWQMWSWGSCV
 VIYMLTPLAENGVRQCYHWPDGNSLYHIYEVNVLSEHIWCEDFLVRSFVLKYLKNLQINETRTVTQPHFLS
 WYDRGVPSRSSLLDFRRKVNKCYRGSCPIIVHCSDDGAGRSQTYVLDMLVNKMAKAKETDIAATLEH
 LRDRQPMVQTKQEFALTAVAEEVNAILKALPQ

>gi|4507335|ref|NP_003886.1| synaptojanin 1; inositol 5'-phosphatase
 (synaptojanin 1); synaptojanin-1, polyphosphoinositide phosphatase
 [Homo sapiens]

MAFSKGFRITYHKLDPFPFSLIVETRHKEECLMFESGAVAVLSSAEKEAIGTYSKVLDAYGLGLVLRNLN
 GDTMLHYLVLVTGCMGVGKIQSEVFRVTSFEFISLRDSSDEDRISEVRVLTSMNGFFAWASAGCSISLD
 LSLNAHRSMQEQTTDNRFMRQVQSLHLHLKHYGVNCDWMLLMCGGVEIRITYAAHKQACSLISRLSE
 RAGTRFRNVGRNTDDGHVANFVETEQQVVYLLDDSVSSFIQIRGSVPLFWEQPGQLQVGSHRVMSRGFEANAP
 ADFRHFRTLKNLYGRQIIVYNLGSKEGEHMLSKAFQSHLKASEHAADQIMVNPFDYHQMVKGGAEBKLHSV
 LKPKQKFLDVGFFYFNGSEVQRCQSGTVRTNCLDCLDRNTNSVQAFGLGLEMLAKLEALGLAEKPLQVTR
 FQEVFRSMWSVNGDSISKIYAGTGALEGKAKLKGARSVTRTQQNNFFDSSKQEAIDVLLGLNTLNSDLA
 DKARALLTTGSLRVSEQTQSASSKVLKSMCENFYKYSKPKKIRVCQTNVWNGGQFRSIAFNQTLTD
 WLLDAPKLAGIQEFQDKRSKPTDIPAIGFEEMVELNAGNIVSASTNQKLWAVELQKTTSRDNKYVLLAS
 EQLVGVCLFVPIRPQHAPPIRDVAVDTVKTGMMGATGNKGAVAIRMLFHTTSLCFVCSHFAGQSQVKER
 NEDFTIARLKSPFMGRMLFSHDYVFWCGDPFNIRIDLNEEVKELIPNEEVKELIPNEEVKELIPNEEVKEL
 RGLFEGKVTFAPTYKYDLFSSDDYDTSEKCRTPAWTDRVLWRRRKWPFDRSADLDDLNASFQDESILTYT
 WTPGTLHYGRABLKTSDHRPVVALIDIDIPEVEAEERQNIYKEVIAVQGPDDTVLVSITKSSLPENNF
 DDALIDELLQQFASFGVEVILIRFVEDKMMVTFLEGSSALNVLSLNGKELLNRTITTAALKSPDWIKNLEEE
 MLEKISIALPSSTSTTLGGEDA EVAADFMEGDVDDYSAEVEELLQPHQLQPSSSSGLGTSPSSPRTSP
 CQSPSTSEGVPLSLPIRPSRAPSPRTPGPPSAQSPIDAPATPLPQKDAQPLEPKRPPPPRPPPPRPPR
 APQPQRPPPPSGARISAPATRKFEFGGIGAPPSPGVARREMAEPKSPGTTRKDNIGRSQSPQAGLAGPGPAG
 YSTARPTIPPRAGVISAQSHARASAGRLTPESQSKTSETSGKSTFLPEPLKPKQAAPFPQSSSLPPPAQRL
 QEPLVPAAMPQSGSQPNLETTPQPPPPRSRSHSLPSEASSQPQVKTNIGSDGKRESPLKIDPFEDLSF
 NLLAVSKAQLSVQTSVPPTDPKRLIQLPSATQSNVNTLSSVSCMPTMPPIPARSQSNMRRSSNPFFIT
 GLTRTNPFSDRTAAPNPFRACKSESEATSWFSKEEPTVTSFPPLQLGHNKSRASSSLDGFKDSFDLQ
 GQSTLKIINPKGMVTFEEEEDFGVKSKSACSDLLGNQPSFSGSNLTLDNDWNKGTIVSFVLPSSRRP
 PPPPVLLPPTGSPPPDPTLASKASPTLDFTER

>gi|26190608|ref|NP_003889.1| synaptojanin 2; inositol phosphate 5'-
 phosphatase 2 (synaptojanin 2) [Homo sapiens]
 MALSKGLRLRLGLGAEGDCSVLLEARGRDDCLLFEAGTVATLAPAEKEVIGQYQKLTDAYCYGLGELRLK
 SGGTSLFSLVLVTGQSVGRIPDAEIKYKATDFPYLQEEAKEEERLILAKKILSSGVFYFSWPNDSGRF
 LDVTRTQFGHDDSSSEWNGSFPWNQLLHVPLRQHQVSCCDWLLKICGVVTTTRTVYASHQAKACLVSRVS
 CERTGTGRQTRGVNDGHSNFEVTEQMIYDDGVSSFVQIRGSVPLFWEQPKQAGVQSGHHLRLHGLEAN
 APAFDRHMVLLKEQYQGVQVVNVLGSRGGEVVLNRAFKKLLWASCHAGDTPMINFDFHQFARGGKLEKLE
 TLLRPQLKLHWEDFDTVKTGENVSPRQKGLRMNCLDCLDRNTVQSFIAQLVHLQLKTLGLSSKPIV
 DRFVSEFKAMVNLNGHSLSVFTGSRALGKAKVGKLDGARSMSRTIQSNFPDGVKQAEAILKLLVGDVY
 GEEVADKGMLMLDSTALLVTPRILKAMTERQSEFTNFKRIRIAMGTNNVWNGGQKFRSNVLRITAEITDWLL
 DSPQLSGATDSQDDSPADIFAVGFEEMVELSAGINVNASTTNKKMWGEQLPKQALSRSHRILLTASQLV
 GVCLYIFVRPHYVFFLRDAIDTVKTMGGKAGNKGAVGIRFQFHSSTFCFICSHLTAGQSQSGKERNEDY
 KEITQKLCFPMGRNVFSHDYVFWCGDFNYRILDTYEEVYFVFRQDKWKLLEFPQLQLQKMSGKIFKDFH
 EGAINFGPTYKYDVGSAAAYDSDKCRTPAWTDRVLWRRKKHFPDKTAGELNLLDSLDVDVTKVRHTWSPG
 ALQYVGRALQASDHRPVLIAIVEVEVQEVVDGARSERVFQEVSSFPGLDATTVVNQLQSPSTLEEKNEPFD
 LRTEMLQTLGSIYGTIVLVRISQGMVLTFADSHSLVLDVDMGMVKGRAVYKIRPKTKDWLKGRLREIIR
 KRDSMAPVSPPTANSCLLEENFDFTSLDYESGDILEDEDDYLVDEFNQPGVSDSELGGDDLSDVPGPTAL
 APPSKSPALTKKKQHTPYKDDADLVELKRELEAVGEFRHRSPSRSLSVNRPFRPPQPPQRPPTGLMVK

KSASDASISSGTHGQYSILQTARLLPGAPQPPKARTGISKPYNVKQIKTTNAQEAEEAIRCLLEARGGA
 SEEALSAVAPRDLEASSEPEPTPGAAPKPTQAPFLPRRPPPRVPAIKKPTLRRTGKPLSPREEQFEQQT
 VHTFTGPPETSVEAPPVVTAPRVPPVPKPRTPQPGKAAERPSHRKPSADSEAPPAGASVPPPLEAPPLVP
 KVPVRRKKSAPAAFLHQLVLSQNSQLLQGLTYNSSDSPSGHPPAAGTVFPQGDFTLSTSSATSPSDSGTKAM
 KPAAAPLLGDYQDPFWNLHHPKLLNNTWLKSSDPLDSGTRSPKRPDPIDPVSAGASAAKAEPLPDHEHK
 TLGHVVTISDQEKRTALQVDFPLAKT

>gi|27485630|ref|XP_209367.1| similar to dJ680N4.2 (ubiquitin-
 conjugating enzyme E2D 3 (homologous to yeast UBC4/5)) [Homo sapiens]
 MALKRINKELSDLARDPPAQCAGSAGVGGDDMFHWQATIMGPHDRPYQGGVFWTIRFTDYPPKPSKVAFT
 TRIYHPNINSNGSIFLDILRSQWSPALTLKSVLLSICSLLCDPNPDDPLVPEIARIYKTRDKYNRISRE
 WTQKYAM

>gi|8393719|ref|NP_057067.1| ubiquitin-conjugating enzyme HBUCE1 [Homo
 sapiens]
 MALKRIQKELTDLQRDDPAQCAGSAGVGGDDLFWHQATIMGPNDSFYQGGVFLTIHFPTDYPPKPKVAFT
 TKIYHPNINSNGSICLDILRSQWSPALTVSKVLLSICSLLCDPNPDDPLVPEIAHTYKADREKYNRLARE
 WTQKYAM

>gi|33188456|ref|NP_862821.1| ubiquitin-conjugating enzyme E2D 2
 isoform 2; ubiquitin carrier protein; ubiquitin-conjugating enzyme E2-
 17 kDa 2 [Homo sapiens]
 MFHWQATIMGPNDSFYQGGVFLTIHFPTDYPPKPKVAFTTRIYHPNINSNGSICLDILRSQWSPALTI
 SKVLLSICSLLCDPNPDDPLVPEIARIYKTRDKYNRAREWTQKYAM

>gi|33149322|ref|NP_871621.1| ubiquitin-conjugating enzyme E2D 3
 isoform 2; ubiquitin-conjugating enzyme E2-17 kDa 3; ubiquitin carrier
 protein [Homo sapiens]
 MALKRINKELSDLARDPPAQCAGSAGVGGDDMFHWQATIMGPNDSFYQGGVFLTIHFPTDYPPKPKVAFT
 TRIYHPNINSNGSICLDILRSQWSPALTISKVLLSICSLLCDPNPDDPLVPEIARIYKTRDKYNRARE
 WTEKYAM

>gi|37539365|ref|XP_353789.1| similar to dopamine beta-hydroxylase-like
 [Homo sapiens]
 MAHDLFLRFLPLLALGVPLQSNRLGPTSRRLRYSRFLDPSNVI FLRWDFLEAEIISFELQVRTAGVWGFG
 VTNRYTNGVSDLVVGGVLPNGNVYFSDQHLVEEDTLKEDGSQDAELLGLTEDAVYTTMHFSRPFRCSDPH
 DLDITSNTVRVLAAYGLDITLKLRYRRTFVKSIPLLQVVPDDLDVPEDTIIHDLBITNFLIPEDDTTYA
 CTFPLPLPIVSEKHIIYKFEPLKVYHNETT VHILVYACGNASVLTGSDCYGADPAFSLCSQVIVGSAV
 GGTLCYDITDVLQGFFTFPIHFIPGAESFMSYGLCRTEKFEEMNGAPMPDIQVGYLLHHLALAGRALQ
 AVQYRGTQLRKICKDSDYDNFLQETRDLSPRVEIKPGDELLVECHYQTLDRDSMTFGGPGSTINEMCLIF
 LFYYPQNNISSCMGYPDIIVAHLEGEASE

>gi|37183305|gb|AAQ89452.1| dopamine-oxygenase [Homo sapiens]
 MCCWPLLLWGLLPCTAAGSGSRTYPHRTLLDSEGGYWLWSQRGSQIAFLRQVRTAGVVGFGFSGPTGAM
 ASADIVGGVAHGRPYLQDYFTNANRELKKDAQDQDYHLEYAMENSTHTIIEFTRELHTCDINDKSIDTST
 VRVIWAYHHEDAGEAGPKYHDSNRGTKSLRLNPEKTSVLSTALPYFDLVNQDVPINPKDITYWCQMKFI
 PVFQEKHHVIVKEPVIQRGHESLVHHILLYQCSNNFNDSVLESAGHECYHNPMPDAFLTCETVIFAWAIGG
 EGFSPYPHVGLSLGTPLDPHYVLLLEVHYDNPTYEEGLIDNSGLRLFYTMDIRKYDAGVIEAGLWVSLFPL
 IPPGMEPFQSEGHCTLECLEALEAEKPSGIHVFAVLLHAHLAAGRGIRLRHFRKGKEMKLLAYDDDFDN
 FQEFQYLKEEQTLIPGDNLTETCRYNTKDRAEMTWGLSTRSEMCLSYLLYYPRINLTRCASIPIIMEQL
 QFTIGVKEYIRPVTTWFFIISKSPKQYKNLSFMDAMNFKWTKKEGLSFNKLVLSPVNVRCSTDNAEWSI
 QGTMALPDIERPDKAEPLVCGTSSSSSLHRDFSINLLVCLLLLSCTLTSTKSL